

NATIONAL GUIDELINES FOR THE MANAGEMENT OF VIRAL HEPATITIS




health

Department:
Health
REPUBLIC OF SOUTH AFRICA



NATIONAL GUIDELINES FOR THE MANAGEMENT OF VIRAL HEPATITIS





Hepatitis

DISCARD AFTER USE

2

FOREWORD

It is my pleasure to present the first National Guidelines for the Management of Viral Hepatitis. Viral hepatitis is defined as inflammation of the liver cells due to viral infection. The burden of liver disease in South Africa is mostly underestimated as viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. However, the burden of disease is likely substantial given the prevalence of chronic viral hepatitis. This burden is further compounded by the lack of screening and access to care and treatment as well as inadequate disease surveillance, human and financial resources.

According to the most recent estimates of the Global Burden of Disease Study, viral hepatitis is responsible for approximately 1.5 million deaths each year, which is comparable to the annual deaths from AIDS (1.3 million), malaria (0.9 million) and tuberculosis (1.3 million). Mortality due to viral hepatitis has increased since 1990 and it is now the seventh leading cause of mortality in the world.

Hepatitis A (HAV) and B (HBV) are highly endemic in South Africa, but there is limited data on hepatitis C, D and E. However, sporadic cases of hepatitis E have been reported as a result of travel to high-risk areas outside South Africa. South Africa has one of the largest HBV burdens globally with an estimated hepatitis B surface antigen (HBsAg) prevalence of 6.7 per cent (3.4 million individuals). Hepatitis C is mainly a concentrated epidemic amongst key populations. Recent studies have demonstrated that the prevalence of hepatitis C is as high as 93 per cent among people who inject drugs (PWID) in Pretoria. If left untreated, around one third of those chronically infected with viral hepatitis will die as a result of serious liver disease, including cirrhosis, liver failure and hepatocellular carcinoma.

It is the role of the Department of Health to decrease morbidity and mortality due to emerging and re-emerging epidemic-prone infectious diseases. Therefore, these guidelines were developed, with the purpose to:

- inform healthcare workers in the public and private sectors about the disease, its epidemiology in South Africa and current methods of diagnosis and therapy
- strengthen the healthcare response to viral hepatitis
- empower communicable diseases workers and stakeholders to make informed decisions regarding appropriate and cost effective interventions

I trust these guidelines will assist health workers by providing information on the disease and prevention and control measures.

Dr ZL Mkhize, MP
Minister of Health
Date: December 2019

ACKNOWLEDGEMENTS

The national Department of Health would like to acknowledge and thank all the members of the Viral Hepatitis Technical Working Group, provincial Centres for Disease Control and Prevention (CDC) and HAS managers as well as World Health Organization (WHO) South Africa, who supported and contributed to the writing of this document:

Prof. CWN Spearman: WHO Africa, national Department of Health Consultant on National Guidelines for the Management of Viral Hepatitis. Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town

Prof. MW Sonderup: Senior Hepatologist, Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town

Dr Y Pillay: Deputy Director-General: Communicable and Non-communicable Disease Prevention, Treatment and Rehabilitation, national Department of Health, Republic of South Africa (RSA)

Dr Z Pinini: Chief Director: HIV and AIDS and STIs, national Department of Health, RSA

Dr A. K Vilakazi-Nhlapo: Medical Coordinator: TB/HIV/Hepatitis Collaboration, national Department of Health, RSA

Dr A Ntilivamunda: WHO Country Office in South Africa

Dr A Hashish: WHO Country Office in Egypt

Dr B Chirombo: WHO Country Office in South Africa

T Nemungadi: Directorate: Communicable Diseases Control (Zoonoses), national Department of Health, RSA

L Seshoka: Comprehensive HIV and AIDS Care, Management and Treatment (CCMT), national Department of Health, RSA

E Marumo: Director: Prevention Strategies and STIs, national Department of Health, RSA

L Chisale-Mashilo: TB/HIV/Hepatitis, national Department of Health, RSA

M Naledi: CCMT, national Department of Health, RSA

Dr N Prabdiel-Sing: Medical Virologist, National Institute for Communicable Diseases (NICD)

Dr A Scheibe: TB HIV Care, 11 Adderley Street, Cape Town, South Africa

Dr S Mayaphi: Clinical Virologist, of Medical Virology, National Health Laboratory Service (NHLS)/ University of Pretoria

Prof P Jeena: University of KwaZulu-Natal

Dr T Neluheni-Tshinaba: National Alliance of State and Territorial AIDS Directors (NASTAD)

N Futwa: NASTAD

S Monareng: South Africa Partners

Dr B Montoedi: Gauteng Department of Health

Dr C Asomugha: Gauteng Department of Health

Dr R Chimatira: CDC/Center for Global Health/Division of Global HIV and TB

T Motladiile: North West Department of Health

G Hottie: Northern Cape Department of Health

B Makalima: Eastern Cape Department of Health

ZM Zwane: Mpumalanga Department of Health

Q Ranoto: Limpopo Department of Health

N Ramalwa: Limpopo Department of Health

TABLE OF CONTENTS

List of Acronyms	vii
Chapter 1: Introduction	1
Chapter 2: Epidemiology of Viral Hepatitis	3
2.1 Epidemiology of Enteric Hepatitis Viruses	4
2.2 Epidemiology of Parenteral Hepatitis Viruses	4
2.3 Rationale for The Consolidated Viral Hepatitis Guidelines	6
2.4 Target Audience	6
Chapter 3: Guiding Principles	7
3.1 Principles Guiding the Approach to Elimination of Viral Hepatitis ¹	7
3.2 Access to Care and Health Equity	7
3.3 Health Systems Strengthening and Integration	8
Chapter 4: Hepatitis A (Hav)	9
4.1 Introduction	9
4.2 Transmission of HAV	9
4.3 Groups at Risk for HAV	9
4.4 Clinical Presentations of HAV	10
4.5 Diagnosis of HAV	11
4.6 Prevention of HAV	11
4.7 Treatment of HAV	12
4.8 Diagnostic, Primary, Secondary and Tertiary Levels Of Care	12
Chapter 5: Hepatitis B (HBV)	15
5.1 Introduction	15
5.2 HBV Genotypes	15
5.3 Transmission of HBV	16
5.4 Clinical Presentations of HBV	17
5.5 Hepatocellular Carcinoma	19
5.6 Diagnosis of Acute and Chronic HBV ^{33,34,47-49}	20
5.7 Goals and Endpoints of Therapy ^{33,34,47,48,51}	22
5.8 Management of Acute HBV ^{33,34,48}	31
5.9 Management of Chronic HBV	31

TABLE OF CONTENTS [CONTINUE]

5.10	Treatment Options for Chronic HBV	25
5.11	Definitions of Treatment Response for Nucleoside Analogue (NUC) Therapy ^{33,34,49}	27
5.12	Indications for Treatment ^{33,34,54,74}	28
5.13	Management of Individuals with HBeAg-Negative Chronic HBV Infection (Immune Control) or HBeAg-Positive Chronic HBV Infection (Immune Tolerant Phase) who require Immunosuppressive Therapy, Rituximab or Chemotherapy	30
5.14	Indications for Combination NUC Therapy	31
5.15	Duration of NUC Therapy ^{33,34,54}	31
5.16	Monitoring on NUC Therapy ^{33,34,48,49}	31
5.17	Monitoring of Patients not Considered for Therapy ^{33,34,48}	32
5.18	Management of Nucleos(T) IDE Resistance ^{33,34,48,54}	33
5.19	Treatment of Special Populations	33
5.20	General Measures for HBV Control:	38
5.21	Role of HBV Vaccine In the Control of HBV	39
5.22	Prep for HIV in Setting of HBsAg-Positivity	41
5.23	Post-Exposure Prophylaxis (Pep) against HBV	41
5.24	Diagnostic, Prevention and Treatment Options: Primary, Secondary and Tertiary Levels of Care	44
Chapter 6: Hepatitis C (HCV)		47
6.1	Introduction	47
6.2	Hepatitis C Genotypes	47
6.3	Transmission of HCV	47
6.4	Groups at Risk for HCV	48
6.5	Clinical Presentation of HCV	48
6.6	Extrahepatic Manifestations of HCV	49
6.7	HIV/HCV Co-Infection	49
6.8	Diagnosis of HCV	49
6.9	Pre-Treatment Clinical Evaluation	50
6.10	Treatment of HCV ³⁹⁻⁴¹	50
6.11	HCV Treatment Options	51
6.12	Treatment of Special Populations	53
6.13	Primary Prevention and Control	54
6.14	Secondary Prevention	55
6.15	Diagnostic, Prevention and Treatment Options at Primary, Secondary and Tertiary Levels of Care	55

TABLE OF CONTENTS [CONTINUE]

Chapter 7: Hepatitis D (Hdv)	57
7.1 Introduction	57
7.2 Transmission of HDV	57
7.3 Groups at Risk for HDV:	57
7.4 Clinical Presentations of HDV:	57
7.5 Diagnosis of HDV:	58
7.6 Prevention of HDV:	58
7.7 Treatment of HDV:	58
Chapter 8: Hepatitis E (Hev)	59
8.1 Introduction	59
8.2 Transmission of HEV: ¹⁵	59
8.3 Groups at Risk for HEV	60
8.4 Clinical Presentations of HEV ²	60
8.5 Diagnosis of HEV	60
8.6 Treatment of HEV	61
8.7 Prevention of HEV	61
8.8 Diagnosis and Treatment Options: Primary, Secondary and Tertiary levels of Care	62
Chapter 9: References	63
Appendix	77
Summaries and Treatment Algorithms for HBV and HCV	77

TABLES AND FIGURES

Table 1: Hepatotrophic viral classification	1
Table 2: Routes of transmission	16
Table 3: Acute, fulminant and chronic HBV infection	17
Table 4: HBV serological markers	20
Table 5: Interpretation of serological markers, HBV DNA and ALT levels	21
Table 6: Management of acute HBV	23
Table 7: Assessment of liver disease prior to therapy ^{33,34,48,49,51-54}	24
Table 8: Nucleos(t)ide analogue options for chronic HBV and dosage regimens ^{33,34,48,49}	26
Table 9: Definitions of treatment response to nuc therapy	27
Table 10: Recommendations for treatment: non-cirrhotic HBeAg-positive patients ^{33,34,49,54}	28
Table 11: Recommendations for treatment: non-cirrhotic HBeAg-negative patients ^{33,34,49,54}	29
Table 12: Management of NUC resistance	33
Table 13: Recommendations for PEP: occupational exposure to HBV ¹³⁶	43
Table 14: Definitions of terms used to evaluate response to HCV treatment	51
Table 15: DAA regimens for Non-Cirrhotic Treatment naive or experienced (Including Peg-IFN/ Ribavirin; Peg-IFN, or Sofosbuvir and Ribavirin) HCV Mono-Infected Patients	52
Table 16: DAA Regimens for compensated cirrhosis treatment naive or experienced (including Peg-IFN/Ribavirin; Peg-IFN, or Sofosbuvir and Ribavirin) HCV Mono-Infected Patients	52

Figures

Figure 1: Phases of Chronic HBV Infection ^{33,34}	19
Figure 2: HBV Testing Algorithm	22
Figure 3: Natural History of HCV Infection	49

LIST OF ACRONYMS

AIDS	Acquired immunodeficiency syndrome
AFP	Alpha-fetoprotein
APRI	AST to Platelet Ratio Index
ALP	Alkaline phosphatase
ALT	Alanine aminotransaminase
anti-HAV IgM	Hepatitis A IgM antibody
anti-HAV IgG	Hepatitis A IgG antibody
anti-HBe	Hepatitis B e antibody
anti-HBs	Hepatitis B surface antibody
anti-HBc total	Total Hepatitis B core antibody
anti-HCV	Hepatitis C antibody
anti-HDV IgG	Hepatitis D IgG antibody
anti-HDV IgM	Hepatitis D IgM antibody
anti-HEV IgG	Hepatitis E IgG antibody
anti-HEV IgM	Hepatitis E IgM antibody
APRI	AST to platelet ratio index
ART	Antiretroviral therapy
AST	Aspartate aminotransaminase
BCG	Bacillus Calmette-Guérin (or Bacille Calmette-Guérin)
cccDN	covalently closed circular DNA
CCMT	Comprehensive HIV and AIDS care, management and treatment
CDC	Centers of Disease Control and Prevention, Atlanta, United States of America (USA)
CHB	Chronic hepatitis B
DAA	Direct acting antivirals
DALY	Disability adjusted life years
DNA	Deoxyribonucleic acid
DM	Diabetes mellitus
ds	double stranded
DSV	Dasabuvir
DTP	A triple vaccine against diphtheria, tetanus, and pertussis
EIA	Enzyme immunoassay
ELISA	Enzyme linked immuno-sorbent assay
EOT	End-of-treatment response
EPI	Expanded Programme on Immunisation
EPP	Exposure-prone procedures
EVR	Early virological response
FBC	Full blood count
FDA	United States Food and Drug Administration
GGT	Gamma-glutamyl transferase

LIST OF ACRONYMS [CONTINUED]

GT	Genotype
HAART	Highly active antiretroviral therapy
HAS	HIV, AIDS and STIs
HAV	Hepatitis A virus
HBsAb	Hepatitis B surface antibody
HBsAg	Hepatitis B surface antigen
HBeAg	Hepatitis B e antigen
HBeAb	Hepatitis B e antibody
HBcAg	Hepatitis B core antigen
HBcAb	Hepatitis B core antibody
HBcIgM	Hepatitis B core IgM antibody
HBIG	Hepatitis B immunoglobulin
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HCWs	Healthcare workers
HDV	Hepatitis D virus
HEV	Hepatitis E virus
HIB	Haemophilus influenzae type B
HIV	Human immunodeficiency virus
IFN	Interferon
IFG	Impaired fasting glucose
IgG anti-HBc	Hepatitis B IgG core antibody
IgM anti-HBc	Hepatitis B IgM core antibody
INR	International normalised ratio
IPV	Intramuscular Polio Vaccine
IRIS	Immune reconstitution inflammatory syndrome
IU/mL	International units per millilitre
IVI	Intravenous injection
KZN	Kwa-Zulu Natal
LFT	Liver function test
MDG	Millennium Development Goal
mRNA	messenger RNA
MSDS	Material safety data sheet
MSM	Men who have sex with men
MTCT	Mother-to-child transmission
NASTAD	National Alliance of State and Territorial AIDS Directors
NAT	Nucleic acid testing
NBI	National Bioproducts Institute

LIST OF ACRONYMS [CONTINUED]

NHLS	National Health Laboratory Services
NICD	National Institute for Communicable Diseases
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIH	National Institutes of Health
NITs	Non-invasive tests
NMC	Notifiable medical condition
NUC	Nucleostide analogue
OMB	Ombitasvir
OPV	Oral polio vaccine
PEP	Post-exposure prophylaxis
PCR	Polymerase chain reaction
PrEP	Pre-exposure prophylaxis
RT-PCR	Reverse transcription-polymerase chain reaction
PEG	Polyethylene glycol
PI	Protease inhibitors
PMTCT	Prevention of mother-to-child transmission
PPV	Positive predictive value
PTV	Paritaprevir
PWID	People who inject drugs
RAS	Resistance associated substitutions
RNA	Ribonucleic acid
RSA	Republic of South Africa
RTV	Ritonavir
RVR	Rapid virological response
SAHPRA	South African Health Products Regulatory Authority
SANBS	South African National Blood Service
SVR	Sustained virological response
TAF	Tenofovir Alafenamide
TB	Tuberculosis
TDF	Tenofovir Disoproxil Fumarate
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNODC	United Nations Office on Drugs and Crime
VCTE	Vibration controlled transient elastography
WHA	World Health Assembly
WHO	World Health Organization
YMDD	Tyrosine-methionine-aspartate-aspartate

...
immunization.

Hepatitis A

Hepatitis B

Tetanus (Td)

REVIEW

INTRODUCTION

CHAPTER

1



Hepatitis is a general term referring to an inflammation of the liver. It occurs as a result of infection with various pathogens; exposure to alcohol, medications, chemicals and toxins; and autoimmune disorders. There are five types of hepatotropic viruses: Hepatitis A, B, C, D and E (HAV, HBV, HCV, HDV and HEV), named according to the order in which they were discovered. In the 1960s, only two types were known (A and B), but by the late 1970s and beyond, new viruses (C and E) were discovered. Hepatitis viruses are either ribonucleic acid (RNA) (hepatitis A, C, D and E), or deoxyribonucleic acid (DNA) viruses (hepatitis B). The five hepatotropic viruses are broadly classified into two groups namely, enteric and parenteral (Table 1).

Table 1: Hepatotropic viral classification

Hepatotropic-viral type	Genetic make up		Classification group
	RNA	DNA	Enteric/parenteral
HAV	✓	...	Enteric
HBV	...	✓	Parenteral
HCV	✓	...	Parenteral
HDV	✓	...	Parenteral
HEV	✓	...	Enteric

Key: ✓ = yes; ... = no

The enteric viruses, HAV and HEV, are transmitted primarily via the faecal-oral route and may be associated with outbreaks of acute illness. Infections frequently occur following ingestion of contaminated food and/or water. Clinical presentations range from asymptomatic to mild or severe disease, but are usually self-limiting with no long-term sequelae. The notable exception is the unusually high mortality caused by the HEV in pregnant women, up to 25 per cent. Measures to improve personal and environmental hygiene are adequate to prevent the spread of these enteric hepatitis viruses.

The parenterally transmitted viruses (B, C and D) are primarily transmitted via exposure to infected blood and body fluids. Common routes of transmission include mother-to-child transmission (MTCT), sexual transmission, blood/blood product transfusions and percutaneous exposure (needle-stick injuries, body piercing/traditional scarification, unsafe injection practices and inadequately sterilised medical equipment). Clinical presentations include acute hepatitis as well as chronic infection leading to the complications of cirrhosis, liver failure and hepatocellular carcinoma.

The clinical symptoms and signs of the different viruses are often indistinguishable, with the epidemiology being markedly different.



Currently effective and licensed vaccines are available for the prevention of HAV, HBV and HEV. Furthermore, HDV can be prevented as HBV immunisation is protective against HDV.


These guidelines have been developed to improve the management of viral hepatitis in South Africa and to enable healthcare workers to implement the WHO goal of eliminating viral hepatitis by 2030^{1,2}.

**IMPORTANT:
VIRAL HEPATITIS IS A NOTIFIABLE
MEDICAL CONDITION (NMC)**

EPIDEMIOLOGY OF VIRAL HEPATITIS

CHAPTER

2



GLOBAL PICTURE

Viral hepatitis is a group of infectious diseases that represent a significant global health challenge. According to the most recent estimates of the *Global Burden of Disease Study*¹, viral hepatitis is responsible for approximately 1.45 million deaths each year, which is comparable to the annual deaths from HIV and AIDS (1.3 million), malaria (0.9 million) and tuberculosis (1.3 million). Mortality due to viral hepatitis has increased by 63 per cent since 1990 and it is now the seventh leading cause of mortality in the world, yet there has been a persistent lack of global awareness of the severity of the problem as well as a lack of commitment to combat the disease²⁻⁶.

An estimated 257 million individuals are chronically infected with HBV, and 71 million with HCV. Globally, most of the morbidity and mortality is caused by HBV and HCV infections: 96 per cent [95 per cent CI 94–97] of mortality and 91 per cent [88–93] of disability adjusted life years (DALYs) in 2013⁶. It is estimated that 95 per cent of individuals with chronic HBV and/or HCV are unaware of their infection and do not benefit from clinical care, treatment and interventions designed to reduce onward transmission. Without appropriate diagnosis and treatment, around one third of those chronically infected with viral hepatitis will die

as a result of serious liver disease, including cirrhosis, liver failure and hepatocellular carcinoma⁴⁻⁶.

SOUTH AFRICAN CONTEXT

The burden of liver disease in South Africa is mostly underestimated. Viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. The burden of disease is likely to be substantial given the prevalence of chronic viral hepatitis, especially HBV. This burden is further compounded by the lack of screening, access to care and treatment, as well as inadequate disease surveillance, human and financial resources.

Despite the availability of HAV and HBV vaccines, effective therapy for HBV, and now a potential cure for HCV with the new direct acting antivirals (DAAs), viral hepatitis remains an important cause of morbidity and mortality in South Africa. Co-infection with HIV further exacerbates the burden of liver disease.

In summary, studies conducted in South Africa, mainly on HBV and HCV, have produced varying seroprevalence estimates. National estimates for each hepatotropic virus remains a significant challenge. This is because the studies were conducted in different population groups (having increased or

lower risk probability), utilised different sample sizes and used different laboratory screening methods, some with and others without confirmatory testing, to arrive at seroprevalence estimations. In addition, the studies have a wide geographical distribution.

Recent national data from different sources may also be utilised to generate more current seroprevalence estimates, such as from antenatal clinic surveillance studies or blood banks. Having recent information can provide more concrete evidence-based input for policy making on prevention and care of viral hepatitis in South Africa.

2.1 Epidemiology of Enteric Hepatitis Viruses

HAV

Globally, HAV affects 1.4 million people annually. In many regions of South Africa, the incidence of HAV is strongly correlated with poor socioeconomic conditions and limited access to safe water and inadequate sanitation contributing to the endemic nature of the disease where up to 80 per cent of children are anti-HAV IgG-positive by between 11 and 13 years⁷⁻⁹.

With environmental stability being the seventh Millennium Development Goal (MDG) to be achieved by 2015, 64 per cent of those in sub-Saharan Africa now have access to an improved drinking water source⁵. In South Africa, although access to safe water and sanitation has improved, significant numbers of people are still reliant on unimproved, potentially faecally contaminated water.

There is a highly effective HAV vaccine available that imparts long-term immunity. This HAV vaccine is not part of South Africa's Expanded Programme on Immunisation (EPI) since HAV is usually a self-limiting subclinical illness in young children in endemic regions. However, there are no recent South African seroprevalence studies and with changing socioeconomic demographics as well as more integrated societies in South Africa, the epidemiology of HAV may be in transition towards a lower HAV endemicity level and a potential increase in symptomatic infections.

HEV

Global infections of HEV are estimated to reach around 20 million cases annually. Documented seroprevalence rates in South Africa range between two and 29 per cent, suggesting that HEV is endemic in South Africa¹⁰. However, no epidemics have occurred in South Africa. HEV is enterally transmitted via faecal-oral (Genotypes 1 and 2) and zoonotic (Genotypes 3 and 4) routes of transmission. Ensuring access to safe water and food supplies and adequate sanitation is important to prevent outbreaks related to HEV Genotype 1 and 2 infections.

2.2 Epidemiology of Parenteral Hepatitis Viruses

HBV

The global burden of HBV is significant and it is estimated that one third of the world's population (about two billion people) have been infected with HBV at some point in their lives; and of these 257 million people are chronically infected⁶. One million people die annually from HBV and its associated complications. HBV is endemic in South Africa, resulting in a significant burden of clinical disease as a result of the progression to cirrhosis and the development of the complications of liver failure or hepatocellular carcinoma. There is a 15 to 25 per cent risk of dying from HBV-related liver diseases¹¹.

HBsAg seroprevalence varies geographically between two and 20 per cent with Asia, sub-Saharan Africa, Southern Europe and Latin America having the highest seroprevalence rates. The estimated HBsAg prevalence in South Africa prior to universal HBV immunisation (administered at 6, 10 and 14 weeks) ranged between 0.2 and 9.6 per cent with evidence of HBV past exposure (HBsAg-negative, anti-HB IgG core positive) between five and 76 per cent. Seroprevalences differed between genders, ethnic groups and between rural and urban areas¹²⁻¹⁴.

In a recent systematic review based on observational studies performed in the general population amongst blood donors, healthcare workers and pregnant women between 1965 and 2013, South Africa had an estimated 6.7 per cent HBsAg seroprevalence, i.e. high intermediate endemicity with an estimated 3 445 477 individuals infected with HBV based on 18 studies and 136 356 participants¹⁵.

South Africa has not introduced compulsory maternal HBsAg screening nor an HBV birth dose vaccine and has had no catch-up HBV immunisation programme (e.g. Taiwan HBV immunisation programme). The aggressive HBV immunisation programme proved exemplary in Taiwan, where universal immunisation, introduced in 1984, together with a catch-up immunisation programme and improved maternal screening, resulted in a decrease in the prevalence of HBsAg-positivity in children aged younger than 15 years from 9.8 per cent in 1984 to 0.7 per cent in 1999^{16,17}. Furthermore, the prevalence of hepatocellular carcinoma (HCC) in children aged between six and nine years in Taiwan decreased from 5.2 cases per million population in 1984 to 1.3 per million in the first immunisation cohort^{18,19}. Apart from healthcare workers, there has been no targeted immunisation of high-risk groups in South Africa.

Despite the documented success of the introduction of HBV immunisation into the EPI in April 1995, with overall seroprevalence of HBsAg declining from 12.8 per cent to three per cent in some studies in the pre-HIV era 20-24, recent studies have shown that HBsAg prevalence in adults ranges from three to 25 per cent. The highest rates are documented in HIV-infected adults 25-30. HIV/HBV co-infection also increases the potential risk of perinatal HBV transmission and is associated with a more aggressive natural history of chronic HBV³¹. A recent key population surveillance study (sample of 3 500 individuals) in people who inject drugs, men who have sex with men (MSM) and sex workers conducted in seven cities in South Africa showed an average of four per cent HBsAg-positivity³².

A retrospective seroprevalence study from Kwazulu-Natal in infants younger than 18 months revealed a 10 per cent overall HBV seroprevalence: 13 per cent (21/161) in HIV-positive infants compared to 7.5 per cent (12/161) in HIV-negative infants despite universal HBV immunisation³³.

HBV endemicity is established in early childhood with HBsAg seroprevalence studies showing no difference between children aged between five and nine years and adults³⁴. In South Africa, in order to eliminate HBV, which is an entirely vaccine-preventable disease, it is essential to prevent the neonatal and early childhood acquisition. This requires the introduction of the maternal HBsAg screening, consideration of Tenofovir in the third trimester of pregnancy to prevent MTCT, administration of HBV birth dose vaccine as recommended by the WHO and the immunisation of high-risk adults⁴⁶.

HCV

Globally, an estimated 71 million people are infected with HCV⁵. Most HCV infections are in North and West Africa; and East and Central Asia. Each year, approximately 704 000 people die from HCV-related liver diseases. HCV is parenterally transmitted with the well-recognised modes of HCV transmission typically being prior (usually pre-1992) blood and blood product exposure or injecting drug use. Other modes of transmission have included percutaneous exposure via unsafe injection practices particularly among PWID; inadequately sterilised medical equipment; needle stick injuries in healthcare workers, body piercings and traditional scarification; sexual transmission; and MTCT. HIV and HCV have common routes of transmission, and it is estimated that globally, 2.3 million persons are HIV/HCV co-infected with a prevalence notably higher in MSM and PWID.³⁶

HCV seroprevalence and identifiable high-risk factors in South Africa are poorly understood and characterised. Previous data suggested a seroprevalence in urban blood donors of 0.01 to 2.6 per cent (low risk), with a higher rate in the rural population (3.8 per cent)³⁵ and recent studies confirm higher prevalences in high-risk key populations^{37,38}. Recent studies have confirmed a high HCV burden among people who use drugs, including people who inject drugs. A 2016/2017 study among 3 500 high-risk key populations (sex workers, men who have sex with men, people who use/inject drugs) across seven South African cities identified an HCV viraemic prevalence of 13 per cent, highest among PWID (44 per cent n=939) ranging from 33 per cent in Durban to 69 per cent in Pretoria³². HCV prevalence among people who use drugs, but had not injected in the previous year was eight per cent (n=224)³². A subsequent bio-behavioural survey conducted in 2017 found HCV viraemic prevalence of 63 per cent in Cape Town (n=348) and 93 per cent in Pretoria (n=544) using respondent driven sampling methodology. Robust national population size estimates of PWID are lacking, but cited as between 67 000 and 75 000^{39,40}. A robust, multi-method assessments of PWID in 2017 estimated the number of PWID to be 4 500 in Pretoria and 1 500 in Cape Town (personal communication with Prof. Tim Lane).⁴¹

South Africa is a “pangenotypic” country with genotypes 1 to 5 occurring. Genotype 5a was first identified in South Africa and is a unique and prevalent genotype⁴². The most prevalent genotypes from the 2017 key population surveillance study (n=413) were type 1a (73 per cent) and 3a (15 per cent) and no

type 5 identified. With the advent of the new DAAs, sustained virological responses (SVR) of more than 90 per cent are now achievable for all genotypes and for almost all patient groups: Treatment naïve and experienced patients, cirrhotic patients, HIV/HCV co-infection and liver transplant recipients. An SVR equates with a cure and improves both liver-related and all-cause mortality in non-cirrhotic and cirrhotic patients. All HCV infected patients are now candidates for DAA treatment. Although, DAAs are not yet registered in South Africa, they are obtainable via a SAHPRA [former Medicines Control Council (MCC)] Section 21 application process for named patients. Registration is anticipated in 2019.

In order to eliminate HCV in South Africa, it will be essential to enhance seroprevalence surveillance and increase screening among high-risk groups, particularly PWID and provide easy, affordable, appropriate and accessible care for HCV-infected individuals.

HDV

HDV is a defective RNA virus that is dependent on HBV for its survival. In South Africa, seroprevalence rates are low, ranging from 0 to 0.6 per cent⁴³. HDV co-infection should be considered in HBV-infected individuals, particularly from countries north of the equator where HDV seroprevalence is high⁴⁴ and present with a clinical deterioration not due to HBV.

2.3 Rationale for The Consolidated Viral Hepatitis Guidelines

The 69th World Health Assembly (WHA) in May 2016 adopted the first viral hepatitis global health sector strategy for 2016 to 2021⁴⁵. The strategy addresses all five hepatitis viruses (A, B, C, D and E), with a particular focus on HBV and HCV, owing to the relative public health burden they represent. The strategy outlines a way ahead, and provides a vision of a world where viral hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and effective care and treatment; a goal of eliminating viral hepatitis as a major public health threat by 2030; and targets that seek to reduce the incidence of hepatitis from the current six to 10 million new infections to 0.9 million infections by 2030, and to reduce the annual deaths from chronic viral hepatitis from 1.4 million to less than 0.5 million by 2030.

Achieving these targets will require a radical change in the hepatitis response, and will mean that hepatitis is elevated to a higher priority in public health responses aiming for a:

- 90 per cent reduction in new cases of chronic HBV and HCV by 2030
- 65 per cent reduction in HBV and HCV deaths by 2030
- 80 per cent of eligible persons with chronic HBV and HCV infections treated by 2030

2.4 Target Audience

These guidelines are aimed at equipping health workers working at primary, secondary and tertiary levels of care in the medical management of individuals with viral hepatitis in South Africa.

GUIDING PRINCIPLES

CHAPTER

3



3.1 Principles Guiding The Approach to Elimination of Viral Hepatitis¹

The ultimate elimination of viral hepatitis requires an effective partnership between:

- affected communities
- professional, civil society and community-based organisations
- government
- researchers and health professionals

This partnership needs to be characterised by consultation, cooperative effort, respectful dialogue, resourcing and action to achieve the goal of the strategies. This includes leadership from the national Department of Health and the appropriate allocation of funds at both national and provincial level as well as the full cooperative efforts of all members of the partnership to implement agreed strategies of elimination.

These guidelines were developed to:

- inform healthcare workers in both the public and private sectors (at all levels of care) about the disease, its epidemiology in South Africa and the current methods of diagnosis and therapy
- strengthen the healthcare response to viral hepatitis
- empower communicable diseases workers and stakeholders to make informed decisions regarding appropriate and cost-effective interventions

3.2 Access to Care and Health Equity

Viral hepatitis is likely to have a disproportionate impact on certain groups within the South African society, including those with low socioeconomic status, those with poor access to healthcare, refugees and marginalised groups such as PWID, MSM, sex workers and inmates in correctional centres. In addition, co-morbidities such as HIV, TB and alcohol use are prevalent in South Africa and further add to the clinical burden of liver disease. In order to promote equity in health and to reduce the burden of disease among these groups, several human rights issues

such as stigma, discrimination, social exclusion and poor access to services need to be addressed from a social justice perspective.

It is important that efforts are undertaken to ensure that the relevant workforce in each setting understands the issues affecting at-risk populations, and how to effectively engage with and support them. All South Africans should have access to diagnosis, preventative measures and treatment for viral hepatitis. Finally, the design and provision of culturally appropriate information about viral hepatitis, and its prevention, treatment and care options are crucial to overcoming the barriers caused by poor health literacy in many settings within South Africa.

3.3 Health Systems Strengthening and Integration

A health system strengthening approach seeks to increase the capacities of individuals, systems and organisations that constitute the healthcare system. The national viral hepatitis plan will include a set of integrated and comprehensive actions to be implemented at a national level under defined objectives to be achieved within a specific time frame with an embedded monitoring and evaluation system. Of paramount importance is integration of disease-specific planning in national health sector planning, and integration of disease-specific services within the currently existing health services e.g. HIV clinics and a decentralised, community-based and largely preventative approach. This is the only way to maximise synergies, avoid duplication, achieve sustainability and promote cost-effectiveness.

The main areas to be addressed in the process of health systems strengthening are:

a) effective and transparent leadership and governance involving:

- strong political commitment, enabling national policy, leadership and accountability, a coordinated response towards the elimination of viral hepatitis
- decriminalisation and destigmatisation of key populations: PWID, MSM

b) fair and sustainable financing mechanisms addressing:

- implementation of diagnostic services, assessment of disease severity (AST to platelet ratio index [APRI] score, Fibroscan), prevention and treatment options for viral hepatitis
- equitable access to these services for those in need, but who cannot afford the required services

c) human resources for health

- an adequate number of appropriately trained workers to deliver high-quality, culturally competent interventions

d) essential medicinal products, infrastructure and technology

- sustained procurement and supply of cost-effective medicines, commodities and tools for prevention, diagnosis and treatment of viral hepatitis

e) service delivery

- delivery of comprehensive viral hepatitis interventions to those individuals that need them in all regions of South Africa, thereby ensuring appropriate linkage to care
- integration of community-based multipurpose healthcare facilities such as primary level healthcare centres, or through HIV/sexually transmitted infection clinics and antenatal services to improve access to care for patients with viral hepatitis
- focused responses towards populations and geographical areas with a disproportionate burden of diseases and risk for infection and onwards transmission e.g. PWID, MSM and prisoners

f) a functioning health information system for monitoring, evaluation and for informing decision-making

- timely analysis and dissemination of reliable information regarding changing epidemiology, potential epidemics, access to care and outcomes of viral hepatitis prevention and treatment strategies

HEPATITIS A (HAV)

CHAPTER

4



4.1 Introduction

HAV is the most common cause of acute viral hepatitis in many parts of the world, including South Africa. The virus is endemic in southern Africa, however the true burden of disease is unknown. Localised and more widespread community and institutional outbreaks occur in South Africa and frequently raise challenges for control, given limited resources. In addition, South Africa has a unique epidemiological pattern of disease with variations in rates of infection across different socioeconomic groups and provinces. In areas where socioeconomic standards are poor and there is inadequate access to clean water and sanitation, infection occurs early in life and produces mostly mild or asymptomatic disease. In these areas, rates of infection are higher, but morbidity considerably less and most people in such communities are immune by adolescence.

HAV characteristics:

- HAV is a picornavirus
- non-enveloped, single-stranded RNA virus
- only one serotype but can be grouped into four human genotypes (I, II, III, VII) using RNA sequencing¹⁻⁴.

- HAV persists in the environment for prolonged periods, but is inactivated by boiling (at more than 85°C for one minute) and on exposure to household bleach (1:100 dilution in tap water)³.

4.2 Transmission of Hav:

- faecal-oral transmission
 - person-to-person spread
 - anal-oral sexual transmission also occurs (MSM)
 - ingestion of faecally contaminated food or water
- transmission via blood products has been described
- no evidence of transmission by saliva

4.3 Groups at Risk for Hav:

- people who are household/sexual contacts of infected individuals
- preschool children attending day care centres, their parents and siblings
- employees of day care centres

- volunteers working with children
- healthcare workers
- MSM
- residents and employees of closed communities (institutions): Personal hygiene of residents is compromised, residents are incontinent or wear nappies
- international travellers from non-endemic to endemic regions
- refugees residing in temporary camps following catastrophes or displacement
- individuals with chronic liver disease: Not at increased risk for infection, but are at risk for severe disease
- raw sewage workers
- food handlers: Not at higher risk for infection, but pose a high risk of transmission

4.4 Clinical Presentations of HAV

The incubation period for HAV is 15 to 50 days (average = 28 days). Individuals are most infectious two weeks prior to the onset of jaundice and infectivity then begins to fall, but most individuals will remain infectious for one to two weeks following the onset of jaundice¹. However, prolonged shedding of the virus in stool has been documented, thus increasing the period of infectivity⁶. HAV infection is usually a self-limiting disease, there is no chronic carrier state and immunity following infection is considered to be life-long. The clinical presentation may vary and is influenced by factors such as age, changing socioeconomic demographics and the presence of underlying risk factors for severe disease^{5,6}.

Mortality rates:

- overall mortality: 0.3 per cent in icteric cases
- 0.1 per cent in those younger than 15 years
- increased mortality in older patients: One to two per cent in those older than 40 years

4.4.1 The different clinical presentations include:

a) asymptomatic infection

- most children younger than four years are completely asymptomatic

b) symptomatic hepatitis without jaundice

- children aged between four and six years: 90 per cent anicteric

c) symptomatic hepatitis with jaundice

- individuals older than 15 years, 40 to 70 per cent present with jaundice⁴
- prodromal illness precedes the jaundice in 85 per cent of individuals
 - o loss of appetite, fatigue and malaise
 - o flu-like symptoms: Fever, cough, coryza, pharyngitis, photophobia and headache
 - o arthralgia and myalgia
 - o nausea, vomiting and abdominal discomfort
 - o diarrhoea
- prodromal symptoms usually decline with the onset of jaundice

d) rare extrahepatic presentations

- aplastic anaemia
- cutaneous necrotising vasculitis
- mononeuritis multiplex
- Guillane Barré Syndrome
- transverse myelitis

4.4.2 Complications of HAV

a) fulminant HAV

- rare complication
- more common in older adults and patients with chronic liver disease
- occurs during the first six to eight weeks of illness
- jaundiced, often nauseous and vomiting, develop hepatic encephalopathy and coagulopathy and can rapidly progress to life-threatening cerebral oedema
- severity of the liver injury is often not appreciated in children younger than five years who present with acute HAV
 - o jaundice is frequently the only initial clinical symptom
 - o hepatic encephalopathy is often a late and terminal presentation
- mortality rates are 70 to 95 per cent
- almost 100 per cent mortality in individuals older than 50 years of age^{1,4}

- liver transplantation: 65 per cent one year survival rates

b) relapsing HAV

- occurs in three to 20 per cent of patients
- four to 15 weeks after the initial symptoms have resolved
- characterised by relapse of symptoms and liver enzyme derangement
- positive anti-HAV IgM
- HAV is shed in the stool, rendering patients infectious
- increased risk in adults who return to work or strenuous exercise too early
- usually resolves within two to six months
- full recovery may take six to 12 months
- multiple relapses may occur over 12 months
- extra hepatic manifestations more common: Vasculitis, nephritis, arthritis
- no chronic carrier state^{1,4}

c) cholestatic hepatitis

- persistent severe jaundice and associated pruritus
- minor elevation of transaminases
- synthetic function normal
- positive anti-HAV IgM
- biopsy: Centrilobular cholestasis
- jaundice may persist for three months or more
- full recovery over time^{1,4}
- steroids should not be used to treat

4.5 Diagnosis of HAV

Viral hepatitis cannot be distinguished clinically or biochemically, but requires a serological diagnosis. Elevated transaminases (the ALT and AST are usually 10 to 100 times to the upper limit of normal) confirm the presence of hepatitis.

- acute HAV: Positive anti-HAV IgM
- previous exposure to HAV or post HAV-immunisation: Positive anti-HAV IgG

Most patients with acute HAV will have a positive anti-HAV IgG at initial presentation.

The latter will persist long term and provide lifelong immunity. Anti-HAV IgM levels will decline over three to six months following infection.

4.6 Prevention of HAV

4.6.1 General control measures to prevent faecal-oral transmission:^{10,11}

- provide adequate water and sanitation
- promote good hand hygiene
- regularly inspect food establishments and compliance with safe food handling practices
- strictly adhere to standard infectious and contact precautions. This is usually sufficient to prevent the spread of infection in healthcare facilities and institutions

4.6.2 Specific control measures

Pooled intramuscular immunoglobulin (human normal immunoglobulin for intramuscular use - HNIG)

- pooled intramuscular HNIG provides passive immunity to HAV
- effective for both pre- and post-exposure prophylaxis when administered correctly
- pre-exposure prophylaxis: 0.02 ml/kg IMI (three months protection) or 0.06 ml/kg IMI four to six months for continued exposure
 - recommended for travellers at high risk for severe disease and/or younger than two years or older than 40 years and departing in less than two weeks
- post-exposure prophylaxis: 0.02 to 0.04 ml/kg IMI, preferably within 72 hours of exposure
 - can be administered up to 14 days post-exposure
 - administration up to four weeks post-exposure may reduce disease severity in high-risk contacts and immunocompromised individuals

HAV vaccines

- effective for both pre- and post-exposure prophylaxis
- HAV vaccine is the method of choice for pre-exposure prophylaxis
 - single dose with a booster at six to 12 months: 95 per cent efficacy after two doses

- with at least 20 years protection, if not lifelong
- special considerations for HAV vaccine use:
 - o pregnancy: single dose of HAV vaccine can be given
 - o infants: HAV vaccine not licensed for use in children younger than one year
 - o immunosuppressed individuals (including HIV positive and transplant patients)
 - inactivated vaccine and safe for use
 - responses to vaccine may be reduced in advanced immunosuppression, including HIV
 - a third booster may need to be considered six to 12 months after the first dose
- in South Africa many adults are HAV immune and it will be cost effective to screen healthcare workers prior to HAV immunisation
- HAV immunisation can be given as soon as travel is considered (regardless of time to travel)
 - o healthy travellers aged between one and 40 years
- HAV immunisation should ideally be administered not later than two weeks from departure and preferably four weeks prior to departure
- children younger than five years have a low risk for symptomatic disease if infected
 - o prevention of infection in these children may protect adult contacts
- post-exposure prophylaxis
 - o the HAV vaccine is not inferior to HNIG if administered within 14 days of exposure in healthy individuals aged between one and 40 years^{12,13}
 - o administer single antigen vaccines only - combination vaccines have reduced immunogenic content
 - o immunoglobulin should be offered post exposure to children younger than two years, adults over 40 years and any immunocompromised individual

4.6.3 Response to HAV outbreaks: NOTIFY local outbreak response team according to outbreak response guidelines (epidemic preparedness and response)

4.7 Treatment of HAV:

- no specific antiviral treatment for HAV infection
- treatment is supportive with intravenous injection (IVI) fluids if persistent vomiting
- hospitalise patients with severe symptomatic disease - Jaundice and associated nausea and vomiting
- liver transplantation - should be considered in patients presenting with fulminant liver failure
- hospitalised cases do not usually require isolation unless they are faecally incontinent
- sanitary disposal of faecal waste and strict hand hygiene is essential
- no special diet is required, but it is recommended that patients should avoid alcohol and the use of any other hepatotoxic drugs
- exclusion from work and school for two weeks after the onset of jaundice, provided the AST and ALT levels are less than 100 U/L
- transaminases should normalise before adults return to fulltime work
- if adults return to work too early, they are at increased risk of developing relapsing hepatitis and this significantly delays return to fulltime work
- patients can return to active sport or strenuous activity once AST and ALT levels have normalised
- adults should return to fulltime work before returning to sport

4.8 Diagnostic, Primary, Secondary and Tertiary Levels of Care

4.8.1 Diagnosis:

- all levels of care: Anti-HAV IgM and anti-HAV IgG

4.8.2 Assessment of clinical severity:

- all levels of care: Liver profile and INR

4.8.3 Prevention:

- all levels of care
 - screening and administration of HAV vaccine or HNIG as indicated to contacts
 - administration of HAV vaccine to high-risk groups

4.8.4 Treatment options:

- primary level care: Uncomplicated cases
- secondary level care:
 - symptomatic cases with jaundice, nausea and vomiting; but no encephalopathy and INR of less than two: Intravenous fluids and monitoring of synthetic function
 - Cholestatic hepatitis: Exclude other causes of cholestasis
 - Relapsing HAV: Exclude other causes of hepatitis, especially autoimmune hepatitis. Refer to tertiary level of care if other causes of liver dysfunction identified or there is more than one relapse or clinical deterioration
- tertiary level care:
 - symptomatic cases not settling on supportive care
 - acute liver failure (jaundice, encephalopathy and INR of more than 1.5): Preferably with potential access to liver transplantation
 - recurrent relapses of HAV





HEPATITIS B (HBV)

CHAPTER

5



5.1 Introduction

HBV is an entirely vaccine-preventable disease. Patients with chronic HBV infection have a 15 to 40 per cent risk of developing cirrhosis, liver failure and/or HCC, and a 15 to 25 per cent risk of dying from HBV-related liver diseases¹.

In a recent systematic review based on observational studies performed in the general population amongst blood donors, healthcare workers and pregnant women between 1965 and 2013, South Africa had an estimated 6.7 per cent HBsAg seroprevalence i.e. high intermediate endemicity². More recent studies have shown that HBsAg prevalence in adults ranges from three to 25 per cent, with the highest rates in HIV-infected adults³⁻⁸. HIV/HBV co-infection increases the potential risk of perinatal HBV transmission and is associated with a more aggressive natural history of chronic HBV⁹. HBV endemicity is established in early childhood with HBsAg seroprevalence studies showing no difference between children aged between five and nine years and adults¹⁰.

5.2 HBV Genotypes

HBV is an enveloped partially double-stranded DNA virus belonging to the *Hepadnaviridae* family and is able to survive in dried blood for longer than one week. Globally, there are 10 genotypes (A-J)^{11,12} and the HBV genotypes influence the spectrum of disease, the risk of hepatocellular carcinoma and the response to antiviral treatment.¹²⁻¹⁴ Genotypes A, D and E are the predominant HBV genotypes in Africa.^{12, 15}

In South Africa, Genotype A (subtypes A1 and A2) predominates with subtype A1 occurring in up to 97 per cent of rural Africans^{15,16}. Varying amounts of Genotype D (less than 10 per cent) and E are reported, and odd cases of imported Genotypes B and C have been encountered, usually in patients from South-East Asia¹⁷.

Genotype A predisposes to chronicity with an elevated risk of hepatocellular carcinoma, but has an increased response rate to interferon therapy. The relative risk of HCC is four times higher in black South Africans with Subgenotype A1 than non-A¹⁶.

Genotype D has a reduced response rate to interferon therapy, and acute infection is associated with increased risk of acute liver failure.

5.3 Transmission of HBV

HBV is transmissible via perinatal, percutaneous or sexual exposure to HBV-infected body fluids including serum, saliva, semen and vaginal fluids (**Table 2**). All HBsAg-positive individuals are infectious, but HBeAg-positive individuals are more infectious as they have higher rates of HBV replication.

HBV IS A 100 TIMES MORE INFECTIOUS THAN HIV AND 10 TIMES MORE INFECTIOUS THAN HCV. HBV IS PREVENTABLE THROUGH IMMUNISATION.

Table 2: Routes of transmission

Routes of transmission			
Horizontal	Perinatal	Sexual	Percutaneous
<p>Occurs mainly through accidental exposure to infected blood and body fluids. Main route of HBV transmission in South Africa.</p> <p>Ages: Mainly less than five years old¹⁷⁻²⁰ from unapparent percutaneous exposure to infected blood or body fluids from:</p> <ul style="list-style-type: none"> o infected older siblings playmates - childcare centres and schools • Sharing of personal items: <ul style="list-style-type: none"> o toothbrushes o razors o hair clippers • Traditional scarification practices • Female genital mutilation 	<p>Occurs at birth.</p> <p>High viral load (>200 000 IU/ml) increases risk of transmission^{7,21-25}</p> <p>Risk of chronic HBV infection at six months in the absence of any intervention:</p> <ul style="list-style-type: none"> 70 to 95 per cent in babies born to HBeAg-positive mothers less than 10 per cent in babies born to HBeAg-negative mothers unless HIV co-infected or HBV DNA >200 000 IU/ml • Risk of transmission from women acutely infected in first or second trimester is low, but increases to approximately 60 per cent if acute infection occurs in the third trimester • Maternal HIV/HBV co-infection increases risk of perinatal transmission up to 2.5 fold^{8,27-31} 	<p>Efficiently transmitted sexually.</p> <p>Exact risk of transmission per sexual contact is unknown</p> <p>A large number of non-immune adults remain at risk of sexually acquired HBV infection</p> <ul style="list-style-type: none"> o No adult HBV vaccine catch-up programme 	<p>Risk of transmission from needle stick injury is:³²</p> <p>30 to 60per cent from exposure to HBeAg-positive blood</p> <ul style="list-style-type: none"> • 10 to 30 per cent with HBeAg-negative blood • Injection drug use poses a high risk of HBV transmission

5.4 Clinical Presentations of HBV

The clinical manifestations of acute and chronic HBV infections are variable. (Table 3)

The risk of chronicity is dependent on age of acute infection:

- 70 to 95 per cent for infants exposed perinatally (HBeAg-positive mother)
- 25 to 50 per cent for children aged between one and five years
- six to 10 per cent for five to 20 years
- one to three per cent for adults older than 20 years

Acute HBV:

- clinical manifestations of acute HBV depend on the age of acquisition (incubation period ranges between one to four months)
 - anicteric, asymptomatic condition in about 70 per cent individuals, especially if infected at birth or during early childhood
 - symptomatic, icteric illness in 30 per cent and fulminant hepatitis in 0.5 to one per cent
- acute HBV infection in adolescents and adults is usually symptomatic, has various phases and is usually associated with full clinical recovery

Table 3: Acute, fulminant and chronic HBV infection

Acute HBV infection			
Early prodromal phase	Preicteric phase	Icteric phase	Convalescent phase
<p>In symptomatic cases: The illness may be heralded by a serum sickness-like syndrome which precedes jaundice by 14 to 21 days and disappears with the onset of jaundice:</p> <ul style="list-style-type: none"> • fever • urticaria • arthralgia and arthritis 	<p>An abrupt or insidious onset of non-specific constitutional symptoms or an influenza-like illness may occur:</p> <ul style="list-style-type: none"> • malaise and fatigue • myalgia • anorexia, nausea, vomiting • epigastric or right upper quadrant discomfort <p>Physical examination:</p> <ul style="list-style-type: none"> • may be unremarkable or may reveal a tender hepatomegaly and splenomegaly • hepatosplenomegaly is usually mild (liver palpable two to three centimetres below the costal margin and spleen tipped) 	<ul style="list-style-type: none"> • With the onset of jaundice approximately a week after the preicteric phase; fever and constitutional symptoms subside. • Anorexia, nausea and vomiting may transiently worsen. • The presence of dark urine and pale stools often raises the clinical concern of obstructive jaundice. • Pruritic scratch marks may be present, if jaundice is severe or prolonged • Weight loss is common. 	<ul style="list-style-type: none"> • Jaundice tends to wane rapidly over days in young individuals, but tends to persist longer (six weeks or more) in adults. • The preicteric phase symptoms disappear, pruritis abates and the hepatosplenomegaly gradually resolves.

Fulminant HBV

<p>Syndrome is characterised by:</p> <ul style="list-style-type: none"> • jaundice • hepatic encephalopathy • Coagulopathy (INR is more than 1.5) Occurring within eight weeks of the onset of the acute illness 	<p>Complications of acute liver failure include:</p> <ul style="list-style-type: none"> • development of acute portal hypertension • hepatorenal syndrome • cardiorespiratory dysfunction • metabolic disturbances, including hypoglycaemia • raised intracranial pressure • life-threatening cerebral oedema • susceptibility to bacterial and fungal infections 	<ul style="list-style-type: none"> • Survival rates: 12 to 36 per cent • Liver transplantation: Excellent outcomes if HBV DNA is undetectable and appropriate antiviral prophylaxis given
---	--	---

Chronic HBV

<p>Persistence of HBsAg-positivity for six or more months:</p> <ul style="list-style-type: none"> • frequently a clinically silent disease • often identified incidentally during blood donation screening or during routine health/insurance examinations <p>Physical examination</p> <ul style="list-style-type: none"> • may reveal no or few signs • peripheral stigmata of chronic liver disease: spider naevi and palmar erythema may be present • signs of portal hypertension: Distended abdominal veins, caput medusa, ascites and splenomegaly may be present depending on the phase of chronic infection • concern for HCC: Weight loss, jaundice and rapidly enlarging, tender, hard nodular liver together with a systolic bruit 	<p>Natural history:^{33,34,39, 40}</p> <ul style="list-style-type: none"> • there are five different phases of chronic infection (Figure 1) <ul style="list-style-type: none"> ○ HBeAg-positive chronic HBV infection (immune tolerant) ○ HBeAg-positive chronic HBV (immune clearance) ○ HBeAg-negative chronic HBV infection (immune control) ○ HBeAg-negative chronic HBV (immune escape) ○ Occult HBV • natural history of HBV is dynamic and complex, and may progress non-linearly through the five different phases <ul style="list-style-type: none"> ○ not every person with chronic HBV will evolve through all the phases ○ some persons will be in the “gray zone” where their ALT and HBV DNA levels fall into different phases³⁴ ○ longitudinal follow up of ALT and HBV DNA levels is necessary to establish the phase of chronic infection³⁴ • HBV DNA levels, ALT levels and HBeAg status are important determinants of the risk of cirrhosis and need for treatment^{35, 36} 	<p>Outcomes of untreated chronic HBV:</p> <ul style="list-style-type: none"> • HBsAg clearance (whether spontaneous or after antiviral therapy) reduces the risk of hepatic decompensation and improves survival • approximately 0.5 per cent of persons with HBeAg-negative infection (immune control phase) will spontaneously clear HBsAg annually and develop anti-HBs • cumulative five-year incidence of cirrhosis: eight to 20 per cent • amongst those with cirrhosis: <ul style="list-style-type: none"> ○ five-year cumulative risk of hepatic decompensation: 20 per cent ○ risk of HCC is two to five per cent^{1,40,41} • HBV DNA more than 2 000 IU/ml, HBeAg status and cirrhosis are key predictors of HCC risk³⁵⁻³⁸. • cumulative five-year survival for compensated cirrhosis is 85 per cent, and for decompensated cirrhosis is 14 to 35 per cent⁴²
---	--	---

Extrahepatic manifestations

Acute infection:


- serum sickness-like syndrome, more common in young adults

Chronic infection (10 to 20 per cent of patients):

- polyarteritis nodosa
- membranous glomerulonephritis
- membrano-proliferative glomerulonephritis

Figure 1: Phases of chronic HBV infection ^{33,34}

Phase of chronic HBV infection¹



EASL nomenclature²	HBeAg - positive chronic HBV infection	HBeAg - positive chronic hepatitis B	HBeAg - negative chronic HBV infection	HBeAg - negative chronic hepatitis B
Phases of infection	Immune Tolerant	Immune Clearance	Immune Control	Immune Escape

1. Lok A, et al. J Hepatol 2017; 67: 847-61;

2. EASL CPG HBV. J Hepatol 2017; 67:370-98

It is important to establish the phase of chronic infection as this determines the risk of cirrhosis and HCC, the frequency of follow up and the need for treatment.

Even if the individual clears HBsAg, the hepatocyte still harbours intranuclear covalently closed circular DNA (cccDNA) which is the transcriptional template for the viral messenger RNAs (mRNAs)³⁹ and this determines the chronicity and the inability to cure HBV with present day therapies. HBV DNA can also integrate into the hepatocyte genome during chronic infection. This integrated DNA plays no role in viral replication, but plays an important and ill-defined role in the development of HCC.

5.5 Hepatocellular Carcinoma

In South Africa, HCC occurs more commonly in rural-born and rural-living black men.⁴⁵ HCC accounts for one-fifth of cancers amongst men and is an aggressive tumour with coexisting cirrhosis occurring in only 60 per cent of patients with chronic HBV.

- risk factors:
 - black race
 - HBV: Genotype A, subgenotype A1 and occult HBV
 - HBV T1762 and A1764 basal core promoter mutations
 - aflatoxin B1 exposure, dietary iron overload, alcohol
 - HCV co-infection
 - HIV co-infection

- management options in advanced HCC are often extremely limited given that complex hepatobiliary surgery, transplantation, interventional radiology and sorafenib are only available in a very limited number of centres
- mean five-year survival rate varies between 25 and 60 per cent depending on tumour resectability
 - non-resectable tumours: Mean survival as low as five months
 - HCC screening: Six-monthly serum AFP and liver ultrasound examinations recommended:
 - all chronically HBV-infected individuals older than 30 years
 - all cirrhotics regardless of age
 - individuals with a family history of HCC regardless of age

In an ideal clinic setting, the combination of serial serum AFP estimation and liver ultrasound examinations has 70 per cent detection sensitivity for HCC⁴⁶

5.6 Diagnosis of Acute and Chronic HBV ^{33,34,47-49}

HBV surface antigen (HBsAg) is the key marker in the diagnosis of HBV infection.

Careful interpretation of transaminases, HBV serological markers, HBV DNA levels and non-invasive markers of fibrosis or liver biopsy helps to distinguish between acute infection, resolution of acute infection, fulminant hepatitis, different phases of chronic infection and immunisation status.

5.6.1 HBV serological markers

Table 4: HBV serological markers

HBV serological markers	
HBsAg	<ul style="list-style-type: none"> • screening marker of infection • first serological marker to appear • may be absent during the window phase of acute infection and in fulminant hepatitis • surrogate marker for transcriptionally active cccDNA • infection is considered chronic if HBsAg persists for more than six months

HBeAg	<ul style="list-style-type: none"> • indicates active replication of virus • absent or low in pre-core or basal core promoter mutations
anti-HBc total (HBcAb total)	<ul style="list-style-type: none"> • includes both IgG and IgM HB core antibody
IgG anti-HBc	<ul style="list-style-type: none"> • most sensitive marker of past exposure to HBV as anti-HBs may be undetectable if HBV infection was acquired in childhood, as is common in South Africa
IgM anti-HBc	<ul style="list-style-type: none"> • marker of acute infection or reactivation • strongly positive in acute infection and possible low positivity in HBV reactivation or flare ⁵⁰
anti-HBs (HBsAb)	<ul style="list-style-type: none"> • recovery and/or immunity to HBV • detectable after immunity is conferred by HBV immunisation
anti-HBe (HBeAb)	<ul style="list-style-type: none"> • HBeAg to anti-HBe seroconversion and usually indicates that the virus is no longer replicating • also present in HBeAg-negative chronic HBV with active replication due to precore or basal core promoter mutants

5.6.2 Virological evaluation of HBV infection:

- serum HBV DNA quantification
- HBV genotype testing: Useful when deciding on potential efficacy of interferon therapy (tertiary care level)
- HBV resistance testing (tertiary care level)

5.6.3 Role of HBV DNA testing:

- differentiates between occult HBV (HBsAg-negative, anti-HBs-negative, IgG anti-HBc-positive, HBV DNA-positive, but less than 200 IU/ml) and resolved infection (HBsAg-negative, anti-HBs-positive, IgG anti-HBc-positive, HBV DNA undetectable)
- differentiates HBeAg-negative chronic HBV (HBV DNA 2 000 or more IU/ml) from HBeAg-negative chronic HBV infection (immune control phase - HBV DNA less than 2 000 IU/ml)

- changes in HBV DNA levels used to monitor response to therapy
- in patients adherent to therapy, increasing HBV DNA levels indicate the emergence of resistant variants - in patients on TDF or TAF that have a high genetic barrier to resistance, need to strongly suspect non-adherence
- HBV DNA levels correlate with disease progression^{35,36}

5.6.4 Interpretation of serological markers, HBV DNA and ALT levels

Table 5: Interpretation of serological markers, HBV DNA and ALT levels

Interpretation of serological markers, HBV DNA and ALT levels	
Successful immunisation	<ul style="list-style-type: none"> • Positive anti-HBs, protective titre more than 10 mIU/ml
Previous exposure to HBV	<ul style="list-style-type: none"> • Positive IgG anti-HBc +/- positive anti-HBs
Acute HBV	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-positive, IgM anti-HBc-positive, elevated ALT
Fulminant HBV	<ul style="list-style-type: none"> • May be HBsAg-negative, but IgM anti-HBc-positive, HBV DNA detectable, elevated ALT with synthetic dysfunction (elevated ammonia and prolonged INR more than 1.5)

Chronic HBV: HBV serology, ALT and HBV DNA levels depends on the phase of chronic infections	
HBeAg-positive chronic HBV infection (immune tolerant phase)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-positive, anti-HBe-negative, high HBV DNA levels (usually more than 200 000 IU/ml, typically more than one million IU/ml) and normal ALT
HBeAg-positive chronic HBV infection (immune clearance phase)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-positive, anti-HBe-negative, HBV DNA 20 000 or more IU/ml, elevated ALT
HBeAg-negative chronic HBV infection (immune control phase)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-negative, anti-HBe-positive, HBV DNA less than 2 000 IU/ml, normal ALT
HBeAg-negative chronic HBV infection (immune escape phase)	HBsAg-positive, HBeAg-negative, anti-HBe-positive, HBV DNA 2 000 or more IU/ml, fluctuating elevated ALT levels, IgM anti-HBc maybe low positive with a flare
Occult HBV infection	HBsAg-negative, anti-HBs-negative, IgG anti-HBc-positive, HBV DNA less than 200 IU/ml, normal ALT

- HBeAg-negative chronic HBV infection (immune control phase)
- occult HBV

c) ensure HBV suppression in acute liver failure

- to prevent recurrence post liver transplantation

d) HIV/HBV co-infection

- dual viral suppression

5.7.2 Endpoints of treatment:

- the ideal endpoint is sustained off-therapy HBsAg loss with/without the development of anti-HBs
- durable suppression of HBV DNA to undetectable or low (below 2 000 IU/ml) levels
- normalisation of ALT
- durable HBeAg loss and seroconversion to anti-HBe in HBeAg-positive disease

5.8 Management of Acute HBV

33,34,48

Treatment is largely supportive:

- more than 95 per cent of immunocompetent adolescents and adults will spontaneously recover, clear HBV and seroconvert to anti-HBs
- infection control measures to prevent secondary transmission especially to sexual partners must be implemented

Pegylated-Interferon therapy is contraindicated:

- exacerbates hepatic necro-inflammation and precipitates acute liver failure, particularly in individuals with synthetic dysfunction

The use of nucleoside/tide analogues such as TDF, TAF, Entecavir and Lamivudine are not routinely advised. Rapid suppression of HBV DNA replication impairs the individual's cellular immune cytotoxic response directed against the infected hepatocytes and promotes chronic infection.

Table 6: Management of acute HBV

NUC therapy currently ONLY recommended in acute infection if:	
<ul style="list-style-type: none"> • Severe disease (rising INR more than two and associated encephalopathy). • Acute liver failure: <ul style="list-style-type: none"> - patients can stabilise and NUCs prevent re-infection of the liver graft • The elderly and immunosuppressed individuals. • HAV, HCV or HDV co-infection. 	<ul style="list-style-type: none"> • Lamivudine should be used in unstable patients at risk of renal impairment: <ul style="list-style-type: none"> - rapidly suppresses HBV viral load - viral resistance does not develop with short term LAM use and dosage can easily be adjusted according to renal function
NUC therapy TDF, TAF, Entecavir and Lamivudine should be continued for:	
<ul style="list-style-type: none"> • three to six months after seroconversion to anti-HBs • 12 months after anti-HBe seroconversion without HBsAg loss • indefinitely, if the patient undergoes liver transplantation 	

5.9 Management Of Chronic HBV

It is important to establish the phase of chronic HBV and the need for anti-viral therapy depending on disease activity, HBV DNA level, the presence of advanced fibrosis/cirrhosis or the use of immunosuppressive therapy.

Fibrosis can be assessed by non-invasive means: APRI or FIB4 score or a Fibroscan.

A liver biopsy is only required if considering Pegylated-Interferon therapy or if assessing the role of other cofactors e.g. non-alcoholic fatty liver disease, alcohol, drugs/toxins and iron overload.^{52,53} These patients should be referred to tertiary level care.

Table 7: Assessment of liver disease prior to therapy ^{33,34,48,49,51-54}

Assessment of liver disease prior to therapy ^{33,34,48,49,51-54}	
Detailed clinical history and physical examination	<ul style="list-style-type: none"> • age and disease duration • complications of chronic HBV • assessment of compliance with follow-up visits and medications is important • family history of HBV infection; and complications of cirrhosis and HCC
Assessment of the severity of the liver disease	<ul style="list-style-type: none"> • full blood count (FBC) and differential count • liver profile: Total bilirubin, conjugated bilirubin, ALT, AST, ALP, GGT <ul style="list-style-type: none"> - aminotransferase levels (ALT and AST) may fluctuate over time - single ALT and AST measurements do not indicate disease activity - ALT levels usually higher than AST, but with disease progression to cirrhosis, AST/ALT ratio may be reversed, but less than two • serum albumin and INR to assess synthetic function • serum creatinine
Look for other co-factors that accelerate fibrosis	<ul style="list-style-type: none"> • viral co-infection: HCV, HDV, HIV • non-alcoholic fatty liver disease and alcohol-related liver disease • iron overload and drug/toxin-induced liver injury
Serological assessment	<ul style="list-style-type: none"> • HBsAg, HBeAg and anti-HBe ± IgM anti-HBc (low positive with a flare) • IgG anti-HBc (if assessing for occult HBV or previous cleared infection) • Anti-HAV IgG to assess need for HAV immunisation • HIV status
Virological assessment	<ul style="list-style-type: none"> • serum HBV DNA quantification • HBV genotype is useful when deciding on potential efficacy of Interferon Rx • precore and basal core promoter mutations help to predict risk of HCC • previous exposure to Lamivudine and concerns re resistance: YMDD mutations can be measured
Alpha fetoprotein	<ul style="list-style-type: none"> • Alpha fetoprotein in the setting of HBV-associated multifocal HCC with a rapid doubling time, remains an important screening and diagnostic tool for HCC in South Africa • may be elevated in a hepatitis flare
Ultrasound of the liver and dopplers	<ul style="list-style-type: none"> • assessment of liver size, contour, echogenicity and presence of focal lesions • assessment of biliary system • assessment of portal vein flow, thrombosis, splenomegaly and splenic varices
Non-invasive tests (NITs) to assess stage of liver disease ^{54,55} NIT results may be impacted by intercurrent diseases that may falsely increase or decrease the scores: ^{54,55}	<ul style="list-style-type: none"> • blood and serum markers for fibrosis (APRI and FIB4) can be measured, or transient elastography (Fibroscan) can be performed to rule out advanced fibrosis and cirrhosis • NITs are validated in adults with chronic hepatitis B (CHB), but not validated to assess all stages of fibrosis/cirrhosis

Assessment of liver disease prior to therapy ^{33,34,48,49,51-54}

<ul style="list-style-type: none"> heavy alcohol intake (AST elevation from alcoholic hepatitis) use of drugs and traditional herbal medicines may increase ALT and AST malaria or HIV (may decrease platelet count) hepatitis flares or acute hepatitis, congestive heart failure or a recent meal may increase liver stiffness (fibroscan) NITs have good diagnostic accuracy for excluding advanced fibrosis and cirrhosis <p>Use alongside clinical criteria and other laboratory criteria (abnormal ALT and ongoing HBV replication to identify those in need of treatment.</p> <ul style="list-style-type: none"> APRI is WHO preferred NIT to assess fibrosis⁵⁴ Online calculator for APRI: http://www.hepatitisc.uw.edu/page/clinical-calculators/apri Online calculator for FIB4: https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 	<p>a) blood/serum-based tests APRI = (AST/ULN) x 100 / platelet count (109/L)</p> <ul style="list-style-type: none"> validated for the diagnosis of both significant fibrosis ≥F2 and cirrhosis (F4) Single high cut-off >2 for identifying adults with cirrhosis (F4) and in need of antiviral therapy adults with an APRI score of >2 <ul style="list-style-type: none"> detects only one third of persons with cirrhosis <p>b) transient elastography measures liver stiffness⁵⁵</p> <ul style="list-style-type: none"> Fibroscan (range is between 0 and 75 kPa) Single cut-off value: Significant fibrosis (≥ F2) >7- 8.5 kPa and Cirrhosis (F4) >11-14 kPa Mean cut-off of 12.5 kPa to diagnose cirrhosis Sensitivity is improved when combined with non-invasive biomarker scores
Liver biopsy	<ul style="list-style-type: none"> a liver biopsy is only required if considering Pegylated Interferon therapy or if assessing the role of other co-factors e.g. non-alcoholic fatty liver disease, alcohol, drugs/toxins and iron overload. These patients should be referred to tertiary level care
Endoscopy	<ul style="list-style-type: none"> to assess for varices in cirrhotic individuals

5.10 Treatment Options for Chronic HBV

The recommended first-line monotherapies include Pegylated-Interferon and the NUCs, TDF, TAF and Entecavir that have a high genetic barrier to resistance.

All patients with chronic HBV are potential treatment candidates, but it is essential to choose the appropriate treatment at the appropriate time.

It is important to assess the clinical situation and not only the HBV viral load.

A liver biopsy is mandatory when considering treatment with Pegylated-Interferon alpha-2a.

5.10.1 Pegylated-Interferon^{33,34,79-83}

- Favourable predictors for response to Pegylated-Interferon: Young individuals, ALT >2 - 5 x ULN, active necro-inflammation on liver biopsy (Metavir Grade ≥A2) and Genotype A and B > C and D
- PegIFN alfa-2a 180 µg/wk by subcutaneous injection for 48 weeks
- Yields HBeAg seroconversion in 20 to 31 per cent and sustained off-treatment HBV DNA suppression less than 2 000 IU/mL in 65 per cent who achieve HBeAg to anti-HBe seroconversion
- Monitoring during treatment:
 - full blood count every one to three months
 - liver profile and TSH every three months
 - HBsAg concentration and HBV DNA levels at 12, 24 and 48 weeks to determine virological response

- clinical monitoring for autoimmune, ischemic, neuropsychiatric, and infectious complications
- Potential AEs: Influenza-like symptoms, fatigue, mood disturbances, cytopenia, and autoimmune disorders in adults

5.10.2 Nucleos(t)ide analogue therapy^{33,34,54}

The majority of patients are candidates for nucleos(t)ide analogue therapy

- Long-term (potentially indefinite) treatment.
- Aim for on-treatment viral suppression (HBV DNA undetectable).
- Maintained through continuous antiviral therapy.
- Suppression of replication to undetectable levels to avoid resistance.

Most patients in South Africa do not meet the clinical criteria for Pegylated-Interferon.

- These patients should be referred to tertiary level care for assessment and management^{33,34}

Table 8: Nucleos(t)ide analogue options for chronic HBV and dosage regimens^{33,34,48,49}

Nucleos(t)ide analogue options for chronic HBV and dosage regimens ^{33,34,48,49,54}	
TDF	<ul style="list-style-type: none"> • recommended dosage for adults with normal renal function (creatinine clearance >50 ml/min): 300 mg per day • dosage reduction necessary in patients with impaired renal function
TAF	<ul style="list-style-type: none"> • adults or adolescents (aged ≥12 years and ≥35 kg body weight) • dosage : 25mg daily • recommended in individuals >60 years • recommended for adults with impaired renal function <ul style="list-style-type: none"> - eGFR <60ml/min/1.73m² - albuminuria >30 mg/24 hrs or moderate dipstick proteinuria - haemodialysis - low phosphate • recommended in adults with bone disease <ul style="list-style-type: none"> - chronic steroid use - osteoporosis - history of fragility fracture • requires Section 21 application to SAHPRA
Entecavir	<ul style="list-style-type: none"> • recommended dosage for adults with normal renal function: eGFR >50 ml/min <ul style="list-style-type: none"> - 0.5mg daily if Lamivudine naïve - 1mg daily if previously exposed to Lamivudine or if Lamivudine refractory or resistant * • dosage reduction necessary in patients with impaired renal function **
Lamivudine	<ul style="list-style-type: none"> • recommended dosage for adults with normal renal function: 100 mg/day (creatinine clearance >50 ml/min) • HIV/HBV co-infection: 300mg Lamivudine daily⁶¹ • recommended dosage for children: 3 mg/kg/day, maximum dosage 100 mg/day • dosage reduction necessary in patients with impaired renal function • recommended in unstable patients with renal impairment – resistance 20per cent at six months⁶¹, if Entecavir or TAF not available

* TAF is preferred to ETV in patients with previous exposure to NAs

** ETV dose needs to be adjusted if eGFR <50 ml/min

No dose adjustment of TAF is required in adults or adolescents (aged ≥12 years and ≥35 kg body weight) with estimated CrCl ≥15 ml/min or in patients with CrCl <15 ml/min who are receiving haemodialysis
EASL CPG HBV. J Hepatol 2017;67:370–98.

5.11 Definitions of Treatment Response for Nucleoside Analogue (Nuc)Therapy^{33,34,49}

Responses may be biochemical, serological, virological or histological and vary according to the type of therapy.

Table 9: Definitions of treatment response to NUC therapy

Term	Definition
Biochemical response	<ul style="list-style-type: none"> normalisation of ALT levels (<25 U/L in females and <35 U/L in males) a minimum follow-up of at least one year post treatment with ALT determinations every three months is required to confirm sustained off-treatment biochemical response
Serological response for HBeAg	<ul style="list-style-type: none"> HBeAg loss and HBeAg seroconversion to anti-HBe positive
Serological response for HBsAg	<ul style="list-style-type: none"> HBeAg loss and HBeAg seroconversion to anti-HBe positive HBsAg loss and development of anti-HBs undetectable HBV DNA by a sensitive PCR assay with limit of detection of 10 IU/ml applies to all patients with chronic HBV
Virological response during NUC therapy	<ul style="list-style-type: none"> undetectable HBV DNA by a sensitive PCR assay with limit of detection of 10 IU/ml
Sustained off-therapy virological response	<ul style="list-style-type: none"> serum HBV DNA <2000 U/ml for at least 12 months after end of therapy
Complete response	<ul style="list-style-type: none"> sustained off-treatment virological response together with loss of HBsAg
Primary non-response	<ul style="list-style-type: none"> <1 log₁₀ IU/ml decrease in HBV DNA levels from baseline at three months of therapy
Partial virological response	<ul style="list-style-type: none"> detectable HBV DNA, but >1 log₁₀ IU/ml decrease in HBV DNA levels should be assessed at 24 weeks for patients on lamivudine, which is moderately potent, but has a low genetic barrier to resistance and at 48 weeks in patients on Entecavir, TDF and TAF which are highly potent with a higher genetic barrier to resistance
Persistent viraemia	<ul style="list-style-type: none"> in patients on entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide is defined as a failure to achieve undetectable HBV DNA after 96 weeks of treatment Should raise concerns of non-adherence
Virological breakthrough	<ul style="list-style-type: none"> confirmed increase in HBV DNA level >1 log₁₀ IU/ml compared with the nadir HBV DNA level on therapy or HBV DNA >100 IU/ml in individuals on therapy with previously undetectable levels (<10 IU/ml). usually precedes a biochemical breakthrough main causes of virological breakthrough are poor adherence to therapy or the development of resistance
Resistance	<ul style="list-style-type: none"> may result in primary treatment failure or virological breakthrough on therapy
Histological response	<ul style="list-style-type: none"> decrease in necro-inflammatory activity by ≥2 points in histological activity index without worsening of fibrosis compared to pre-treatment histological findings

5.12 Indications for Treatment

33,34,54,74

5.12.1 Patients who must be treated:

33,34,48,49,51,54,57-60,70-74

- acute liver failure: In order to suppress ongoing HBV replication in an attempt to prevent ongoing hepatocyte necrosis or to render HBV DNA undetectable prior liver transplantation
- clinical evidence of compensated or decompensated cirrhosis (or cirrhosis based on an APRI score of more than two in adults) regardless of ALT levels, HBeAg status or HBV DNA levels
- HBeAg-positive chronic HBV (immune clearance phase)
- HBeAg-negative chronic HBV (immune escape phase)
- all HBV-infected individuals receiving chemotherapy, rituximab or immunosuppressive therapy regardless of the phase of infection
- select group of immune-tolerant adults (HBeAg-positive chronic HBV infection) older than 30 years of age:
 - normal ALT and elevated HBV DNA (1 000 000 IU/mL)
 - Fibroscan showing significant fibrosis or liver biopsy specimen showing significant necroinflammation or fibrosis
- additional factors to be considered when deciding on treatment:
 - age, family history of HCC or cirrhosis, previous treatment history, presence of extrahepatic manifestations
- if treatment not indicated, actively monitor as candidacy for treatment may change with disease progression

Table 10: Recommendations for treatment: Non-cirrhotic HBeAg-positive patients ^{33,34,49,54}

HBV DNA ^a	ALT ^b	Treatment strategy
≥20 000 IU/ml	Normal	<p>HBeAg-positive chronic HBV infection (immune tolerance):</p> <ul style="list-style-type: none"> • younger patients often immune tolerant (HBV DNA usually >200 000 IU/ml and typically >1x 10⁶ IU/ml) • low rate of HBeAg seroconversion for all therapies • monitor ALT and HBV DNA every three to six months for one year, then six-monthly • monitor HBeAg annually <p>No treatment required if persistently normal ALT</p> <ul style="list-style-type: none"> • consider treatment if >30 years and evidence of fibrosis on Fibroscan or histologically or family history of HCC or cirrhosis
≥20 000 IU/ml	ALT >ULN but <2x ULN	<ul style="list-style-type: none"> • exclude other causes of ALT elevation <ul style="list-style-type: none"> - treat if ALT elevation persists, especially if >30 years of age • evaluate fibrosis/inflammation <ul style="list-style-type: none"> - Treat if ≥F2 or ≥A3 • TDF, Entecavir, Peginterferon-2a: Preferred first line therapy^{cd} • NUC therapy: Continue for 12 months after HBeAg seroconversion to anti-HBe and HBV DNA undetectable
≥20 000 IU/ml	≥2x ULN	<p>HBeAg-positive chronic HBV (immune clearance):</p> <p>Needs treatment</p> <ul style="list-style-type: none"> • liver biopsy only required for Pegylated-Interferon-based therapy or if other causes of liver injury suspected • TDF, Entecavir, Peginterferon-2a: Preferred first line therapy^{cd} • NUC therapy: Continue for 12 months after HBeAg seroconversion to anti-HBe and HBV DNA undetectable

HBV DNA ^a	ALT ^b	Treatment strategy
2000 - 20 000 IU/mL	≥2x ULN	<ul style="list-style-type: none"> exclude other causes of ALT elevation <ul style="list-style-type: none"> - treat if ALT elevation persists, especially if >30 yrs of age evaluate fibrosis/inflammation <ul style="list-style-type: none"> - treat if ≥F2 or ≥A3 TDF, Entecavir, Peginterferon-2a: Preferred first line therapy^c this may represent HBeAg seroconversion <ul style="list-style-type: none"> - monitor HBV DNA every one to three months - treat if HBV DNA > 2 000 IU/mL persists for more than six months

a Values shown in IU/mL (1 IU/mL is equivalent to approximately 5.6 copies/mL).

b On initial diagnosis, ideally every three months for one year to ensure stability.
ALT ULN: 25 IU/ml (females) and 35 IU/ml (males)

c Genotyping may be useful to help decide between treating with peginterferon alfa-2a or NUC (Peginterferon is more effective in patients with genotype A vs D)

d Peginterferon alfa-2a, entecavir, and tenofovir are preferred over lamivudine because they have been shown to be superior in randomised clinical trials and/or have lower rates of resistance

Table 11: Recommendations for treatment: Non-cirrhotic HBeAg-negative patients^{33,34,49,54}

HBV DNA ^a	ALT ^b	Treatment strategy
<2 000 IU/ml	Normal	<p>HBeAg-negative chronic HBV infection:</p> <ul style="list-style-type: none"> No treatment: Majority in immune control phase monitor ALT and HBV DNA every three months for one year to confirm immune control phase, then six to 12-monthly monitor HBsAg annually if unable to monitor closely: Treat consider therapy in patients with known significant histologic disease or advanced fibrosis on Fibroscan even if low-level replication and normal ALT
<2 000 IU/ml	ALT >ULN but <2x ULN	<ul style="list-style-type: none"> exclude other causes of ALT elevation <ul style="list-style-type: none"> o treat if ALT elevation persists, especially if >30 yrs of age evaluate fibrosis/inflammation <ul style="list-style-type: none"> o treat if ≥ F2 or ≥ A3
≥2 000 IU/ml	Normal	<ul style="list-style-type: none"> monitor ALT and HBV DNA every three months for one year then every six months monitor HBsAg annually persistently elevated ALT: Treat consider monitoring for pre-core and basal core promotor mutations which are associated with increased HCC risk: <ul style="list-style-type: none"> o consider treatment if high risk mutations present and fibrosis present on Fibroscan o consider treatment if family history of HCC or cirrhosis Tenofovir, Entecavir, or Peginterferon-2a: Preferred first line therapy^c NUC therapy : Long-term treatment recommended
≥2 000 IU/ml	ALT >ULN but <2x ULN	<p>exclude other causes of ALT elevation</p> <p>treat if ALT elevation persists, especially if >30 yrs of age</p> <p>evaluate fibrosis/inflammation</p> <p>Treat if ≥F2 or ≥A3</p>

HBV DNA ^a	ALT ^b	Treatment strategy
≥2 000 IU/ml	≥2x ULN	HBeAg-negative chronic HBV (immune escape) <ul style="list-style-type: none"> • needs treatment • Liver biopsy only required for Pegylated-Interferon-based therapy or if other cause of liver injury suspected • Tenofovir, Entecavir, or Peginterferon-2a: preferred first line therapy NUC therapy: Long-term treatment recommended

a Values shown in IU/mL (1 IU/mL is equivalent to approximately 5.6 copies/mL)

b On initial diagnosis, ideally every three months for one year to ensure stability
ALT ULN: 35 IU/ml in males and 25 IU/ml in females

c Peginterferon alfa-2a, Entecavir, and Tenofovir are preferred over lamivudine because they have been shown to be superior in randomised clinical trials and have lower rates of resistance.

5.12.2 Patients who do not require immediate therapy, but should be monitored^{33,34,49,54}

- HBeAg-positive chronic HBV infection (immune tolerant phase): younger than 30 years old with persistently normal ALT, no evidence of liver disease, and no family history of cirrhosis or HCC
- HBeAg-negative chronic HBV infection (immune control phase): Normal ALT and HBV DNA less than 2 000 IU/ml
- Occult HBV: Only treat if on immunosuppressive therapy
- HBsAg-negative, IgG anti-HBc positive and HBV DNA detectable: NUC therapy is indicated as for HBsAg-positive individuals
- HBsAg-negative, IgG anti-HBc positive and HBV DNA undetectable: No treatment is needed except if receiving Rituximab
- ALT and HBV DNA levels should be monitored at regular intervals (one to three-monthly) depending on immunotherapy type
- treatment should be initiated when HBV DNA becomes detectable
- if regular HBV DNA level monitoring is not possible, NUC therapy is also indicated

5.13 Management of individuals with HBeAg-Negative chronic HBV Infection (Immune Control) or HBeAg-Positive Chronic HBV Infection (Immune Tolerant Phase) who require Immunosuppressive Therapy, Rituximab or Chemotherapy

HBsAg and IgG anti-HBc should be tested before the introduction of immunosuppressive therapy, rituximab or chemotherapy.^{33,34, 75-77}

- HBsAg or IgG anti-HBc positive: HBV DNA levels should be measured
- Lamivudine can be used, if anticipated duration of treatment is not more than 12 months and HBV DNA level is less than 2 000 IU/ml
- HBsAg-positive and HBV DNA 2 000 or more IU/ml: NUC with a high genetic barrier to resistance (tenofovir or entecavir) should be used and continued until the usual treatment endpoint has been achieved
- IgG anti-HBc-positive patients receiving bone marrow or stem cell transplants should also receive NUC prophylaxis regardless of HBsAg and HBV DNA status where possible, antiviral therapy should be initiated before the onset of immunosuppressive therapy, Rituximab or chemotherapy, and HBV DNA levels should be undetectable
- if patients are unstable with impaired renal function, then treatment with Lamivudine can be initiated and TDF added once clinically stable or motivate for TAF or Entecavir

5.14 Indications for Combination Nuc Therapy

There are as yet no data confirming the advantage of combination NUC therapy as standard of care. The most commonly used combination therapies are TDF plus Lamivudine or TDF plus Emtricitabine, which may be considered in the following situations: ^{33,34,51,78}

- unstable patients: Lamivudine initiated for HBV viral suppression with the addition of TDF when clinically stable with normal renal function or motivate for TAF or Entecavir
- post-liver transplantation together with HBV immune globulin (HBIG)
- HIV/HBV co-infection where there is a risk of resistance with monotherapy
- suboptimal response to an initial drug, especially in the presence of high HBV DNA levels
- established resistance to an NUC

5.15 Duration of Nuc Therapy

^{33,34,54}

5.15.1 Life-long treatment with NUCs

- stopping antiviral therapy is associated with risk of reactivation, which can cause severe acute-on-chronic liver failure
 - cirrhosis based on clinical evidence and APRI score of more than two in adults, or on histology
 - previous hepatic decompensation

5.12.2 HBeAg-positive chronic HBV (immune clearance)

- HBeAg to anti-HBe seroconversion with persistently normal ALT and undetectable HBV DNA levels:
 - treatment with TDF or TAF or Entecavir should be consolidated and continued for at least 12 months after anti-HBe seroconversion
 - careful follow-up after the cessation of successful treatment is essential: 20 per cent of patients may relapse and become HBeAg-positive
 - after stopping NUCs, monitor every three months for at least one year for recurrent

viraemia, ALT flares, HBeAg seroreversion and clinical decompensation

continuation of therapy until HBsAg seroconversion is advisable⁸⁴ with ongoing monitoring after therapy cessation to detect HBsAg seroreversion

5.15.3 HBeAg-negative chronic hepatitis:

- life-long NUC therapy is recommended in individuals who remain HBsAg-positive
- can stop NUCs 12 months after HBsAg seroconversion with ongoing monitoring for relapse

Most patients with chronic HBV in South Africa will need life-long NUC therapy.

Where HBV DNA testing is not available discontinuation of NUC therapy may be considered in persons who have evidence of persistent HBsAg loss and after completion of at least 12 months additional treatment, regardless of prior HBeAg status. ⁵⁴

Discontinuation of antiviral therapy can only be considered in individuals who can be followed up regularly long term for reactivation. ⁵⁴

5.16 Monitoring On Nuc Therapy

^{33,34,48,49}

- FBC, differential count, INR, liver profile, serum creatinine: Baseline, week four and then three to six-monthly if stable
- TDF: Serum creatinine and phosphate and urinary protein dipstick should be measured at baseline. Subsequent frequency depends on baseline renal function and risk for renal dysfunction, but should be performed at least annually
- HBV DNA levels: Baseline and week 12 to assess virological response and then every six to 12 months
 - HBV DNA monitoring is critical to detect treatment failure
 - undetectable HBV DNA levels by real-time PCR (detection level less than 10 - 15 IU/ml) needs to be achieved to prevent the development of resistance
- partial responses (HBV DNA level detectable, but less than 2 000 IU/ml) assessed at:
 - 24 weeks for Lamivudine

- 48 weeks for TDF, TAF and Entecavir. If HBV DNA levels are still positive, but declining at 48 weeks on TDF, TAF or Entecavir, monotherapy can be continued
- bone mineral density: Annually if risk factors for osteoporosis present
- risk factors for renal dysfunction: Decompensated cirrhosis, creatinine clearance less than 60 ml/min, poorly controlled hypertension, proteinuria, uncontrolled diabetes, active glomerulonephritis, concomitant nephrotoxic drugs, solid organ transplantation
 - NUCs require dosage adjustments in the setting of renal impairment. Consider use of TAF or Entecavir
- if TDF associated renal dysfunction or osteoporosis occurs, TDF should be discontinued and TAF or Entecavir considered for ongoing treatment
- HCC screening: Baseline AFP and ultrasound liver every six to 12 months depending on risk factors
- persistently normal ALT for one year: ALT and HBV DNA every six months
- ALT 1 - 2 x ULN, recheck ALT every one to three months
- HBeAg status: Every 12 months
- annual non-invasive monitoring of fibrosis: APRI score or Fibroscan
- evaluate for fibrosis and inflammation and consider treatment:
 - if the patient is older than 30 years of age
 - if ALT is borderline or less than 2x ULN elevated on serial tests
 - exclude other causes of ALT elevation and treat if \geq A3 or \geq F2 on histology or \geq F2 on Fibroscan
- HCC screening: Baseline AFP and ultrasound liver every six to 12 months depending on risk factors

5.16.1 HBeAg-positive disease:

- HBeAg and anti-HBe measured every 12 months
- HBsAg should be checked six-monthly after anti-HBe seroconversion

5.16.2 HBeAg-negative disease:

- a virological response (HBV DNA less than 2 000 IU/ml) is associated with disease remission
- monitor HBsAg six-monthly, if HBV DNA levels are undetectable
- lifelong NUC therapy is recommended in individuals who remain HBsAg positive

5.17 Monitoring of Patients Not Considered for Therapy

33,34,48

5.17.1 HBeAg-positive chronic HBV infection: Immune tolerant phase (HBsAg-positive, HBeAg-positive, HBV DNA >20 000 IU/ml, normal ALT)

- ALT and HBV DNA levels: Every three to six months for one year, more often if ALT becomes elevated

5.17.2 HBeAg-negative chronic HBV infection: Immune control phase (HBsAg-positive, HBeAg-negative, HBV DNA <2 000 IU/ml, normal ALT)

- ALT and HBV DNA levels: Every three months for one year, more often if ALT becomes elevated
 - persistently normal ALT and HBV DNA less than 2 000 IU/ml for one year: ALT and HBV DNA every six to 12 months
 - ALT 1 - 2 x ULN: check serum HBV DNA level and exclude other causes of liver disease
- Evaluate for fibrosis and inflammation and consider treatment:
 - if ALT is borderline or mildly elevated on serial tests
 - if HBV DNA is persistently on 2 000 or more IU/ml
 - exclude other causes of ALT elevation and treat if ALT elevation persists especially if older than 30 years of age
 - treat \geq A3 or \geq F2 on histology or \geq F2 on Fibroscan
- HCC screening: Baseline AFP and ultrasound liver and every six to 12 months depending on risk factors

5.18 Management of Nucleos(T)ide Resistance^{33,34,48,54}

Drug resistance is defined as a more than one log₁₀ IU/mL increase in HBV DNA from nadir documented on two consecutive serum samples collected at least one month apart in patients who initially responded to therapy and who have been adherent.⁸⁵

The emergence of antiviral resistance usually leads to an increase in HBV DNA levels or viral rebound after an initial response during therapy, which is likely to be followed by biochemical breakthrough with a rise in ALT levels and, in some cases, hepatitis flares and progression to hepatic decompensation.

Elevation in ALT level tends to occur late and is a relatively poor predictive marker of resistance.

Therapy should be altered by substitution with another drug or adding to the existing regimen (preferable to add another agent to prevent rebound of wild-type virus) if:

5.18.1 Primary antiviral therapy failure:

- failure of drug to reduce HBV DNA levels by more than one x log₁₀ IU/mL within three months following initiation of therapy
- rare in persons initiating and adherent to TDF, TAF or Entecavir therapy
- can occur in persons treated with Lamivudine, Adefovir or Telbivudine

5.18.2 Secondary antiviral treatment failure:

- rebound of HBV DNA levels of more than one x log₁₀ IU/mL from the nadir in persons with an initial antiviral treatment effect (more than one x log₁₀ IU/mL decrease in serum HBV DNA)

In patients on TDF, TAF or Entecavir with high genetic barrier to resistance, HBV DNA levels should be undetectable by 48 weeks. Patients with persistent low level viraemia or virological breakthrough on on TDF, TAF or Entecavir should be counseled about adherence.

In settings without access to HBV DNA testing and where treatment failure and drug resistance is suspected:

- use of antiviral drugs with a low barrier to resistance
- rising transaminases
- evidence of progressive liver disease

Table 12: Management of NUC resistance

NUC resistance	Management
Lamivudine	<ul style="list-style-type: none"> • add Tenofovir or switch to Tenofovir/Emtricitabine • screen for tyrosine-methionine-aspartate-aspartate (YMDD) mutations, if available
Entecavir	<ul style="list-style-type: none"> • add or switch to TDF or switch to TDF plus Emtricitabine • safety of an Entecavir/Tenofovir combination is not known
TDF	<ul style="list-style-type: none"> • resistance has not been described up to 10 years of treatment

5.19 Treatment of Special Populations

5.19.1 Healthcare workers (HCWs):³³

- HBsAg-positive HCWs performing exposure-prone procedures with HBV DNA levels more than 200 IU/ml: TDF or TAF or Entecavir therapy to reduce transmission risk if not requiring treatment for HBeAg-positive and HBeAg-negative chronic HBV
- HBV DNA level should preferably be undetectable or at least less than 200 IU/ml before returning to exposure-prone procedures
- HBV infection alone does not disqualify HCWs from surgery, dentistry, medicine or allied health fields

5.19.2 Pregnancy

There is no worsening of liver disease in most women, but case reports have suggested that HBV reactivation, hepatic exacerbations and fulminant liver failure may occur. There are reports of higher rates of preterm births, lower APGAR scores, gestational diabetes and antepartum haemorrhage.

HBsAg-positive mothers need close follow up during pregnancy.

HBsAg screening of pregnant women is essential:^{33,34,54}

- during the first trimester of each pregnancy
- pregnant women not immune to HBV and with risk factors for infection should be vaccinated against HBV – the vaccine is safe in pregnancy
- ongoing high-risk behavior during pregnancy and HBsAg status unknown:
 - test for HBsAg at admission for delivery
- HBsAg-positive women must be referred for additional testing, counseling and medical management

Most women of childbearing age (20s and 30s) are likely to be in the immune tolerant or immune control phase and are not candidates for HBV treatment, but the risk of MTCT needs to be considered in pregnant women with high HBV viral loads (HBV DNA more than 200 000 IU/ml) in both HBeAg-negative and positive pregnant women.^{33, 34}

a) acute HBV:

- antivirals are generally not recommended, unless there is evidence of acute liver failure
- patient should be monitored closely and treated conservatively
- increased risk of MTCT if the mother acquires acute HBV in the second or third trimester and if HBV DNA levels are more than 200 000 IU/ml in the third trimester - administer antivirals to prevent MTCT

b) chronic HBV:

Indications for therapy in a HBV-infected pregnant mother are the same as in other HBV-infected individuals:

- HBeAg-positive chronic HBV
- HBeAg-negative chronic HBV
- cirrhosis

c) Therapy:

- the use of Lamivudine, Emtricitabine and TDF in HIV-positive pregnant women is safe⁸⁶
- drug of choice is TDF^{33,34,54} and has similar rates of birth defects to the general population
- no data available on safety of TAF in pregnancy
- Pegylated-Interferon is contraindicated

There is a risk of HBV flare and close monitoring is required if the mother is untreated or if antivirals are stopped during pregnancy or soon after delivery.

i. women requiring HBV treatment and considering pregnancy:

- TDF is the treatment of choice of HBV viral suppression prior to pregnancy
- increased risk of HBV MTCT in the third trimester if HBV DNA is more than 200 000 IU/ml
- can consider a finite course of pegylated IFN (if favourable clinical profile) before pregnancy

ii. pregnant whilst on HBV treatment

- TDF is the preferred NUC to maintain HBV suppression
- review type of treatment: Stop pegylated IFN and switch to antivirals, Entecavir should be switched to TDF

iii. pregnant and treatment not clinically indicated for HBV infection:

- assess risk of HBV MTCT and treat as necessary in third trimester
- refer for ongoing follow-up and assessment after delivery. HBV/HIV co-infection align with prevention of mother-to-child transmission (PMTCT) guidelines for HIV-positive pregnant women

iv. prevention of HBV MTCT - see also 5.23.4 PEP for babies born to HBV-infected women

- HBV DNA more than 200 000 IU/ml: Recommend antiviral therapy to prevent perinatal transmission⁸⁷⁻⁸⁹ regardless of HBeAg status
- TDF is the preferred agent and should be started at 28-32 weeks gestation³⁴ - as fits best with the planned antenatal visits
- NUC therapy can be stopped 12 weeks post delivery, if only used for HBV MTCT prevention in HIV-negative pregnant women
- all neonates must receive HBV birth dose vaccine within 24 hours of delivery. Although HBIG is advised if pregnant women is HBeAg-positive, this is expensive and not readily available
- caesarean section is not indicated to prevent HBV MTCT

- breastfeeding is not contraindicated if mother is HBV virally suppressed either on or off tenofovir disoproxil fumarate
 - if not HBV virally suppressed, bleeding, cracked nipples are a potential source of infection to neonate

5.19.3 Dialysis and renal transplant patients:^{33,34}

- all dialysis and renal transplant recipients should be screened for HBsAg, anti-HBs and IgG HBV core Ab
- TAF and Entecavir should be used for prophylaxis or treatment
 - Entecavir dosages need to be adjusted in patients with impaired renal function
- HBsAg-positive dialysis patients requiring therapy should receive TAF or Entecavir
- all HBsAg-positive patients undergoing renal transplantation should receive NUC therapy as prophylaxis or treatment
- Pegylated-Interferon therapy is not recommended in renal transplant recipients because of the risk of graft rejection
- HBsAg-negative, IgG HBV core Ab positive: Treat if HBV DNA-positive and on immunosuppression

5.19.4 Children:^{33,34,90}

- chronic HBV is typically benign as children are usually in the immune tolerant phase
- liver biopsy is helpful in guiding need for therapy in children with abnormal liver profiles
- treatment is recommended in HBeAg-positive children with persistently elevated ALT of more than 30 IU/ml
- HBV DNA usually more than 10⁶ IU/ml, therefore no recommended HBV DNA threshold for treatment
- if HBV DNA is less than 10⁴ IU/ml, defer therapy until other causes of liver disease or spontaneous HBeAg seroconversion are excluded

Treatment recommendations:^{33,34}

- Lamivudine: Children of two years and older, but long-term use of Lamivudine is associated with the development of resistance (70 per cent at five years)
- Entecavir: In children of two years and older and weighing at least 10kg. Dose is determined by weight (see package insert). Children that weigh

more than 30kg receive 0.5mg daily

- TDF: 300 mg daily in adolescents of 12 years and older and 35kg or more body weight
- TAF: 25mg daily in adolescents aged 12 and older and with a 35kg or more body weight
- treatment with NUCs continued until HBeAg seroconversion followed by an additional 12 months consolidation therapy³⁴
- on stopping NUC therapy, need to monitor every three months for at least one year for HBV flares and clinical decompensation
- Pegylated-Interferon-alpha-2a: 180ug/1.73m² body surface area, maximum 180ug weekly³³

5.19.5 HBV/HCV co-infection:

- all HBV-infected individuals must be screened for HCV
- HCV super-infection can lead to more severe acute symptoms and liver failure
- HCV super-infection also associated with HBsAg clearance, HBeAg seroconversion, and/or a reduction in HBsAg titres⁹¹⁻⁹³
- increased risk of cirrhosis, hepatocellular carcinoma and death^{94,95}
- histological progression over a time period as short as three years⁹⁶
- HBV super-infection of chronically infected HCV patients can also lead to fulminant liver failure^{94,97-99}

In HBV/HCV co-infection, HCV is often the dominant driver of chronic inflammatory activity^{100, 101}. HBV DNA levels are usually low but HBV reactivation can occur during or after HCV clearance on DAA therapy. A meta-analysis and systematic review demonstrated that the pooled proportion of patients with HBV reactivation on DAA therapy was higher in HBsAg-positive patients: 24 per cent (95 per cent CI 19–30) versus 1.4 per cent (0.8–2.4) in those with resolved HBV infection.¹³⁸ Hence, HBsAg, anti-HBc and anti-HBs testing is recommended prior to DAA therapy. If HBsAg is positive, concurrent HBV NUC therapy is advised and HCV DAA therapy commenced once HBV DNA levels suppressed. Treatment should be continued for 12 weeks post DAA therapy with requisite monitoring after stopping, unless HBV requires longterm therapy. Serum ALT levels should be carefully monitored (baseline, end of DAA therapy and during followup) in HBsAg-negative but IgG anti-HBc-positive patients.⁵⁰

5.19.6 HBV/HIV co-infection

Liver disease, particularly in the post antiretroviral era of HIV/AIDS, has emerged as a major cause of morbidity and mortality in HBV or HCV co-infected patients¹⁰². In contrast to developed countries, HBV/HIV co-infection outnumbers HCV/HIV co-infection in South Africa and probably reflects the present lower prevalence of injecting drug use, although this is increasing particularly in cities. There is usually independent transmission and acquisition of HBV and HIV. HBV is generally acquired in childhood under the age of five years and HIV infection occurs later in life, primarily via heterosexual sex.

HIV co-infection promotes:

- increased HBV replication and rates of HBV reactivation
- acute liver failure
- increased rates of occult HBV
- chronicity of newly acquired HBV infections
- accelerated progression to fibrosis and cirrhosis
- HCC occurs at a younger age and is more aggressive
- increased risk of ART hepatotoxicity
- ART-related immune reconstitution hepatitis

Liver-related mortality is twice as high for HBV/HIV co-infected as for HCV/HIV co-infected individuals. A CD4 count of less than 200 cells/ml is associated with a 16.2 fold increase in risk of liver-related deaths compared to a CD4 count of more than 350 cells/ml¹⁰². Additionally, a potential association with adverse HIV outcomes in HBV co-infected individuals was demonstrated in the SMART study where HIV-associated immune deficiency was enhanced by active HBV replication resulting in increased progression to AIDS-related outcomes and all-cause mortality.¹⁰³

Aetiology of abnormal liver profile in HIV/HBV co-infected individuals is often multifactorial:

- drug/toxin induced liver injuries: Highly active antiretroviral therapy (HAART), tuberculosis (TB) drugs, Cotrimoxazole, Fluconazole, traditional, herbal/alternative supplements
- HIV-related opportunistic infections
- HBV clearance
- emergence of drug resistance
- immune reconstitution inflammatory syndrome (IRIS)
- reactivation after withdrawal of therapy
- super-infection with HCV, HAV, HDV and HEV

- co-morbidities: Non-alcoholic fatty liver disease, alcoholic liver disease, iron overload

As the aetiology of deranged liver enzymes is often multifactorial and in the setting of a more aggressive natural history of HBV, there should be a lower threshold for performing a liver biopsy to assess the differential diagnosis and the stage and grade of histological injury.

a) recommendations for the initiation of ART in HBV/HIV co-infection:

- South Africa follows the WHO 2016 HIV treatment guidelines to treat all people with HIV, including children and pregnant or breastfeeding women regardless of CD4 cell count

b) goals of therapy:

- virological suppression of both HBV and HIV replication
- amelioration of transaminitis and histological injury and prevention of liver-related complications

c) choice of ARV regimen in HBV/HIV co-infected individuals

- ART regimen containing two agents that are also active against HBV, thereby preventing the selection of HIV and HBV resistant mutants
- TDF and Lamivudine/Emtricitabine and Efavirenz as a fixed drug combination is first line therapy for adults, adolescents and children older than three years
- TDF, TAF, Lamivudine or Entecavir should not be used as single agents

d) outcomes after five years of FDC therapy (TDF, Lamivudine/Emtricitabine and EFV)

HBeAg-positive patients have high rates of: ^{104,105}

- HBV DNA suppression (90 per cent)
- HBeAg loss (46 per cent)
- HBsAg loss (12 per cent)
- no evidence of resistance
- reduced progression to cirrhosis
- risk of HCC persists, but is low

There was no significant difference in response rates compared with HBV mono-infection:

- HIV treatment regimens that exclude Tenofovir may lead to flares of HBV due to ART-associated IRIS

- treatment discontinuation, especially Lamivudine, is associated with HBV reactivation, ALT flares and hepatic decompensation
- if ARVs need to be changed because of HIV drug resistance or toxicity, then TDF and Lamivudine or TDF/Emtricitabine should be continued together with the new ARV drugs

e) **monitoring of FDC**

- recommend serum creatinine at baseline, three, six and 12 months and then annual renal function assessment
 - more frequently if high risk for renal dysfunction
- HIV-associated nephropathy:
 - Tenofovir Alafenamide can be accessed via a Section 21 application to SAHPRA
 - consider Entecavir as part of ART regimen, provided no previous exposure to Lamivudine or no evidence of Lamivudine-associated HBV polymerase resistance
- consider annual assessment of bone function:
 - TDF in children of 12 years and older and weighing at least 35kg

5.19.7 Extrahepatic disease

Patients with chronic HBV and active HBV replication who present with extrahepatic disease (vasculitis, polyarteritis nodosa, glomerulonephritis, purpura, arthralgias and peripheral neuropathy) should receive NUC therapy, but efficacy is variable:

- Lamivudine has been most widely used, but TDF, TAF or Entecavir are now preferable and the NUC depends on the renal function
- Plasmapheresis and steroids, in combination with a NUC, have been used in the initial phases of extrahepatic disease
- Interferon-based therapy may worsen immune-mediated extrahepatic manifestations

5.19.8 Liver transplant recipients

Recurrent HBV infection occurs in 70 to 90 per cent of HBsAg-positive recipients without immunoprophylaxis.¹⁰⁶ Patients with high serum HBV DNA levels and HBeAg-positivity at the time of liver transplantation have the highest rate of recurrence post-transplantation, with a corresponding decrease in patient and graft survival.¹⁰⁷⁻¹⁰⁹

a) **pre-transplant management**

- antiretroviral therapy given before transplantation

aims to reduce serum HBV DNA to low or undetectable levels¹¹⁰⁻¹¹³

- this may delay or even prevent the need for transplantation
- TDF, TAF and Entecavir are the preferred NUCs for patients undergoing liver transplantation for end-stage liver disease or HCC.^{33,34} NUC choice is determined by renal function and previous exposure to Lamivudine
- Lamivudine improves liver function, reduces fibrosis and decreases risk of HCC in pre-transplant patients¹¹⁴⁻¹¹⁷
 - significant risk of drug resistance
 - can be used in clinically unstable patients with decompensated cirrhosis or acute liver failure as the risk of resistance is not immediate (20 per cent at six months)

b) **post-transplant management**

- NUC therapy in combination with HBIG is recommended to prevent HBV recurrence^{118,119}
- Lamivudine has been used in combination with HBIG
- reduced the risk of recurrent HBV at three years post transplant to less than ten per cent
- Entecavir or TDF or TAF or combination NUC therapy (Lamivudine and TDF or TDF/Emtricitabine) is now recommended together with HBIG
- the optimum dosage, mode of administration (IVI or IMI) and duration of HBIG therapy in combination with potent NUCs is not yet established¹²¹
- life-long antiviral therapy to prevent recurrent HBV is required

5.19.9 Management of patients receiving anti-HB IgG core antibody positive donor livers:

- overall risk of de novo HBV infection is reported to be as high as 75 per cent¹²⁰⁻¹²² depending on the HBV immune status of the recipient
- the risk is particularly high in endemic countries such as South Africa, where these donors often have occult HBV
- in the absence of HBV prophylaxis, risk of de novo HBV^{123,124}
 - 58 per cent in HBV non-immune individuals

- 18 per cent in previously vaccinated individuals with protective anti-HBs titres
- 14 per cent in isolated anti-HB IgG core positive individuals
- four per cent in naturally immune individuals – anti-HBs and anti-HB IgG core positive
- liver grafts from anti-HB IgG core positive donors can be safely used¹²⁵
 - preferentially in HBsAg-positive or anti-HBc/anti-HBs-positive recipients
 - non-immune HBsAg-negative recipients should receive Lamivudine prophylaxis
 - anti-HB IgG core and anti-HBs-positive recipients may not need prophylaxis
- Lamivudine is recommended as the most cost effective treatment option to prevent de novo HBV¹²⁵
- HBV hyperimmunoglobulin (HBIG) is not required¹²⁵
- lifel-ong antiviral therapy is recommended in recipients with:
 - no immunity or vaccine-induced immunity, but not in liver recipients with natural immunity (IgG anti-HBc and anti-HBs positive)¹²⁵

5.19.10 Management of transplant recipients of non-hepatic organs from donors who are HBsAg-negative and anti-HB IgG core antibody positive:

- reported risk of de novo HBV in HBV non-immune kidney transplant recipients ranges from 0 to 27 per cent¹²⁶
- three per cent risk of de novo HBV has been reported in HBV non-immune cardiac recipients¹²⁷
- risk of transmission varies depending on HBV DNA level, immunisation status and antiviral therapy
- anti-HB IgG core positive grafts should ideally be given to a HBV immune recipient (anti-HBs >10mIU/ml) if the recipient is HBV seronegative, antiviral therapy should be given to prevent de novo HBV, especially if donor has detectable HBV DNA
- optimal duration of prophylactic antiviral therapy is not known
- Lamivudine is recommended for one year in HBV seronegative non-liver transplant recipients

- anti-viral prophylaxis is not recommended in HBV-immune non-liver transplant recipients
- HBV hyperimmunoglobulin (HBIG) is not required

5.20 General Measures for HBV Control:

- introduction of the HBV birth dose vaccine as part of the EPI vaccination schedule in 2019 to reduce MTCT
- prevention of exposure through the use of standard infection precautions amongst HCWs
- screening of blood, blood products and organs for HBV
- implementation of rigorous infection control procedures for haemodialysis patients
- introduction of needle exchange programmes and opiate substitution for injecting drug users to reduce the spread of HBV, HCV and HIV
- advice on ethanol intake: more than 20 g/day in women and more than 40 g/day in men is associated with an increased risk of development of cirrhosis^{128,129}

5.20.1 Management of HBsAg-positive persons to reduce the risk of secondary transmission:

- refer HBsAg-positive individuals for clinical assessment and management
- active counseling:
 - risk of transmission to infants and household, sexual and needle sharing contacts
 - cannot donate blood, plasma, tissue, ova or semen
 - avoid sharing household items that may be contaminated with blood such as toothbrushes, razors, hairclippers, nail-grooming equipment, etc
 - inform their dentist of their HBV status
- all household, sexual and needle-sharing contacts should be identified and tested for susceptibility to HBV infection (HBsAg, anti-HBs, IgG anti-HBc)
- identified susceptible non-immune contacts should be vaccinated against HBV
 - sexual partners should be counselled to use barrier methods such as condoms to prevent exposure to sexual fluids until they have documented protective anti-HBs titres

5.21 Role of HBV Vaccine in the Control of HBV

HBV and its associated complications is an entirely vaccine preventable disease:¹³⁰

- HBV vaccines are produced by recombinant DNA technology or are plasma-derived
 - both formulations are safe and do not transmit HBV, HCV or HIV
 - plasma-derived vaccines are thought to be more immunogenic
 - combined HAV and HBV vaccines are available
 - vaccine stored at two to eight degrees Celcius, but is thermostabile outside the cold chain ^{131,132}
 - dosing schedules depend on:
 - type of vaccine
 - age of administration
 - need for rapid immunisation
 - previous non-response to HBV immunisation
 - usual HBV vaccine dosage:
 - 20mcg/ml IMI into deltoid muscle in adults
 - 10mcg/0,5ml IMI into anterolateral aspect of the thigh in neonates and infants
 - three-dose series administered at birth, one and six months produces a protective anti-HBs response in:
 - 30 to 55 per cent of healthy adults aged 40 years or younger after the first dose
 - 75 per cent after the second dose
 - more than 90 per cent after the third dose
 - these response rates decline when the vaccine is given to older individuals
 - less than 90 per cent in persons older than 40 years
- 75 per cent in those older than 60 years
- alternative immunisation schedules: birth, one and four months or birth, two and four months or birth, one, two and 12 months
 - similar rates of protection as those described above
 - useful schedule in travelers who present at least two months before departure
 - ensures better compliance with completion of the immunisation schedule

- host factors (e.g. age, smoking, obesity, cirrhosis, genetic factors, immune suppression, renal failure, etc.) result in a decreased vaccine response

5.21.1 HBV immunisation in the EPI

- April 1995: HBV immunisation was incorporated into the South African EPI schedule
 - DtaP-IPV/Hib + HBV is given at six, 10 and 14 weeks of age and a booster at 18 months
- if a hexavalent vaccine is given according to the EPI schedule (six, 10 and 14 weeks), then a HBV monovalent vaccine birth dose is recommended for improved immunogenicity and protection against perinatal vertical transmission
- 2019: HBV monovalent birth dose vaccine to be introduced: Should be given at the same time as the oral polio and BCG to prevent perinatal transmission any child, who has missed any HBV immunisation dose, should receive the necessary catch-up doses, with four-week periods between doses until all doses are received for age
- 2020: HBV monovalent birth dose vaccine to be introduced: Should be given at the same time as the oral polio and BCG to prevent perinatal transmission

5.21.2 Pre-exposure immunisation of non-immunised infants, adolescents and adults

- a) **individuals recommended to receive pre-exposure HBV immunisation:** ^{130,133,134}
- infants and adolescents not previously immunised who should have received routine immunisation through the EPI (catch-up immunisation)
 - persons at risk for infection by percutaneous or mucosal exposure to blood/body fluids or by sexual exposure or at increased risk of severe illness if infected with HBV:
 - healthcare workers, student healthcare workers and workers in healthcare facilities with reasonable anticipated risk for exposure to blood or blood-contaminated body fluids- all laboratory workers working with clinical specimens
 - workers and residents of facilities for the developmentally disabled with a high risk of HBsAg-positive residents with aggressive

behaviour or special medical problems which increase the risk of HBV exposure

- workers and residents of correctional service facilities
- members of the police, firefighters and members of the armed forces
- household contacts of HBsAg-positive persons
- sex partners of HBsAg-positive persons
- persons who inject or use drugs
- men who have sex with men
- persons seeking evaluation for treatment of a sexually transmitted disease
- patients receiving frequent transfusions of blood or blood components
- persons with endstage renal disease requiring dialysis
- transplant candidates before transplantation
- persons with chronic liver disease
- persons with HIV infection
- all other persons seeking protection from HBV infection, including travelers

b) post-immunisation testing for immunity:

- up to ten per cent of healthy adults receiving three doses of the HBV vaccine according to the recommended schedule may not develop protective anti-HBs ≥ 10 mIU/ml
- routine post-immunisation anti-HBs testing for immune response to immunisation is recommended
- post-immunisation anti-HBs testing is recommended in high-risk individuals:
 - high-risk healthcare workers
 - sex and needle sharing partners of HBsAg-positive individuals
 - household contacts of HBsAg-positive persons
 - HIV-infected individuals
 - haemodialysis patients
 - individuals with chronic liver disease
 - MSM
 - immuno-compromised individuals

c) re-immunisation in adults:

- persons who do not respond to a primary immunisation schedule should be offered re-

immunisation with three doses of HBV vaccine, one month apart

- re-immunisation gives rise to protective anti-HBs titres:
 - 25 to 50 per cent of non-responders with a single additional dose
 - 44 to 100 per cent with a three-dose re-immunisation series
- individuals who do not develop protective anti-HBs titres one to two months after re-immunisation may be:
 - primary non-responders
 - infected with HBV and should be tested for HBsAg
- repeat immunisation (nil, one and two months with a six-month booster) with double the standard dose has been demonstrated to enhance the re-immunisation response in one study, but not in another^{133,134}
- individuals who do not respond to HBV immunisation should be given HBV Immunoglobulin (HBIG) as post-exposure prophylaxis (PEP) following HBV exposure

5.21.3 HBV immunisation of haemodialysis and immuno-compromised patients:

- patients with pre-endstage renal disease, ideally before they become dialysis dependent
- patients with endstage renal disease requiring haemodialysis or peritoneal dialysis¹³⁵
- higher HBV vaccine doses recommended: Adult haemodialysis or peritoneal dialysis patients
 - four doses of HBV vaccine containing 40 μ g HBsAg at nil, one, two and six months¹³⁴
- limited data on immune response of paediatric patients on haemodialysis
 - protective anti-HBs titres achieved in 75 to 97 per cent of children receiving higher dosages (20 μ g HBsAg) in a three- or four-dose schedule
- anti-HBs testing recommended after final dose of HBV vaccine series to determine the need for re-immunisation
- haemodialysis patients: Annual testing of anti-HBs titres with booster doses if titre is less than 10 mIU/ml
- immuno-compromised patients (HIV infection, diabetics, individuals on immunosuppression or receiving chemotherapy):

- reduced humoral response to HBV immunisation
- modified dosing regimens, including doubling the dose or administering additional doses may increase response, but evidence is limited to support these schedules

5.22 Prep for HIV in setting of HBsAg-Positivity

Pre-exposure prophylaxis (PrEP) is the use of Tenofovir and Emtricitabine/Lamivudine preferably as a combination pill by HIV-negative individuals before potential exposure to HIV to prevent them from acquiring HIV infection. Consult the most recent national Department of Health Guideline for PrEP eligibility criteria.

PrEP should be used as part of a package including condoms, lubricants for anal sex, STI management, screening and management of intimate partner violence, sexual and reproductive health services, medical male circumcision and HIV services, including counseling and testing, HIV management, ART, PEP, and PrEP:

- it is essential to test for HBsAg and HBsAb to diagnose HBV-infected individuals as well as to identify those in need of HBV immunisation
- if HBsAg positive, do ALT and decide on need for long-term NUC therapy
- if ALT persistently elevated or other abnormal liver function tests, refer for assessment for long-term NUC therapy
- it is safe to initiate PrEP in the setting of acute and chronic HBV
- PrEP users with chronic HBV infection who develop abnormal liver function tests should be referred for assessment
- if PrEP is stopped, monitor ALT every three months

Discontinuation of Tenofovir and Emtricitabine/Lamivudine in patients with HBV requires referral to a specialist because of a risk of a hepatitis flare.

5.23 Post-Exposure Prophylaxis (Pep) Against HBV

5.23.1 Indications for PEP

PEP is indicated following exposure to blood or body fluids of a known or potential HBsAg-positive source if the exposed individual does not have protective anti-HBs ≥ 10 mIU/ml or if anti-HBs status is unknown and testing will delay administration of HBV immunisation or HBIG.

Exposures in which HBV PEP should be given include:

- ercutaneous (e.g. bite or needlestick) or mucosal exposure to blood or body fluids of a known or potential HBsAg-positive source
- neonates born to HBV-infected women
- sex or needle sharing contact of a HBsAg-positive person or a person of unknown HBsAg status
- victims of sexual assault/abuse by a perpetrator who is HBsAg-positive or of unknown HBsAg status

5.23.2 Effectiveness of PEP:

- a combination of HBIG and active HBV immunisation is highly effective in preventing transmission after exposure to HBV
- HBIG provides passively acquired anti-HBs which is immediately protective and lasts for three to six months
- HBIG is approximately 75 per cent effective in preventing clinical HBV infection if administered soon after HBV exposure
- HBIG alone does not confer long-lasting protection against HBV
- HBIG is the primary means of protection of non-responders to immunisation

5.23.3 Timing of PEP:

- the most important determinant of PEP effectiveness is the timing of administration of HBIG and the first HBV vaccine dose
- PEP effectiveness decreases with increasing delay in administration following exposure and is unlikely to be effective:

- more than seven days after perinatal and needle stick exposures
- more than 14 days after sexual exposure

5.23.4 PEP for babies born to HBV-infected women

Perinatal transmission usually occurs at birth and is a risk for any baby born to an HBsAg-positive woman. The risk is highest from mothers with HBeAg-positivity or if the HBV DNA is more than 200 000 IU/ml.

Screening pregnant women for HBsAg is essential in order to timeously administer PEP to babies born to HBsAg-positive women:

- neonates born to HBsAg-positive mothers should receive 0.5 ml (200 IU) HBIG and HBV monovalent vaccine within the first 24 hours, but preferably within 12 hours of delivery at different injection sites (anterolateral thigh)
- probably remains protective if administered up to 72 hours after exposure

thereafter, the same immunisation schedule is followed as for other infants, with the additional HBV vaccine doses given at six, 10 and 14 weeks of age either as a monovalent vaccine or as a component of the hexavalent vaccine

- the combination of HBIG and HBV immunisation is 95 per cent effective in preventing MTCT
- HBIG is expensive and not readily available
- pregnant mothers with HBV DNA of more than 200 000 IU/ml should receive Tenofovir at 28 to 32 weeks to further reduce the risk of MTCT and continue for 12 weeks after delivery
- children born to HBsAg-positive mothers should be offered post-immunisation testing for HBsAg and anti-HBs at nine to 18 months of age
- children with anti-HBs of 10 mIU/ml or more are protected and need no further management
- children who have anti-HBs of less than 10mIU/ml should be given a second course of immunisation as they may be at risk of exposure in the household
- children who are HBsAg-positive should be referred for clinical management

5.23.5 PEP for HBV in the healthcare setting

a) *pre-exposure measures:*

- routine pre-exposure HBV immunisation must be provided to all HCWs, including laboratory and cleaning workers who may perform tasks involving contact with blood, blood-contaminated body fluids or sharps
- pre-immunisation screening for HBV infection is not necessary unless the healthcare facility finds this to be cost-effective
- post-immunisation anti-HBs testing should be performed one month after completion of the immunisation schedule
 - if non-immune, consider screening for HBsAg and if negative, re-immunise
- administration of HBV vaccine doses to workers should be recorded in his/her workers file
- standard infection control precautions should be implemented at all times

b) *post-expose management: (see Table 13)*

- exposure should be reported according to standard procedures for the institution
- wounds should be washed with soap and water and mucous membranes should be flushed with water
- exposure should be evaluated for the potential to transmit HBV
- establish HBsAg status of the source patient and HCW
- if HBsAg source status is not obtainable, the HCW should be managed as if source individual is HBV infected
- establish anti-HBs status of HCW

Table 13: Recommendations for PEP: Occupational exposure to HBV¹³⁶

Immunisation and anti-HBs status of exposed HCW*	Management		
	Source HBsAg-positive	Source HBsAg-negative	Source unknown or unavailable for testing
Unvaccinated	<ul style="list-style-type: none"> HBIG and initiate HBV vaccine series 	<ul style="list-style-type: none"> initiate HBV vaccine series 	<ul style="list-style-type: none"> HBIG and initiate HBV vaccine series
Previously immunised			
Known responder**	<ul style="list-style-type: none"> no action 	<ul style="list-style-type: none"> no action 	<ul style="list-style-type: none"> no action
Known non-responder***	<ul style="list-style-type: none"> HBIG and initiate HBV re-immunisation (if not previously attempted) repeat HBIG at one month 	<ul style="list-style-type: none"> re-immunisation (if not previously been attempted) 	<ul style="list-style-type: none"> HBIG and initiate HBV re-immunisation (if not previously attempted) repeat HBIG at one month
Anti-HBs response unknown	<p>Test exposed person for anti-HBs:</p> <ul style="list-style-type: none"> if anti-HBs positive: no action if anti-HBs negative: Administer HBIG and HBV vaccine booster and re-check titre in one month 	<p>Test exposed person for anti-HBs:</p> <ul style="list-style-type: none"> if anti-HBs positive: no action if anti-HBs negative: HBV vaccine booster and re-check titre in one month 	<p>Test exposed person for anti-HBs (if the delay is more than 24 hours treat as known non-responder):</p> <ul style="list-style-type: none"> if anti-HBs positive: no action if anti-HBs negative: HBIG and HBV vaccine booster and re-check titre in one month

HCW: Healthcare worker: Test for HBsAg and anti-HBs status

HBIG: Dose is 0.06ml/kg (500 IU) intramuscularly

*If HCW is known to be previously HBV-infected, they cannot be re-infected and do not require PEP

**A responder is an individual who developed adequate anti-HBs titres ($\geq 10\text{mIU/ml}$) following immunisation

***A non-responder is an individual who developed inadequate anti-HBs titres ($< 10\text{mIU/ml}$) following immunisation

HBIG and first dose of HB vaccine should be given at the same time at different sites

5.23.6 PEP for sexual exposure to HBV align with PEP guidelines 2016:

- victims of sexual assault should receive comprehensive investigation and management as per the National Management Guidelines for Sexual Assault Care and National Sexual Assault Policy 2005¹³⁷
- HBV is transmitted sexually, but the risk of transmission per exposure is unclear
- HBV vaccine must be administered to all sexual assault victims who are not already fully immunised
- HBIG must be considered in high-risk exposures due to the increased protection afforded by a PEP regimen combining HBV vaccine and HBIG
- the HBV vaccine should be given in three doses immediately and at one and two months
- HBsAg of the exposed individual should be performed at baseline, 12 and 24 weeks
- if the individual is found to be HBsAg-positive at baseline, the vaccine schedule can be discontinued
- HBIG is approximately 75 per cent effective in preventing acute or chronic HBV infection following sexual exposure if given within seven days of exposure, but should not be used alone unless HBV vaccine is unavailable as it does not afford long-lasting protection
- victims of sexual assault must be screened for HIV, HCV and other sexually transmitted diseases

5.23.7 PEP in other situations

HBV exposure may occur in situations other than in the setting of perinatal, sexual or occupational exposure in the healthcare setting.

Such situations include exposure following wounds such as human bites, exposure in the situation of mass casualty events or exposure following needle sharing. The PEP recommendations in these situations are the same as for occupational exposure.

The principles of management of such exposures are similar to those described in paragraph 5.23.6 and include:

- establish HBsAg status of source individual and the exposed individual
- establish the anti-HBs status of the exposed individual
- unknown HBV status of the exposed individual: HBsAg and anti-HBs should be performed at baseline
- exposed individual is HBsAg-positive at baseline: HBV vaccine schedule can be discontinued
- individuals with documented completion of HBV immunisation schedule who did not receive post immunisation testing should receive a booster dose of vaccine at the time of exposure if the source is HBsAg-positive or unknown: HBV vaccine and HBIG should be given

5.24 Diagnostic, prevention and Treatment Options: Primary, Secondary and Tertiary Levels of care

5.24.1 Diagnosis:

- all levels of care: Viral serology (HBsAg, anti-HBs, HBeAg, anti-HBe, IgG and IgM anti-HB core), HBV DNA quantification with gene expert technology
- secondary and tertiary level care: HBV DNA quantification
- tertiary level care: HBV genotype and HBV resistance testing

5.24.2 Assessment of clinical severity:

- all levels of care: FBC, INR, serum creatinine and liver profile; enables APRI scoring to assess for cirrhosis and choice of NUC
- secondary and tertiary levels of care: Ultrasound liver ± mobile fibroscan
- tertiary level care: Fibroscan and liver biopsy

5.24.3 Treatment:

- acute HBV:
 - uncomplicated cases: Managed at primary level care including screening at six months to exclude progression to chronic HBV
 - complicated cases with synthetic dysfunction: Refer to secondary level care
 - fulminant hepatitis: Refer to tertiary level care
- chronic HBV
 - HBeAg-negative chronic HBV infection (immune control): Follow up at primary level care
 - HBeAg-positive chronic HBV infection (immune tolerant): Follow up at primary level care
 - hepatitis BeAg-positive chronic HBV (immune clearance): Secondary and tertiary level care with option of down-referral to primary level care when stable on therapy
 - hepatitis BeAg-negative chronic HBV (immune escape): Secondary and tertiary level care with option of down-referral to primary level care when stable on therapy
 - cirrhotics (compensated and decompensated): Tertiary level care
- HIV/HBV co-infection:
 - primary level of care, unless abnormal LFTs, then referral to secondary level care.
 - cirrhotics managed at tertiary level care
- HBV/HCV and HBV/HCV/HIV co-infection:
 - tertiary level care and with option of down-referral to primary level care, once HCV successfully treated and stable on NUC or ARV therapy


5.24.4 Therapeutic options:

- Lamivudine and TDF: All levels of care for both HBV mono-infected and HBV/HIV co-infected individuals
- Entecavir, TAF and Pegylated Interferon: Tertiary level care

5.24.5 Prophylaxis:

- all levels of care:
 - screening of contacts: HBsAg, anti-HBs and IgG anti-HBc
 - HBV immunisation and HBIG

ENTER YOUR PATIENT
CHARACTERISTICS
FOR INSTANT GUIDANCE ON
MANAGEMENT CLINICAL OPTIONS.
COM/HEPBCONSULT





HEPATITIS C (HCV)

CHAPTER

6



6.1 Introduction

Globally, 71 million people are viremic for HCV infection^{1,2}. About 15 to 25 per cent of infected individuals spontaneously clear the virus within six months of infection. However, the remaining 75 to 85 per cent will develop chronic HCV³. Of those chronically infected, the risk of cirrhosis is 15 to 30 per cent within 20 years with a one to four per cent per annum risk of hepatocellular carcinoma³.

HCV epidemiology in South African is poorly understood and characterised. An estimated 600 000 South Africans (95 per cent UI 400 000 – 800 000) are chronically infected. Previous data suggests a seroprevalence in urban blood donors (low risk) of 0.01 - 2.6 per cent, with a higher rate in the rural population (3.8 per cent)⁴. Seroprevalence rates are higher in high-risk groups with recent data suggesting almost 50 per cent of PWID and three to six per cent of MSM, especially if HIV positive, are HCV infected. With PWID, there is significant regional variation in viremic prevalence, highest in Pretoria (~75 per cent) and between 30 and 40 per cent in Durban and Cape Town^{5,6}.

6.2 Hepatitis C Genotypes

HCV is a linear, single-stranded, positive-sense RNA virus belonging to the Flaviviridae family and has no polymerase proofreading ability, producing heterogeneous viral populations or quasispecies. There are six clinically relevant HCV genotypes and more than 80 subtypes. Genotype prevalence varies according to geographic region and route of acquisition⁷⁻⁸. South Africa is a “pan-genotypic” country with genotypes 1 to 5 being observed, however genotype 1 and 5 are predominant with genotype 4 being detected with increasing frequency. Genotype 5a, first identified in South Africa, is a genotype unique to South Africa⁹⁻¹². Viral genotype is a strong determinant of responsiveness to Interferon/Ribavirin based combination therapy, but not with the newer DAAs. In PWID, genotype 1a (73 per cent) and 3a (15 per cent), predominated.

6.3 Transmission of Hcv

HCV remains viable on environmental surfaces at room temperature for at least 16 hours, but typically no longer than four days, ,13,14 and transmission occurs via parenteral and non-parenteral routes. Ten to 40 per cent of HCV-infected individuals have no clear identifiable risk factor.

6.3.1 Parenteral transmission:

- HCV is most efficiently transmitted through parenteral inoculation:
 - predominant risk is in PWID through the sharing of syringes and needles¹⁵
 - risk is as high as 90 per cent after five years in PWID
 - tattooing, body piercing, traditional scarification or circumcision
 - needle-stick injuries

6.3.2 Non-parenteral transmission:

This is less well defined and includes:

- sexual transmission:
 - infrequent in heterosexual couples^{16,17}
 - HIV-infected heterosexual partners of HCV-infected individuals
 - high-risk behaviour sexual practices
 - MSM, especially if HIV positive¹⁶⁻¹⁹
- MTCT: 20-22
 - two to four per cent of infants born to HCV-infected women
 - vertical transmission risk increases to 10.8 to 25 per cent in HIV/HCV co-infected mothers

6.3.3 Household transmission:

- percutaneous/mucosal exposure to blood and sharing of contaminated personal items such as razors, toothbrushes, nail-grooming equipment is described, but uncommon.^{23,24}

The typical routes of transmission occur in South Africa with previous or current injecting drug use and blood/blood products before 1992 being most prevalent. However, the extent to which tattooing, body piercing and in particular traditional practices play a role, are unclear. Universal infectious precaution principles through maintaining clean, aseptic techniques and disinfection procedures in healthcare facilities, are important in preventing nosocomial transmission.

6.4 Groups at Risk for Hcv

Individuals at higher risk for CV infection include:

- PWID
- recipients of blood, blood products and solid organ transplants before 1992

- unsafe medical injection practices
- occupational exposure e.g. HCWs with needle stick injuries
- chronic haemodialysis (up to 10 per cent risk)
- high-risk/traumatic sexual practices
- MSM
- use of intranasal cocaine
- tattoos, body piercing, acupuncture
- surgical procedures, including dental/orthodontic procedures without proper sterilisation procedures
- traditional/cultural practices e.g. circumcision, scarification rituals


6.5 Clinical Presentation of Hcv

Variation in disease progression is characteristic of HCV infection and contributing factors include environmental, host genetic and immunological factors. Several factors including alcohol, HIV or HBV co-infection, iron overload states and obesity accelerate the clinical course of chronic HCV infection. HCV viral load or genotype does not influence the clinical course.

After the initial infection, HCV usually has an incubation period of four to 16 weeks. Most individuals who develop acute HCV are completely asymptomatic²⁵. Jaundice is uncommon and fulminant liver failure complicating acute HCV infection is rare. Anti-HCV antibodies can take 12 to 16 weeks, from the time of first infection to develop. However, HCV RNA is detectable in serum as early as one to three weeks after exposure. The persistence of HCV RNA beyond 24 weeks after acute infection marks the onset of chronic infection. The natural history of chronic infection is long and typically exceeds 20 years. Up to 25 per cent will develop progressive chronic liver disease and progress to cirrhosis and endstage liver disease. Once cirrhotic, the risk of hepatocellular carcinoma is one to four per cent per annum. Individuals are usually asymptomatic until presentation with complications of cirrhosis²⁵.

6.5.1 Natural history:

Figure 3: Natural history of HCV infection



6.6 Extrahepatic Manifestations of Hcv

HCV has been associated with several extrahepatic manifestations:

- autoimmune (e.g. Sjögren's syndrome, cryoglobulinaemia, polyarteritis nodosa)
- porphyria cutanea tarda
- lymphoproliferative diseases (e.g. B-cell non-Hodgkin's lymphoma)
- insulin resistance: Progressive insulin resistance, impaired fasting glucose (IFG) and/or type 2 diabetes mellitus (DM) are higher in chronic HCV patients (50 per cent) than in the general population (14.5 per cent)²⁶
- neurocognitive dysfunction

6.7 HIV/HCV Co-Infection

Documented HIV/HCV co-infection prevalence in South Africa ranges from one to 13.4 per cent and three to six per cent in MSM 27. HIV co-infection significantly alters the natural history of HCV 28-333 and is regarded as a priority for HCV treatment with DAAs given that there is:

- accelerated fibrosis and progression to cirrhosis
- increased hepatocellular carcinoma risk

- increased HCV infectivity risk, especially MTCT of HCV
- increased risk of ART and TB drug-induced liver injuries
- reduced response to interferon-based therapy

6.8 Diagnosis of HCV

- anti-HCV (EIA-antibody)
 - more than 95 per cent sensitivity
 - detects anti-HCV antibodies in 80 per cent infected individuals within six weeks of primary infection
 - screening test of choice:
- ELISA in a central laboratory
- RDT: Point-of-care anti-HCV using blood or saliva (more than 95 per cent sensitive and specific (positive predictive values more than 99 per cent and negative predictive values more than 95 per cent) in a local study

There are two WHO pre-qualified RDTs Test Kits:

- quantitative HCV PCR (viral load quantification):
 - mandatory if HCV EIA or RDT-positive - confirms active viraemia and is the preferred HCV PCR option

- Xpert HCV is WHO pre-qualified HCV quantification platform – assays available for both serum and fingerprick blood with desktop point-of-care s available
- central laboratories provide strong support – can utilise Roche Cobas Amplicor, Cepheid Xpert
- genotype testing
 - required to assist in choosing DAA treatment regimens - with pangenotypic DAA therapies this may not be required – genotyping to remain central laboratory function
- resistance associated substitution testing
 - for treatment failures (provided by a national centre) - managed at tertiary level care

6.9 Pre-Treatment Clinical Evaluation

6.9.1 Medical evaluation includes:

- clinical history and physical examination
- assessment of the liver disease:
 - liver profile: total bilirubin, conjugated bilirubin, albumin, ALT, AST, ALP, GGT
 - FBC and differential count
 - INR to assess synthetic function
 - fibrosis assessment: see 6.9.2
- assessment for other co-factors that accelerate fibrosis progression:
 - viral co-infection: HIV, HBV
 - alcohol use
 - non-alcoholic fatty liver disease
 - iron overload
 - drug/toxin-induced liver injury
- HBV and HAV serology to assess need for immunisation:
 - anti-HAV IgG negative: Needs HAV immunisation
 - HBsAg, anti-HBs and IgG HBcore negative: Needs HBV immunisation
- HCC screening: Alpha fetoprotein and ultrasound of the liver (six-monthly) if cirrhosis present even after SVR

6.9.2 Assessment of fibrosis

Assessing the degree of fibrosis remains an important aspect of management as it determines prioritisation and duration of therapy:

a) *histological assessment*

Liver biopsy remains the golden standard for the assessment of fibrosis^{34,35} as well as the contribution of ancillary pathology, e.g. steatosis, iron overload, alcohol and DILI.

b) *non-invasive assessment for fibrosis - preferred option for rapid linkage to care*

- serum-based markers: APRI (platelets and AST) score; FIB-4 (age, ALT, AST, platelets)³⁶
- vibration controlled transient elastography (VCTE): FibroScan©: Measures liver stiffness through doppler pulse ultrasound^{37,38}

Non-invasive techniques have excellent utility for the identification of HCV-related cirrhosis. Serum markers are less accurate at earlier disease stages, whilst VCTE has a better predictive value for milder (F0, F1) and more severe fibrosis ($\geq F3$) and slightly less so for mid-range fibrosis.

6.10 Treatment of HCV39-41

All patients with HCV must be offered therapy unless concomitant co-morbidities will result in short-term mortality.

6.10.1 Acute HCV:

- diagnosing suspected acute HCV is clinically challenging and tertiary level referral is strongly advised
- regular laboratory monitoring is recommended in the setting of acute HCV
- if a decision has been made to initiate treatment during the acute infection period, monitoring HCV RNA for at least 12 to 16 weeks before starting treatment is recommended to allow for spontaneous clearance
 - usually in setting of high risk for ongoing transmission: PWID and MSM
- if a delay in treatment initiation is acceptable, monitoring for spontaneous clearance is recommended for a minimum of six months

The same DAA regimens that are recommended for chronic HCV infection are recommended for acute infection - shorter durations of treatment are acceptable (eight weeks), but ideal timing of DAA initiation have not yet been established.

6.10.2 Chronic HCV

The aim of treatment is to achieve a SVR that results in:

- reduced necro-inflammation and progression to fibrosis, cirrhosis and endstage liver disease
- reduction in risk of HCC
- improved liver-related morbidity and mortality
- improved all-cause mortality
- prevents onward transmission

6.10.3 Treatment prioritisation i.e. patients who need to be treated first when the national programme is initiated:

- significant fibrosis (F3) or F4/cirrhosis (including compensated cirrhosis)
- HIV or HBV co-infection
- extrahepatic manifestations
- acute HCV
- liver transplant and other solid organ transplant recipients
- PWID

6.11 HCV Treatment Options

All HCV-infected patients should receive general counselling about the disease and must be referred for treatment to a treatment facility or centre experienced in managing HCV. PWID must receive additional harm reduction support.

Table 14: Definitions of terms used to evaluate response to HCV treatment

Term	Explanation
Sustained virological response (SVR)** • DAA-based therapy	• Undetectable HCV RNA at least 12 weeks after the end of DAA therapy
SVR is associated with a significant improvement in liver-related and all-cause morbidity and mortality and improved quality of life	

**DAAs are currently not registered by SAHPRA. The process to obtain DAAs is to apply to the Drug and Therapeutic Committee of the individual hospital for permission to use their budget for DAAs or for support to fund DAAs. Then apply for a SAHPRA Section 21 approval, and then arrange for generic DAA drugs to be supplied via India.

6.11.1 DAA therapy

The DAA regimens combine drugs from different classes that target multiple sites of the HCV life cycle. DAA combinations increase efficacy, decrease the risk of viral resistance and act synergistically to increase SVR.

The three main classes of DAAs are:

a) NS3/4A Protease Inhibitors (PI): Simeprevir, Grazoprevir, Voxilaprevir, Glecaprevir

- these PIs have a high potency, but a low barrier to resistance. Voxilaprevir and Glecaprevir are pangenotypic

b) NS5A inhibitors: Daclatasvir, ledipasvir, Elbasvir, Velpatasvir, Pibrentasvir

- these DAAs have a very high potency, a low barrier to resistance and are mostly active against all genotypes, except Elbasvir and ledipasvir

c) NS5B polymerase inhibitors: Sofosbuvir, Dasabuvir

- the nucleoside NS5B polymerase inhibitor, Sofosbuvir is the first in this class. It has intermediate potency with pangenotypic activity and a high barrier for resistance
- non-nucleoside polymerase inhibitors, including Dasabuvir have intermediate potency, a more limited genotypic activity and a low barrier to resistance

6.11.2 Current HCV treatment recommendations

Genotype		SOF-VEL	SOF-LDV	SOF-DCV3	GLE-PIB
Genotype 1a	Naive	12w	8w – 12w1	12w	8w
	Experienced	12w	12w2	12w	8w
Genotype 1b	Naive	12w	8w – 12w1	12w	8wk
	Experienced	12w	12w	12w	8w
Genotype 2	Naive	12w	No	12w	8w
	Experienced	12w	No	12w	8w
Genotype 3	Naive	12w	No	12w	8w
	Experienced	12w	No	12w	12w
Genotype 4	Naive	12w	12w	12w	8w
	Experienced	12w	12w2	12w	8w
Genotype 5	Naive	12w	12w	12w	8w
	Experienced	12w	12w2	12w	8w

Table 15: DAA regimens for non-cirrhotic treatment naive or experienced (including PEG-IFN/Ribavirin; PEG-IFN, or Sofosbuvir and Ribavirin) HCV mono-infected patients

SOF - Sofosbuvir; **VEL** - Velpatasvir; **LDV** - Ledipasvir; **DCV** - Daclatasvir; **GLE** - Glecaprevir; **PIB** - Pibrentasvir; **w** - weeks. Pangenotypic regimens are shaded. Ledipasvir active against GT1, 4, 5

- eight weeks if HCV RNA is less than 6 000 000IU/ml, HIV-negative and non-black
- requires addition of weight based dosed Ribavirin
- as per WHO guidance; if treatment experienced consider addition of ribavirin

Genotype		SOF-VEL	SOF-LDV1	SOF-DCV2	GLE-PIB
Genotype 1a	Naive	12w	12w	12w	12w
	Experienced	12w	12w	12w	12w
Genotype 1b	Naive	12w	12w	12w	12w
	Experienced	12w	12w	12w	12w
Genotype 2	Naive	12w	No	12w	12w
	Experienced	12w	No	12w	12w
Genotype 3	Naive	12w	No	12w	12w
	Experienced	12w	No	12w	16w
Genotype 4	Naive	12w	12w	12w	12w
	Experienced	12w	12w	12w	12w
Genotype 5	Naive	12w	12w	12w	12w
	Experienced	12w	12w	12w	12w

Table 16: DAA regimens for compensated cirrhosis treatment naive or experienced (including PEG-IFN/Ribavirin; PEG-IFN, or Sofosbuvir and Ribavirin) HCV mono-infected patients

SOF - Sofosbuvir; **VEL** - Velpatasvir; **LDV** - Ledipasvir; **DCV** - Daclatasvir; **GLE** - Glecaprevir; **PIB** - Pibrentasvir; **GZR** - Grazoprevir; **EBR** - Elbasvir; **w** - weeks. Pangenotypic regimens are shaded.

- with compensated cirrhosis or treatment-experienced, consider adding weight based dosed Ribavirin
- as per WHO guidance; consider add Ribavirin if compensated cirrhosis or treatment-experienced
- if ribavirin intolerant, consider 24 weeks of SOF-LDV, SOF-DCV or SOF-VEL

DAAs are not as yet registered in South Africa. However, in the interim, DAAs are available via a SAHPRA Section 21 application process for named patients. Registration is anticipated in 2019 and beyond.

6.11.3 DAA treatment efficacy

SVR rates for DAA therapies exceed 90 per cent for all genotypes. Sofosbuvir/Velpatasvir, Sofosbuvir/Daclatasvir or Glecaprevir/Pibrentasvir offer a pan-genotypic option with SVR of 95 per cent or more. The presence of cirrhosis and previous treatment determines duration of treatment or need for Ribavirin, but no longer determines SVR. Individuals with stage 4 chronic kidney disease or on dialysis have been difficult to treat, but Glecaprevir/Pibrentasvir is effective and safe with SVR of 90 per cent and more. If Glecaprevir/Pibrentasvir is unavailable, Sofosbuvir-based therapy must be discussed with an expert. The major factor influencing DAA therapy is drug-drug interactions (especially with ARVs) that alter DAA efficacy through pharmacokinetic interactions as a result of enzyme induction or inhibition of the CYP P-450 enzyme subunits involved in the metabolism of DAAs. All potential drug-drug interactions must be checked before initiation of DAA therapy. <https://www.hep-druginteractions.org>

6.11.4 Monitoring on DAA therapy

Patient monitoring is substantially simplified on DAA therapy as a result of the reduced side effect profile.

Recommended monitoring is as follows:

- baseline: FBC, Creatinine, liver profile, HCV RNA quantification
- week 4: FBC, INR, ALT, HCV RNA quantification
- week 8: FBC, differential (only if Ribavirin used)
- week 12 and 24: FBC, differential (only if Ribavirin used), Creatinine, limited liver profile, HCV RNA quantification (to assess EOT response)
- 12 weeks after EOT: Liver profile, HCV quantification (to assess for SVR)

If a patient has cirrhosis, monitor more frequently for decompensation.

6.12 Treatment of Special Populations

With the introduction of DAA therapy, there are now very few difficult-to-treat populations. Some populations require particular attention:

6.12.1 PWID

The WHO, United Nations Office on Drugs and Crime (UNODC), Joint United Nations Programme on HIV/AIDS (UNAIDS) and other normative agencies recommend treating PWID living with HCV infections using DAAs. Real world data on SVR among people with recent illegal drug use ranges between 95 per cent and 98 per cent. Abstinence from ongoing use of illegal drugs is not a pre-requisite for DAA therapy, but counselling around potential risks of ongoing substance use and harm reduction is encouraged. Accessing HCV care and treatment within hospitals is challenging with community-based services with hepatologist support a proven and viable model for PWID with HCV mono-infection in locations with a high concentration of PWID. Treatment services should be accompanied by voluntary access to psychosocial services, sterile injecting equipment and opioid substitution therapy. DAA treatment should include counselling around potential re-infection, mechanisms to prevention infection and need for routine screening. Treatment approaches for PWID should take a public health approach and aim for rapid scale-up to enable treatment of PWID networks to reduce community viral load and risk of re-infection.

6.12.2 HCV/HIV co-infection

HIV co-infection significantly alters the natural history of HCV and is regarded as a priority for HCV treatment. In the PEG-IFN/RBV era of treatment, co-infection significantly and negatively influenced response rates. SVR rates for genotype 1 HCV were reduced to 30 to 40 per cent, whilst SVR rates were better for genotype 2 and 3. Only patients with a CD4 > 500 mm³ (either on ART or not) were eligible for therapy and cytopenias on therapy were significant. DAA therapy has completely altered therapeutic options for co-infected patients. Co-infection is no longer regarded as a “difficult to treat” population. SVR rates for co-infected patients are no different than that for HCV mono-infected patients. Treatment regimen recommendations for co-infection are the same as for HCV mono-infection. Drug-drug interactions need to be carefully assessed prior to selecting and initiating DAA therapy.

6.12.3 Decompensated liver disease

The ASTRAL-4 study showed that the combination of Sofosbuvir/Velpatasvir resulted in overall SVR rates of more than 90 per cent in patients with decompensated liver disease (Genotypes 1, 2, 3, 4 and 6).⁴²

6.12.4 Treating children

Therapy has proven safe and effective in adolescents aged 12 to 17 years and weighing more than 35kg.⁴³ Treatment duration is dependent on treatment history, genotype and cirrhosis. Data supports 12 weeks of Sofosbuvir-Ledipasvir for GT 1, 4, 5 and 6 and Sofosbuvir-Ribavirin for GT2 (12 weeks) or GT3 (24 weeks). The United States Food and Drug Administration (FDA) has recently approved Glecaprevir-Pibrentasvir for treatment of adolescents with GT1-6 with or without compensated cirrhosis.

6.12.5 Pregnancy

Ribavirin is teratogenic and is contraindicated during pregnancy. In addition, pregnancy should be avoided for six months after the end of Ribavirin-based therapy. The new DAA therapies are currently contraindicated during pregnancy. For now, women with HCV who wish to have children should either consider DAA therapy before pregnancy or defer treatment till after successful pregnancy. With effective short duration DAA therapy, the prior strategy is preferred. New, but very preliminary data suggests that DAA therapy in pregnancy may be safe, but more work is needed. Appropriate contraceptive measures should be used by women of childbearing age using Ribavirin or DAAs as well as the partners of men on therapy. Caesarean section does not reduce the risk of perinatal MTCT of HCV and instrumentation (e.g. foetal scalp monitoring, and forceps delivery) should be avoided as it increases the HCV transmission risk.

6.13 Primary Prevention and Control

There is no effective vaccine or immunoglobulin available for the prevention of HCV infection.

The major principles of prevention and control are to:

- reduce the number of new infections through prevention of transmission
- treat those who may transmit HCV e.g. PWID, MSM

Treatment with effective DAA therapy as a means of viral eradication has become a reality and may well reduce the need for a vaccine.

6.13.1 Blood and blood products:

- all blood and blood products are screened for HCV by the SANBS by EIA since 1991 and anti-HCV positivity is confirmed by NAT testing since 2005
- all plasma-derived products are subjected to virus inactivation
- all HCV-positive blood and blood products are removed from the pool of transfusion units
- disease transmission has been documented from HCV antibody-negative and PCR-negative blood units and for this reason blood products should only be used when necessary

6.13.2 HCW exposure:

- all HCWs must implement standard infection precautions and adhere to infection control practices at all times to limit and prevent infection of blood-borne infections including HCV, HBV and HIV
- reusable surgical and medical instruments must be adequately sterilised

Management of HCW following needle stick exposure to HCV: ⁴⁴

Risk of HCV acquisition following percutaneous exposure is 1.8 per cent (range nil to seven per cent), but rare from mucous membrane exposure. One study indicated that transmission only occurred following exposure to hollow bored needles.⁴²

- establish HCV, HIV and HBV status of the source patient and HCW
- baseline testing of HCW within 48 hours of exposure (anti-HCV and HCV PCR and ALT) as well as screening for HBV and HIV
- frequency of follow up anti-HCV and HCV PCR testing depends on management objectives:
 - monthly testing if considering early initiation of treatment, otherwise at 12 and 24 weeks
- efficacy of DAA therapy is the same as for chronic HCV infection, although timing of treatment not yet clear
- post-exposure use of immune globulin or DAAs is ineffective in preventing HCV and is not recommended

6.13.3 PWID:

- strengthening and expansion of needle and syringe programmes and provision of opioid substitution therapy to reduce the spread of HCV, HBV and HIV in South Africa is required and noted in South Africa's *National Strategic Plan on HIV, TB and STIs (2017 – 2021)*
- treatment for this group should be prioritised as a means of avoiding further HCV transmission in an injecting group
- referral to organisations and individuals providing evidence-based substance use prevention, treatment and support services is recommended

6.13.4 Haemodialysis patients

Patients with renal failure on haemodialysis have a high risk of blood-borne viral infections:

- HCV seroprevalence ranges from less than 10 to 90 per cent in haemodialysis patients
- improved HCV NAT screening techniques will reduce the incidence of HCV infection
- nosocomial/HCAI transmission is the most probable cause of HCV in these patients when parenteral transmission cannot be identified
- strict adherence to universal precautions against nosocomial infections/HCAI reduces the risk of transmission ⁴⁵

6.14 Secondary Prevention

The following secondary prevention activities are recommended for HCV-infected persons:

- HCV testing should be offered to household and sexual contacts and injecting partners of PWID followed by counselling and linkage to treatment. This will enable proper medical management of the disease in infected persons as well as the introduction of control measures to prevent transmission to contacts
- those with chronic HCV should be advised to avoid alcohol and be given the appropriate support to achieve abstinence as alcohol exacerbates HCV liver disease
- HCV-infected patients should receive immunisation against HAV and HBV and be screened for HIV

6.15 Diagnostic, Prevention and Treatment Options at Primary, Secondary and Tertiary Levels of Care

6.15.1 Diagnosis:

- all levels of care: anti-HCV (EIA) and HCV PCR (NAT)
- secondary and tertiary level care: HCV RNA quantification
- tertiary level care: HCV genotype and HCV resistance associated substitution testing (RAS)

6.15.2 Assessment of clinical severity:

- all levels of care: FBC, INR, serum creatinine and liver profile; enables APRI scoring to assess for cirrhosis and choice of NUC
- secondary and tertiary levels of care: Ultrasound liver ± mobile fibroscan
- tertiary level care: Fibroscan and liver biopsy

6.15.3 Treatment:

- acute HCV:
 - diagnosing suspected acute HCV is clinically challenging and tertiary level referral is strongly advised
- chronic HCV
 - all HCV-infected individuals are candidates for DAA therapy
 - no DAAs are registered as yet in South Africa and presently all HCV-infected individuals are treated at tertiary level
 - a Section 21 SAHPRA application for DAA therapy must be made
- on registration of DAAs in South Africa:
 - uncomplicated cases of chronic HCV: Treat at secondary and tertiary levels of care or at community-based clinics for key populations (PWID and MSM)
 - cirrhotics (compensated and decompensated): Tertiary level care
 - HIV/HCV co-infection: Tertiary level care and with option of down-referral to secondary or primary level care, once HCV



- successfully treated and stable on ART
 - HBV/HCV/HIV co-infection: Tertiary level care and with option of down-referral to secondary or primary level care, once HCV
 - successfully treated and stable on ART

6.15.4 DAA regimens: 12 weeks therapy

- Sofosbuvir/Ledipasvir: Genotypes 1, 4, 5 and 6*
- Sofosbuvir /Daclatasvir: Genotypes 1 to 5*
- Sofosbuvir/Velpatasvir: Genotypes 1 to 6*
- Glecaprevir/Pibrentasvir: Genotypes 1 to 6
 - * If cirrhosis present, add Ribavirin or extend to 24 weeks of therapy

6.15.5 Prophylaxis:

- all levels of care:
 - screening of contacts: anti-HCV
 - HBV immunisation

HEPATITIS D (HDV)

CHAPTER

7



7.1 Introduction

HDV is a unique RNA virus that is dependent on HBV for survival. HDV is a defective or incomplete virus that does not encode its own replicase and is dependent on HBV providing HBsAg to coat its virion in order to replicate.^{1,2} Thus, there are no viral replicative enzymes for drugs to target. Eight HDV genotypes have been identified and are associated with variable clinical courses. In Africa, where HBV is endemic, documented HDV seroprevalence rates vary geographically from low rates in countries south of the equator (0 to 0.6 per cent) to high rates north of the equator (two to 67 per cent).^{1,3} In South Africa, seroprevalence rates of 0 to 0.6 per cent are documented.⁴⁻⁷ HDV co-infection should always be considered in stable HBV-infected individuals who deteriorate for no apparent cause if they originate from parts of Africa where HDV is more prevalent.

7.2 Transmission of HDV

HDV is transmitted via the parenteral route:

- sexual transmission
- perinatal transmission (MTCT): low risk
- IUD

7.3 Groups at Risk for HDV:

- individuals co-habiting with an HDV-infected HBsAg carrier in the setting of an overcrowded family household
- IUD: Risk of triple infection with HBV, HDV and HIV

7.4 Clinical Presentations of HDV:

- clinically, HDV-related disease can be separated into three entities.⁸ Refer to Chapter 5: HBV for signs and symptoms

7.4.1 Acute HBV/HDV co-infection (including fulminant hepatitis):

- if acquired in adulthood, more than 95 per cent of individuals will clear both HBV and HDV, although there is a greater risk of fulminant hepatitis than with acute HBV

7.4.2 Acute HDV super-infection of a patient with chronic HBV:

- can present as an acute hepatitis in a previously asymptomatic HBsAg carrier or result in further clinical deterioration in individuals with established HBV disease

7.4.3 Chronic HDV

- HBV replication is usually suppressed (low or undetectable HBV DNA) and HBeAg is negative
- HDV becomes chronic in 70 to 90 per cent of individuals with superinfection and there is more rapid progression to cirrhosis and decompensation, especially in PWID where end-stage liver disease can occur in less than two years
- increased risk of hepatocellular carcinoma
- HBV/HDV/HCV triple infection: HDV is usually the dominant virus, inhibiting the replication of HBV and HCV

7.5 Diagnosis of HDV:

- acute HBV/HDV co-infection:
 - anti-HDV IgM-positive and detectable HDV RNA
 - HBsAg-positive and IgM anti-HBc-positive
- acute HDV super-infection of patient with chronic HBV:
 - anti-HDV IgM-positive and detectable HDV RNA; HBsAg-positive
 - HBeAg and anti-HBe-positivity will depend on the phase of chronic HBV infection
- chronic HDV:
 - anti-HDV IgG-positive and detectable HDV RNA; HBsAg-positive
 - HBeAg and anti-HBe-positivity will depend on the phase of chronic HBV infection
- HBV DNA levels: Vary depending on the HBV replication
- markers of HDV infection decrease rapidly and disappear after the clearance of HBsAg
- diagnostic serology and HDV DNA not routinely available – refer to tertiary level care for diagnosis and management

7.6 Prevention of HDV:

- no immunoglobulin available
- no specific HDV vaccine
- HBV immunisation is effective prophylaxis against HDV

7.7 Treatment of HDV:

- current recommended treatment of compensated chronic HDV disease: Peginterferon-alfa given weekly for 48 weeks, leading to HDV RNA clearance in 17 to 47 per cent, but relapse is common.⁹ Low baseline HBsAg and HDV RNA titers may predict a positive response to therapy
- control of HDV infection may be associated with HBV reactivation requiring antiviral therapy
- liver transplantation for HBV/HDV cirrhosis has a better prognosis than transplantation for HBV cirrhosis

Refer all suspected cases to tertiary level care for diagnosis and management as new therapies are in development.¹⁰

HEPATITIS E (HEV)

CHAPTER

8



8.1 Introduction

Hepatitis E is caused by the hepatitis E virus (HEV), which is a major etiologic agent of enterically transmitted non-A, non-B, non-C viral hepatitis worldwide.¹⁻⁷ HEV is a small, single-stranded ribonucleic acid (RNA) virus. It has at least four different types: genotypes 1, 2, 3 and 4. Genotypes 1 and 2 have been found only in humans.^{8,9} Genotype 3 and 4 viruses circulate in several animals (including pigs, wild boars, deer) without causing any disease. There are clear differences in the epidemic potential of the various genotypes.^{1, 4} Documented seroprevalence rates in South Africa range between two and 29 per cent, suggesting that HEV is endemic in South Africa.¹⁰⁻¹² Both acute and chronic cases of HEV have been reported in South Africa.^{13,14}

8.2 Transmission of HEV:15

- faecal-oral transmission:
 - ingestion of faecally contaminated food or water
 - person-to-person spread
- zoonotic transmission through consumption of raw/undercooked meat (pork or deer) of infected animals

- parenteral transmission has been described in:
 - blood transfusions¹⁶
 - perinatal transmission¹⁷

Compared to HAV, HEV is less resistant to environmental conditions such as temperature; and prolonged excretion of HEV in stool following symptomatic/asymptomatic infections is rare. The modes of transmission vary dependent on the HEV genotype.

8.2.1 Genotypes 1 and 2:

- epidemic outbreaks, usually faecal-oral transmission
- men are more likely to present with symptomatic disease, but most patients have a self-limiting hepatitis
- outbreaks of HEV have been documented in sub-Saharan Africa^{7,18}

8.2.2 Genotypes 3 and 4:

- primarily a zoonosis associated with eating pork, deer and mussels
- parenteral transmission via blood transfusion and perinatal routes is described^{16,17}

- usually asymptomatic or a mild disease
- increased risk for symptomatic disease in older men and HBV infected individuals

8.3 Groups at Risk for HEV

Individuals at higher risk for HEV infection include:

- people who are household/sexual contacts of infected individuals
- healthcare workers
- preschool children attending daycare centres, their parents and siblings
- employees of daycare centres
- residents and employees of closed institutions where personal hygiene is compromised
- individuals living in refugee camps or internally displaced persons camps
- handlers of domestic animals are at risk of occupational exposure
- individuals with chronic liver disease: These individuals are not at increased risk for infection, but are at risk for severe disease
- immunosuppressed individuals including solid organ transplants, HIV-positive individuals and individuals with haematological malignancies: These individuals are not at increased risk for infection, but are at risk for severe disease and potentially chronic infection
- food handlers: These individuals are not at higher risk for infection, but pose a higher risk of transmission

8.4 Clinical Presentations of HEV2

The clinical presentation is modulated by the underlying epidemiological pattern of a particular region, by genotype; and the immune status and age of the individual:

- mild fever during initial phase
- anorexia
- nausea and vomiting lasting for a few days
- abdominal pain
- pruritus, skin rash or joint pains
- jaundice
- slightly enlarged tender liver
- acute liver failure (rare cases)

8.4.1 The different levels of disease severity include:

a) *mild subclinical illness:*

- asymptomatic infections tend to be more common in children¹⁹

b) *self-limiting acute hepatitis resembling HAV20*

- attack rate highest in men aged 15 to 40 years (10 to 30 per cent)
- symptomatic acute hepatitis occurs in up to 15 per cent during an outbreak

c) *severe disease*

- pregnant women in the third trimester^{21,22}
- individuals with chronic liver disease

d) *chronic hepatitis: HEV RNA-positivity in stool or serum persisting for more than six months:*

- solid organ transplant recipients, HIV patients and haematological malignancies²³⁻²⁷
- transaminitis is usually mild in the range of 100 to 300 U/L, usually not jaundiced
- progression to chronicity occurs in approximately 60 per cent immunosuppressed solid organ transplant recipients as a result of impaired specific T-cell responses
 - o rapid progression to cirrhosis can occur
 - o tacrolimus therapy is the main predictive factor for chronic hepatitis
- chronic hepatitis has only occurred with Genotype 3 infections²⁴

8.5 Diagnosis of HEV

Elevated serum transaminases (ALT and AST usually 10 to 100 times upper limit of normal) confirm the presence of an acute hepatitis:

- acute HEV: Positive anti-HEV IgM and positive HEV PCR (blood)
- previous exposure to HEV: Positive anti-HEV IgG
- chronic HEV: Positive anti-HEV IgG and a positive HEV PCR (blood) for more than six months

Most patients with acute HEV will also have anti-HEV IgG at initial presentation. Anti-HEV IgM levels decline rapidly during early convalescence, whilst anti-HEV IgG persists long term. HEV has been found to be the cause of deranged liver enzymes in a number of cases of hepatitis diagnosed as drug-induced liver injury.²⁸

8.6 Treatment of HEV

8.6.1 Acute HEV:

- treatment of acute HEV is generally supportive
- refer patients with severe symptomatic disease and pregnant women to hospital
- liver transplantation: May be considered in patients presenting with fulminant liver failure
- adherence to standard infection and contact precautions is usually sufficient to prevent spread of infection in healthcare facilities and institutions
- sanitary disposal of faecal waste and strict hand hygiene is essential
- no special diet is required, but patients should be advised to abstain from alcohol and the use of any other hepatotoxic drugs
- exclusion from work and school for two weeks after the onset of jaundice, provided the AST and ALT levels are less than 100 U/L. Patients can only return to active sport or strenuous activity once AST and ALT levels have normalised
- adults should return to fulltime work before returning to sport

8.6.2 Chronic HEV:

- decrease in the immunosuppression: First step in management of chronic HEV in solid organ transplant recipients:
 - 30 per cent will clear HEV, if immunosuppression is reduced
- in the absence of an adequate response to reduced immunosuppression:
 - discuss the use of Ribavirin 600-800 mg/day for three months with a hepatologist
- overall mortality: 0.5 to four per cent
- increased mortality in certain groups:
 - children younger than three years: five to eight per cent^{18, 20}

- pregnant women in the third trimester: 25 per cent^{21,22}
- patients with chronic liver disease: 75 per cent¹⁵

8.7 Prevention of HEV

There is no immunoglobulin and the HEV vaccine is currently unavailable in South Africa.

8.7.1 General measures to prevent the spread of HEV:

- improving sanitation and safety of public water supplies
- maintaining good hygienic practices such as hand washing with soap
- standard food and water hygiene and infectious precautions are recommended:
- avoid intake of raw, uncooked meat to prevent zoonotic HEV transmission
- risk decreased by cooking the meat to temperatures higher than 70°C

8.7.2 Response to HEV outbreaks

All HEV outbreaks should prompt the following actions:

- notify the case investigate a single sporadic case, and an outbreak of HEV (≥ 2 epidemiologically linked cases) should be thoroughly responded to, by following the epidemic preparedness and response guidelines
- thorough environmental assessment including inspection of food preparation and common food sources, water quality and general hygiene
- if a common source outbreak is suspected and the source is unknown, further analytical epidemiology is required to determine the potential source



8.8 Diagnosis and Treatment Options: Primary, Secondary and Tertiary Levels of Care

8.8.1 Diagnosis:

- all levels of care: anti-HEV IgM and anti-HEV IgG
- tertiary level care: HEV PCR and HEV Genotype

8.8.2 Assessment of clinical severity:

- all levels of care: Liver profile and INR

8.8.3 Treatment:

- primary level care: Uncomplicated cases
- secondary level care: Symptomatic cases with jaundice, nausea and vomiting; but no encephalopathy and $INR < 2$: Intravenous fluids and monitoring of synthetic function
- tertiary level care:
 - o acute liver failure (jaundice, encephalopathy and $INR > 1.5$): Preferably with potential access to liver transplantation
 - o chronic HEV

REFERENCES

CHAPTER

9



CHAPTER 1: INTRODUCTION

1. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending Viral Hepatitis. June 2016. <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1> (Accessed 1 May 2019)
2. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. *The Lancet Gastroenterology and Hepatology* 2019; 4(2): 135-84.

CHAPTER 2: EPIDEMIOLOGY OF VIRAL HEPATITIS IN SOUTH AFRICA

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *Lancet*.2012;380(9859):2095-128

2. Peter Byass. The global burden of liver disease: a challenge for methods and for public health. *BMC Medicine* 2014, 12:159
3. Mokdad AA, Lopez DL, Shahrzad S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Medicine* 2014, 12:145
4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet*. 2016 Jul 6. Epub ahead of print
5. WHO Executive Board (134th session). Hepatitis: improving the health of patients with viral hepatitis. Report by the Secretariat. Geneva:WHO;2014[EB134/36] (http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_36-en.pdf, accessed 10 May 2019)
6. WHO. Global hepatitis report, 2017. Geneva: World Health Organization, April, 2017. www.who.int/hepatitis/publications/globalhepatitis-report2017/en/ (accessed May 24, 2019).
7. Martin DJ, Blackburn NK, Johnson S, McAnerney JM. The current epidemiology of hepatitis A infection in South Africa: implications for vaccination. *Trans R Soc Trop Med Hyg* 1994;88(3):288-291

8. Schoub BD, Blackburn NK, Martin DJ, McAnerney JM, Sim JG. A Study of Sero-prevalence of Hepatitis A in Infants and Children in South Africa. *Hepatitis Update* 1999;1-7
9. Schoub BD, Blackburn NK, Martin DJ, McAnerney JM, Sim JG. Should hepatitis A vaccination be routinely given to children? *S Afr Med J.* 1999;89 (10):1074-5
10. Madden RG, Sebastian Wallace S, Mark Sonderup M et al. Hepatitis E Virus: Western Cape, South Africa. Submitted 2015
11. McMahon BJ. The natural history of chronic hepatitis B virus infection. *Hepatology.* 2009;49 (5 Suppl):S45-55
12. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical Africa. *Gut* 1996;38(Suppl 2): S5-S12
13. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. *Vaccine* 2012; 30 Suppl 3:C45-51
14. Kew M. Hepatitis B virus infection: the burden of disease in South Africa. *The Southern African Journal of Epidemiology and Infection.* 2008;23(1):4-8
15. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; 386: 1546–55
16. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. *JAMA* 1987;257(19):2597-2603
17. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. *JAMA* 1988;260(15):2231-2235
18. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. *JAMA* 1996;276(11):906-908
19. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 2001;135(9):796-800
20. Mphahlele MJ, Tshatsinde EA, Burnett RJ, Aspinall S. Protective efficacy and antibody follow-up of hepatitis B vaccine within the South African expanded programme on immunisation. *S Afr Med J* 2002;92(8):612-613
21. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. *Vaccine* 2001;19(28-29):3912-3918
22. Tsebe K, Burnett RJ, Hlungwani NP, et al. The first five years of universal hepatitis B vaccination in South Africa: Evidence for elimination of HBsAg carriage in under 5-year-olds. *Vaccine* 2001;19(28-29):3919-3026
23. Schoub BD, Matai U, Singh B, et al. Universal immunization of infants with low doses of a low-cost plasma-derived hepatitis B vaccine in South Africa. *Bull World Health Organ* 2002;80(4):277-281
24. Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. *Vaccine* 2009;27(1):146-151
25. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of Hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012;30(12):2212–9
26. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. *J Med Virol* 2009;81(3):406–12
27. Boyles TH, Cohen K. The prevalence of hepatitis B infection in a rural South African HIV clinic. *S Afr Med J* 2011;101(7):470–1
28. Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. *S Afr Med J* 2008;98(7): 541-4
29. Burnett RJ, Ngobeni JM, Francois G, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. *Int J STD AIDS* 2007;18(3):152–6

30. Andersson MI, Maponga TG, Ijaz S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. *Vaccine* 2013;31(47):5579-84
31. Puoti M, Torti C, Bruno R, Filice G, Carosi G Natural history of chronic hepatitis B in co-infected patients. *J Hepatol.* 2006; 44(1 Suppl):S65-7
32. Scheibe A et al. TB HIV Care, University of Cape Town, Anova Health Institute, OUT Wellbeing, National Institute of Communicable Diseases. Viral Hepatitis C initiative for key populations in South Africa. Interim study findings report. 2018. Cape Town: TB HIV Care.
33. Mdlalose N, Parboosing R, Moodley P. The prevalence of hepatitis B virus infection in HIV-positive and HIV-negative infants: KwaZulu-Natal, South Africa. *African Journal of Laboratory Medicine* 2016;5(1):1-5
34. Maynard JE. Hepatitis B: Global importance and need for control. *Vaccine* 1990;8(SUPPL.):S18-S20
35. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *The Lancet Infectious Diseases* 2016; 16(7): 797-808.
36. Ellis LA, Brown D, Conradie JD, Paterson A, Sher R, Mollo J, et al. Prevalence of hepatitis C in South Africa: detection of anti-HCV in recent and stored serum. *J Med Virol.* 1990;32(4):249-51
37. Gogela NA, Sonderup MW, Rebe K, CHIVese T, Spearman CW. Hepatitis C prevalence in HIV-infected heterosexual men and men who have sex with men. *South African medical journal.* 2018;108(7):568-72.
38. Scheibe A, Young K, Moses L, Basson RL, Versfeld A, Spearman CW, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. *Harm reduction journal.* 2019;16(1):28
39. Petersen Z, Myers B, van Hout M-C, Plüddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. *Harm Reduct J* [Internet]. 2013 Aug 19 [cited 2013 Aug 26];10(1):13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23957896>
40. UNAIDS. Do No Harm. Health, human rights and people who use drugs. Report [Internet]. Geneva: UNAIDS; 2016. Available from: <http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=54015717&lang=tr&site=ehost-live>
41. Prof. Tim Lane (principal investigator) and South African National AIDS Council at the South African Key Populations Cascades Workshop, Pretoria, 6 February 2018).
42. Davis GL. Hepatitis C virus genotypes and quasispecies. *Am J Med* 1999;107(6B):21S-6S
43. Tucker TJ, Keen GA, Yeats J, Hardie D, Van der Ryst E, Cloete K, et al. Hepatitis D virus - How prevalent? *South African Medical Journal* 1997;87(10):1386-8
44. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. *Lancet* 2011; 378:73-85
45. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending Viral Hepatitis. June 2016. <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1> (Accessed 1 May 2019)
46. Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets.; *Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA).* *Lancet Gastroenterol Hepatol.* 2017 Dec;2(12):900-909

CHAPTER 3: GUIDING PRINCIPLES

1. WHO Manual for the Development and Assessment of National Viral Hepatitis Plans. A provisional document, September 2015 www.who.int/hepatitis/publications/manual-hep-plan/en/ Accessed 24 May 2019

CHAPTER 4: HEPATITIS A (HAV)

1. Koff RS. Hepatitis A. *Lancet.* 1998; 351:1643-49

2. Brown EA, Stapleton JT. Hepatitis A Virus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC, eds. *Manual of Clinical Microbiology*. Vol 2. 8th ed. Washington D.C: ASM Press; 2003: 1452
3. Centers for Disease Control and Prevention. Prevention of Hepatitis A through Active or Passive Immunisation. *MMWR*. 2006;55(No. RR-7):1-23
4. Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, eds. *Mandell, Douglas and Bennett's: Principles and Practice of Infectious Diseases*. Vol 1. 6th ed. Philadelphia, PA: Elsevier; 2005:1426
5. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. *Int J Health Geogr* 2011; 18;10:57
6. Jacobsen KH. Hepatitis A virus in West Africa: Is an epidemiological transition beginning? *Niger Med J*. 2014;55(4):279-84
7. Immunoglobulins: Human normal immunoglobulins, page 349 in *South Africa Medical Formulary*. 12th ed. 2016 A joint initiative of Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town and the Health and Medical Publishing Group, publishers for the South African Medical Association.
8. Viral Vaccines: Hepatitis A vaccines, page 361 in *South Africa Medical Formulary*. 12th ed. 2016 A joint initiative of Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town and the Health and Medical Publishing Group, publishers for the South African Medical Association.
9. WHO: Position paper Hepatitis A vaccine. *WER*. 2000; 75:37-44
10. Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. *Commun Dis Public Health* 2001; 4:213-27
11. Fiore AE. Hepatitis A Transmitted by Food. *Clinical Inf Dis*. 2004;38:705-15
12. Centers for Disease Control and Prevention. Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007;56;1080-84
13. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A Vaccine versus Immune Globulin for Post-exposure Prophylaxis. *NEJM*. 2007;357;1685-94

CHAPTER 5: HEPATITIS B (HBV)

1. McMahon BJ. The natural history of chronic hepatitis B virus infection. *Hepatology*. 2009;49(5 Suppl):S45-55
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; 386: 1546–55
3. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of Hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012;30(12): 2212–9
4. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for Highly active antiretroviral therapy at a Tertiary Hospital. *J Med Virol* 2009;81(3):406–12
5. Boyles TH, Cohen K. The prevalence of hepatitis B infection in a rural South African HIV clinic. *S Afr Med J* 2011;101(7):470–1
6. Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. *S Afr Med J* 2008;98(7):541-4
7. Burnett RJ, Ngobeni JM, Francois G, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. *Int J STD AIDS* 2007;18(3):152–6
8. Andersson MI, Maponga TG, Ijaz S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. *Vaccine* 2013;31(47):5579-84
9. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. *J Hepatol* 2006; 44(1 Suppl):S65-70
10. Maynard JE. Hepatitis B: Global importance and need for control. *Vaccine* 1990;8(SUPPL.):S18-S20

11. Norder H, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar IK, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. *Journal of General Virology* 1993;74(7):1341-8
12. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. *J Viral Hepat*. 2005;12(5):456-64
13. Schaefer S. Hepatitis B virus: Significance of genotypes. *Journal of Viral Hepatitis* 2005;12(2):111-24
14. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. *Liver Int*. 2005; 25(6):1097-107
15. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. *Hepatology Res*. 2007;37(s1):S9-S19
16. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodgkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. *J Med Virol*. 2005; 75(4): 513-21
17. Kew MC, Reis P, Macnab GM. The witch doctor and tribal scarification of the skin and the hepatitis B antigen. *South African Medical Journal* 1973;47(50):2419-20
18. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. *Journal of Medical Virology* 1999;58(2):111-5
19. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004;11(2):97-107
20. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. *Vaccine* 2017;35(3):C45-51
21. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. *J Infect Dis* 1994;170(6):1418-23
22. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. *Epidemiol Infect*. 1996;117(2):313-25
23. van Zonneveld M1, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. *J Viral Hepat* 2003;10(4):294-7
24. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. *J Viral Hepat* 2009;16(2):94-103
25. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesselning AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. *JAMA* 2011; 305(6):576-584
26. Petrova M, Kamburov V. Breastfeeding and chronic HBV infection: clinical and social implications. *World J Gastroenterol* 2010;16(40):5042-6
27. Sangaré L, Sombié R, Combasséré AW, Kouanda A, Kania D, Zerbo O, Lankoandé J. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. *Bull Soc Pathol Exot* 2009;102(4):226-9
28. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. *Lancet Infect Dis* 2007;7(6):402-9
29. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection—a global challenge. *N Engl J Med* 2012;366(19):1749-52
30. Matthews PC, Geretti AM, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. *J Clin Virol* 2014; 61: 20-33
31. Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. *Vaccine* 2015; 33: 4618-4622
32. De Schryver AA, Van Hooste W, et al. Managing risk of hepatitis B after sharps injuries. *BMJ* 2015;351:h5568
33. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *European Association For The Study Of The Liver. J Hepatol* 2017; 67:370-98
34. Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance *Hepatology*. 2018 Apr;67(4):1560-1599

35. Chen CJ, Iloeje UH, Yang H. Long-term outcomes in Hepatitis B: The REVEAL-HBV study. *Clin Liver Dis* 2007; 11: 797-816
36. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006;130(3):678-86
37. Yang H, Lu S, Liaw Y, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med* 2002;347:168-174
38. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004;127(5 Suppl 1):S35-50
39. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. *J Virol* 2005;79(15):9369-80
40. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. *Hepatology* 2006;43(2 Suppl1):S173-S181
41. Fattovich G. Natural history and prognosis of hepatitis B. *Semin Liver Dis* 2003; 23(1):47-58
42. Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. *Journal of Hepatology* 2008;48(2):335-52
43. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus: A prospective study with long-term observation of 41 patients. *Medicine*. 1995;74(5):238-53
44. Mast EE MH, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A Comprehensive Immunisations Strategy to Eliminate Hepatitis B Virus Transmission in the United States. Part 1: Immunisation of Infants, Children and Adolescents. *MMWR*. 2005;54 (RR-16):1-3
45. Kew MC. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. *Ann Hepatol* 2013;12:173-182
46. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther*. 2009; 30(1): 37-47
47. Keefe EB, Dieterich DT, Han SH, et al. A treatment algorithm for management of chronic Hepatitis virus infection in the United States. *Clin Gastroenterol Hepatol* 2004;2 (2): 87-106
48. Lok ASF, McMahon BJ. AASLD PRACTICE GUIDELINES. Chronic Hepatitis B: Update 2009. *Hepatology* 2009: 50 (3): 1-65
49. Spearman CWN, Sonderup MW, Botha JF et al. South African Guideline for the Management of Chronic Hepatitis B: 2013. *SAMJ* 2013;103(5): 1-13
50. Colloredo MG, Leandro G, Brunetto MR, et al. Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. *Arch Virol Suppl* 1993; 8: 203-211
51. Lok AS, McMahon BJ. Chronic Hepatitis B. *Hepatology* 2007;45 (2): 507-539
52. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *Journal of Hepatology* 1995;22(6):696-9
53. Bedossa P, Bioulac-Sage P, Callard P, et al. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology*.1994;20(1):15-20
54. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015 www.who.int/mediacentre/news/releases/2015/hepatitis-b-guideline/en/ Accessed 4 December 2015
55. Vigano M, Paggi S, Lampertico P, et al. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. *Aliment Pharmacol Ther* 2011;34:353-362
56. Seeger C, Mason WS. Hepatitis B virus biology. *Microbiol Mol Biol Rev* 2000; 64 (1): 51- 68
57. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). *J Viral Hepat* 2004; 11(5): 427-431

58. Lok AS. Indications for therapy in Hepatitis B. *Hepatology* 2009; 49 (Suppl 5): S129-S137
59. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic Hepatitis B and advanced liver disease. *N Eng J Med* 2004; 351: 1521-1531
60. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 2008; 148 (7): 519-528
61. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: Clinical and virologic issues. *AIDS Reviews*. 2007;9(1):40-53
62. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005; 365(9454): 123-129
63. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HB eAg-positive chronic Hepatitis B. *N Engl J Med* 2005; 352(26): 2682-2695
64. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peginterferon alpha-2b for HB eAg-positive chronic hepatitis B: HB sAg loss is associated with HBV genotype. *Am J Gastroenterol* 2006; 101(2): 297-303
65. Fried MW, Piratvisuth T, Lau GK, et al. HB eAg and Hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HB eAg-positive chronic Hepatitis B. *Hepatology* 2008; 47(2): 428-434
66. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. *Gut*. 2005; 54(11): 1604-9
67. Gane E, Jia J, Han K et al. NEPTUNE Study: On-treatment HBsAg level analysis confirms prediction of response observed in Phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. *J Hepatol* 2011; S31
68. Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. *Hepatol Int* 2013;7(2):429-36
69. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon {alpha}-2a, lamivudine and the two combined for HB eAg-negative chronic Hepatitis B. *Gut* 2007; 56(5): 699-705
70. Degertekin B, Lok AS. Indications of therapy in Hepatitis B. *Hepatology* 2009; 49 (Suppl 5): S129-S137
71. Tilmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicentre experience. *J Viral Hepat* 2006,13(4): 256-263.
72. Hoofnagle HR. Reactivation of Hepatitis B. *Hepatology* 2009;49:S156-165
73. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. *Ann Intern Med* 2009; 150: 104-110
74. Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update *Hepatol Int* 2016;10(1):1-98
75. Hanbali A, Khaled Y. Incidence of Hepatitis B reactivation following Rituximab therapy. *Am J Hematol* 2009; 84(3): 19
76. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. *Br J Hematol* 2007; 136(5): 699-712.
77. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. *Clin Gastroenterol Hepatol* 2006; 4(9): 1076-1081
78. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic Hepatitis B virus infection in the United States: 2008 update. *Clin Gastroenterol Hepatol* 2008; 6(12): 1315-1341
79. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? *Liver Int*. 2014;34 Suppl 1:112-9
80. Moucari R, Mackiewicz V, Lada O, et al. Early serum HB sAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HB eAg-negative patients. *Hepatology* 2009; 49(4): 1151-1157
81. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis

- B using on-treatment hepatitis B surface antigen decline. *Hepatology* 2010; 52(4):1251-1257
82. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. *Hepatology* 2010; 52(2):454-61
 83. Rijckborst V, Hansen BE, Ferenci P, et al. HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. *J Hepatol.* 2012;56(5):1006-11
 84. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. *Gastroenterology* 2010;139(2):491-498
 85. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. *Antiviral Therapy.* 2007;12 (Suppl. 3):H15-H23
 86. Giles ML, Grace R, Tai A, et al. Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: current standards of care. *Aust N Z J Obstet Gynaecol* 2013;53: 231-5
 87. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. *J Viral Hepat* 2012;19:e18-25
 88. Brown RS, McMahon BJ, Lok AS et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. *Hepatology* 2016; 63(1): 319-33
 89. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta- analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. *World J Gastroenterol* 2011;17:4321-4333
 90. Jonas MM, Lok AS, McMahon BJ, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. *Hepatology* 2016; 63(1):307-18
 91. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. *J Gastroenterol Hepatol* 2001;16:636-640
 92. Haushofer AC, Hauer R, Brunner H, et al. Hepatitis B virus activity in patients with anti-hepatitis C virus antibody positivity and hepatitis B antigen positivity. *J Clin Virol* 2002;25:S99-S102
 93. Rautou PE, Asselah T, Saadoun D, et al. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. *Eur J Gastroenterol Hepatol* 2006;18:1019-102
 94. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus super-infection in patients with chronic hepatitis B virus infection. *Gastroenterology* 2004;126:1024-1029
 95. Kruse RL, Kramer JR, Tyson GL, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. *Hepatology* 2014; 60:1871-1878
 96. Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfecting with human immunodeficiency virus/hepatitis C virus. *Hepatology* 2009;50:1056-1063
 97. Hytioglou P, Dash S, Haruna Y, et al. Detection of hepatitis B and hepatitis C viral sequences in fulminant hepatic failure of unknown etiology. *Am J Clin Pathol* 1995;104:588-593
 98. Lee K, Smith PT. Fulminant liver failure from acute HCV superinfection in a patient with HIV, HBV, and HDV coinfections. *AIDS Read.* 2000;10:398-401
 99. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. *Am J Gastroenterol* 2000;95:2978-2980
 100. Ohkawa K, Hayashi N, Yuki N et al. Long-term follow up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients co-infected with both viruses. *J Med Virol.* 1995;46: 258-264
 101. Zarski JP, Bohn B, Bastie A, et al. Characteristic of patients with dual infection by hepatitis B and C viruses. *J Hepatol* 1998;28:27-33
 102. Thio CL, Seaberg EC, Skolasky R, Jr. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002; 360 (9349):1921-1926

103. Falade-Nwulia O, Seaberg EC, Rinaldo CR et al. Comparative Risk of Liver-Related Mortality from Chronic Hepatitis B Versus Chronic Hepatitis C Virus Infection. *Clinical Infectious Diseases* 2012; 55(4):507-513
104. De Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. *Gastroenterology*. 2010;139(6):1934-41
105. Plaza Z, Aguilera A, Mena A et al. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. *AIDS*. 2013;27(14):2219-24
106. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. *Hepatology* 1991;13 (4):619-26
107. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. *Hepatology* 2002;35(6):1528-35
108. Samuel D, Roque-Afonso AM. New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: what will be their impact on the prophylaxis of HBV infection? *Liver Transpl* 2007; 13(8):1084-7
109. Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? *Liver Transpl* 2008 ;14 Suppl 2:S23-6
110. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. *Lancet* 1996; 348 (9036): 1212-1215
111. Samuel D. Management of hepatitis B in liver transplantation patients. *Semin Liver Dis* 2004, 24 (Suppl 1): 55-62
112. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B : final long-term results. *Liver Transplant* 2007; 13(3): 349-360
113. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. *J Viral Hepat* 2007; 14 (suppl 1): 37-44
114. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. *Hepatology* 2001;33(2):424-32
115. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003;124(1):105-17
116. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003;125(6):1714-22
117. Fontana RJ. Management of patients with decompensated HBV cirrhosis. *Semin Liver Dis*. 2003;23(1):89-100
118. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. *Am J Transplant* 2003;3(8):999-1002
119. Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. *Hepatobiliary Pancreat Dis Int*. 2013;12(5):465-72
120. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. *Liver Transpl* 2001;7(1):51-8
121. Dickson RC, Everhart JE, Lake JR, et al. Transmission of Hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. *Gastroenterology* 1997;113(5): 1668-1674
122. Terrault N, Roche B, Samuel D. Management of the Hepatitis B virus in the liver transplantation setting: a European and an American perspective. *Liver Transplant* 2005; 11(7): 716-732
123. Skagen CL, Jou JH, Said A, et al. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. *Clin Transplant*. 2011 May-Jun;25(3):E243-9
124. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. *J Hepatol* 2010; 52(2):272-9

125. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. *Am J Transplant* 2015;15(5):1162-72
126. Ouseph R, Eng M, Ravindra K, et al. Review of the use of hepatitis B core antibody-positive kidney donors. *Transplant Rev (Orlando)*. 2010; 24(4):167-71
127. Pinney SP, Cheema FH, Hammond K, et al. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. *J Heart Lung Transplant* 2005;24(1):34-7
128. Villa ERL, Barchi T, Ferretti I, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. *Lancet* 1982; 2(8310): 1243-1245
129. Chevillotte G, Durbec JP, Gerolami A, et al. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: An epidemiologic study. *Gastroenterology* 1983; 85(1): 141-145
130. WHO. Weekly epidemiological record. Hepatitis B vaccines: WHO position paper – 7 July, No 27, 2017, 92, 369–392
131. Hipgrave DB, Maynard JE, Biggs BA. Improving birth dose coverage of hepatitis B vaccine. *Bull World Health Organ* 2006; 84(1): 65-71
132. Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. *Lancet Glob Health*. 2018 Jun;6(6):e659-e667.
133. Previsani N and Lavanchy D. Hepatitis B. World Health Organization; 2002. www.who.int/csr/disease/hepatitis/HepatitisB_whodscsrlyo2002_2.pdf. Accessed 19 December 2015
134. Mast EE WC, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 11: immunization of adults. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control*. 2006;55 (RR-16):1-33
135. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. *Nephrol Dial Transplant*. 2002;17 Suppl 7:72-87
136. MMWR Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. *MMWR* 2001;50(RR-11):1-52
137. National Management Guidelines for Sexual Assault Care 2003. www.cecinfo.org/SouthAfrica-Sexual-Assault-Guidelines-2003.pdf. Accessed 19 December 2015
138. Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology* 2018; 3(3): 172-80.

CHAPTER 6: HEPATITIS C (HCV)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013;57(4):1333-42
2. Lavanchy D. The global burden of hepatitis C. *Liver Int*. 2009;29 Suppl 1:74-81.
3. Marcellin P. Hepatitis C: the clinical spectrum of the disease. *J Hepatol* 1999;31 Suppl 1:9-16
4. Ellis LA, Brown D, Conradie JD, Paterson A, Sher R, Mollo J, et al. Prevalence of hepatitis C in South Africa: detection of anti-HCV in recent and stored serum. *J Med Virol* 1990;32(4):249-51
5. Gogela NA, Sonderup MW, Rebe K, CHIVese T, Spearman CW. Hepatitis C prevalence in HIV-infected heterosexual men and men who have sex with men. *South African medical journal*. 2018;108(7):568-72.

6. Scheibe A, Young K, Moses L, Basson RL, Versfeld A, Spearman CW, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. *Harm reduction journal*. 2019;16(1):28
7. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci U S A*. 1991;88(6):2451-5
8. Davis GL. Hepatitis C virus genotypes and quasispecies. *Am J Med* 1999;107(6B):21S-6S
9. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015;61(1):77-87
10. Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. *J Clin Microbiol*. 1995;33(6):1679-81
11. Prabdial-Sing N, Chirwa T, Thaver J, Smuts H, Vermeulen M, Suchard M, et al. Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012. *J Viral Hepat*. 2016;23(11):881-8
12. Ohno T, Mizokami M, Tibbs CJ, et al. New genotype of hepatitis C virus in South Africa. *J Med Virol*. 1994;42(4):409-13
13. Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. *Infect Control Hosp Epidemiol* 2007;28(5):519-24
14. de Moreau de Gerbehaye AI, Bodeus M, Robert A, Horsmans Y, Goubau P. Stable hepatitis C virus RNA detection by RT-PCR during four days storage. *BMC Infect Dis* 2002;2:22
15. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet*. 2011;378(9791):571-83
16. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. *Hepatology*. 2013;57(3):881-9
17. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. *Sex Transm Infect* 2003;79(2):160-2
18. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *AIDS* 2007;21(8):983-91
19. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology*. 2009;136(5):1609-17
20. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. *Clin Infect Dis*. 2014;59(6):765-73
21. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis*. 2005;192(11):1880-9
22. Thomas DL, Villano SA, Riester KA, Hershov R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. *Women and Infants Transmission Study*. *J Infect Dis*. 1998;177(6):1480-8
23. Floreani A. Hepatitis C and pregnancy. *World J Gastroenterol*. 2013;19(40):6714-20
- Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. *Int J Infect Dis*. 2010;14(11):E928-E940
24. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. *J Viral Hepat*. 2006;13(11):775-82
25. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol* 2014;61(1 Suppl):S58-68
26. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. *Am J Gastroenterol*. 2005;100(1):48-55

27. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. *HIV Med.* 2004;5(3):174-9
 28. Parboosing R, Paruk I, Lalloo UG. Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naive patients is associated with renal insufficiency and increased mortality. *J Med Virol* 2008;80(9):1530-6
 29. N Gogela N, Sonderup M, K Rebe, CW Spearman. The sero-prevalence of hepatitis C infection in an HIV-infected male population of heterosexual and men who have sex with men (MSM) in Cape Town S Afr Med J 2013;103(8):568-75
 30. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. *Gut.* 2003;52(7):1035-40
 31. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology.* 1999;30(4):1054-8
 32. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology.* 2001;34(6):1193-9
 33. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis.* 2001;33(4):562-9
 34. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol.* 1995;22(6):696-9
 35. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology.* 1996;24(2):289-93
 36. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. *Journal of clinical gastroenterology.* 2006;40(6):535-42
 37. Brenner S. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ontario health technology assessment series. 2015;15(18):1-45
 38. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. *Alimentary pharmacology & therapeutics.* 2009;30(6):557-76
 39. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* 2018; 69(2): 461-511.
 40. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis* 2018; 67(10): 1477-92.
 41. Sonderup MW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. *Lancet Gastroenterol Hepatol.* 2017;2(12):910-9.
 42. Curry MP, O'Leary JG, Bzowej N, et al; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med* 2015; 373(27):2618-28
 43. Balistreri WF et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. *Hepatology.* 2017 Aug;66(2):371-378.
 44. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. *Am J Infect Control.* 1995;23(5):273-7
 45. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. *Kidney Int.* 2004;65(6):2335-42
- ## CHAPTER 7: HEPATITIS D (HDV)
1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. *Lancet* 2011; 378:73-85

2. Rizzetto M. Hepatitis D Virus: Introduction and Epidemiology. *Cold Spring Harb Perspect Med* 2015;5(7):a021576
3. Stockdale AJ, Chaponda M, Beloukaa A, et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health* 2017;5(10):e992-e1003
4. Dusheiko GM, Brink BA, Conradie JD, Marimuthu T, Sher R. Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: A large population survey. *American Journal of Epidemiology* 1989;129(1):138-45
5. Abdool Karim SS, Windsor IM, Gopaul W. Low prevalence of delta hepatitis virus infection among blacks in Natal. *South African Medical Journal* 1991; 80(4):193-4
6. van der Ryst E, Cloete K, van Heerden A, Smit EJ, Williams MM. Hepatitis D virus-how prevalent? *South African Medical Journal* 1997; 87(10):1387
7. Tucker TJ, Keen GA, Yeats J, Hardie D, Van der Ryst E, Cloete K, et al. Hepatitis D virus - How prevalent? *South African Medical Journal* 1997;87(10):1386-8
8. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. *J Viral Hepat* 2011; 18: 434-442
9. Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. *Aliment Pharmacol Ther*. 2014; 40:93-104
10. Bahcecioglu IH, Sahin A. Treatment of Delta Hepatitis: Today and in the Future - A review. *Infect Dis (London)* 2017 Apr;49(4):241-250.
4. Dalton HR, Pas SD, Madden RG, van der Eijk AA. Hepatitis E: current concepts and future perspectives. *Curr Infect Dis Rep* 2014; 16(4); 399
5. Teshale EH, Hu DJ. Hepatitis E: Epidemiology and prevention. *World J Hepatol* 2011; 3(12): 285-291
6. Teshale EH, Hu DJ, Holmberg SD. The two faces of Hepatitis E. *Clin Infect Dis* 2010;51:328-334
7. Kim JH, Nelson KE, Panzner U et al. A systematic review of the epidemiology of hepatitis E virus in Africa. *BMC Infect Dis*. 2014; 5;14:308
8. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. *Rev Med Virol* 2006; 16: 5-36
9. Okamoto H. Genetic variability and evolution of hepatitis E virus. *Virus Research* 2007; 127: 216-228
10. Grabow WO, Favorov MO, Khudyakova NS, et al. Hepatitis E sero-prevalence in selected individuals in South Africa. *J Med Virol*. 1994; 44(4): 384-388
11. Tucker TJ, Kirsch RE, Louw SJ, Isaacs S, et al. Hepatitis E in South Africa: evidence for sporadic spread and increased seroprevalence in rural areas. *J Med Virol* 1996;50(2): 117-119
12. Madden RG, Sebastian Wallace S, Mark Sonderup M et al. Hepatitis E Virus: Western Cape, South Africa. *World J Gastroenterol*. 2016 Nov 28; 22(44): 9853–9859.
13. Andersson MI, Preiser W, Maponga TG, et al. Immune reconstitution hepatitis E: A neglected complication of antiretroviral therapy in Africa? *AIDS* 2013; 27(3): 487– 489
14. Andersson MI, Stead PA, Maponga T, van der Plas H, Preiser. Hepatitis E virus infection: An underdiagnosed infection in transplant patients in Southern Africa? *W J Clin Virol* 2015;70:23-5.
15. Mushahwar IK. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. *J Med Virol*. 2008; 80(4): 646-658
16. Ankhorn MJ, Tedder RS. Hepatitis E: the current state of play. *Transfus Med* 2017;27(2):84-95

CHAPTER 7: HEPATITIS E (HEV)

1. Khurro MS, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. *World J Gastroenterol* 2016;22(31):7030-45
2. Lenggenhager D, Weber A. Hepatitis E Virus and the Liver: Clinical Settings and Liver Pathology. *Gastroenterol Clin North Am* 2017;46(2):393-407
3. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. *Lancet Infect Dis* 2008;8:698-709



17. Khurro MS and Kamil S. Clinical course and duration of viraemia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. *J Viral Hepat* 2009; 6:519-523
18. Teshale EH, Howard CM, Grytdal SP, Handzel TR, Barry V, Kamili S, Drobeniuc J, Okware S, Downing R, Tappero JW, Bakamutumaho B, Teo CG, Ward JW, Holmberg SD, Hu DJ. Hepatitis E epidemic, Uganda. *Emerg Infect Dis* 2010; 16: 126-12
19. Khurro MS, Rustgi VK, Dawson GJ et al. Spectrum of hepatitis E virus infection in India. *J Med Virol* 1994; 43: 281-286
20. Sharapov MB, Favorov MO, Yashina TL et al. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. *BMC Infect Dis* 2009; 9: 35:1-9
21. Khurro MS and Kamil S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. *J Viral Hepat* 2003; 10:61-69
22. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. *Int J Gynaecol Obstet* 2004;85:240-244
23. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med* 2008; 358:811-817
24. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with Chronic Hepatitis in patients with Hepatitis E Virus Infection who have received Solid Organ Transplants. *Gastroenterology* 2011; 140: 1481-1489
25. Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients *Liver Transpl.* 2008; 14(4): 547-553
26. Dalton HR, Bendall R, Keane F, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. *N Engl J Med* 2009; 361:1025-1027
27. Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. *Ann Intern Med* 2009;150:430-431
28. Dalton HR, Fellows HJ, Stableworth W et al. The role of Hepatitis E virus testing in drug-induced liver injury. *Aliment Pharmacol Ther* 2007; 26:1429-1435

SUMMARIES AND TREATMENT ALGORITHMS FOR HBV AND HCV



APPENDIX

1. Summary of Main Characteristics of HBV

HBV is endemic in South Africa, resulting in a significant burden of clinical disease. Patients with chronic HBV infection have a 15 to 40 per cent risk of developing cirrhosis, liver failure or hepatocellular carcinoma (HCC)/liver cancer, and 15 to 25 per cent risk of dying from HBV-related liver diseases.

The risk of chronic infection is dependent on the age of first infection: 70 to 90 per cent for infants exposed perinatally (from an HBeAg-positive mother); 25 to 50 per cent for children between one and five years; six to 10 per cent for five to 20 years and one to three per cent for adults older than 20 years.

HBV is an entirely vaccine-preventable disease.

EPIDEMIOLOGY AND TRANSMISSION IN SOUTH AFRICA:

- estimated 6.7 per cent HBsAg seroprevalence in low risk groups. Up to 25 per cent in HIV infected individuals

- parenteral transmission: Main route of transmission is horizontal between ages six months to five years. Other routes of parenteral transmission include perinatal, sexual and percutaneous routes
- increased risk of perinatal transmission in HIV/ HBV coinfecting mothers

CLINICAL PRESENTATIONS:

- acute infection: Usually asymptomatic and subclinical in neonates and children. Adolescents and adults usually present with symptomatic hepatitis with/without jaundice
- fulminant hepatitis with acute liver failure (0.1 to 0.5 per cent)
- Chronic infection - five different phases of infection.

Depending on the phase of infection, the individual maybe completely asymptomatic or present with a hepatitis flare or complications of cirrhosis including jaundice, portal hypertension (varices and ascites) and hepatocellular carcinoma. Hepatocellular carcinoma can occur in the absence of cirrhosis

- extrahepatic manifestations

Can occur in both acute and chronic HBV:

- o polyarteritis nodosa
- o membranous glomerulonephritis
- o membranoproliferative glomerulonephritis

DIAGNOSIS:

- depends on combination of ALT, HBV serology, HBV DNA levels and non-invasive markers of fibrosis.
- liver biopsy seldom required

Intepretation of serological markers, HBV DNA and ALT levels	
Successful immunisation	<ul style="list-style-type: none"> • positive anti-HBsAb (titre >10 IU/ml)
Previous exposure to HBV	<ul style="list-style-type: none"> • positive HB IgG core antibody +/- positive anti-HBsAb
Acute HBV	<ul style="list-style-type: none"> • HBsAg positive, HB IgM core antibody positive • elevated ALT
Fulminant hepatitis	<ul style="list-style-type: none"> • may be HBsAg-negative, but HB IgM core antibody positive • HBV DNA detectable • elevated ALT • Synthetic dysfunction (elevated ammonia and prolonged INR>1.5)
Chronic HBV ALT, serology and HBV DNA levels depend on phase of chronic infection	
HBeAg-positive chronic HBV infection (immune tolerant)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-positive • hhigh HBV DNA (usually >200 000 IU/ml, typically >1M IU/ml) • normal ALT
HBeAg-positive chronic hepatitis (immune clearance)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-positive • HBV DNA >20 000 IU/ml • elevated ALT
HB-eAg-negative chronic HBV infection (immune control)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-negative • HBV DNA <2 000 IU/ml • normal ALT

Chronic HBV ALT, serology and HBV DNA levels depend on phase of chronic infection	
HB-eAg-negative chronic hepatitis (immune escape)	<ul style="list-style-type: none"> • HBsAg-positive, HBeAg-negative • HBV IgM core antibody maybe low positive with a flare • HBV DNA >2 000 IU/ml • fluctuating elevated ALT
Occult HBV infection	<ul style="list-style-type: none"> • HBsAg-negative, anti-HBsAb-negative, • HBV IgG core antibody positive • HBV DNA <200 IU/ ml • normal ALT

ASSESSMENT OF LIVER DISEASE AND NEED FOR THERAPY:

- establish phase of chronic infection
- detailed clinical history and physical examination
- assessment of the severity of the liver disease:
 - o liver profile: total bilirubin, conjugated bilirubin, ALT, AST, ALP, GGT
 - o FBC including a differential count
 - o Albumin and INR to assess synthetic function
- look for other co-factors
 - o viral co-infection: HIV, HCV
 - o alcohol
 - o non-alcoholic fatty liver disease
 - o iron overload
 - o drug/toxin-induced liver injury
- serological assessment
 - o HBsAg, anti-HBs, HBeAg and anti-HBe ± HB IgM Ab (note – can be low positive with a flare)
 - o hepatitis B IgG core antibody (if assessing for occult HBV or previous cleared infection)
 - o anti-HAV IgG to assess need for HAV immunisation
- Alpha fetoprotein
- ultrasound of the liver and dopplers
- non-invasive markers of fibrosis:

- o APRI score = $(\text{AST/ULN}) \times 100 / \text{platelet count (109/L)}$
 - APRI score >2 identifies adults with cirrhosis (F4) and in need of antiviral therapy
- o vibration controlled transient elastography (FibroScanR)
- liver biopsy no longer routinely required
 - o excluding other contributing forms of acute/chronic liver disease e.g. Drug or toxin-induced liver injury

GOALS OF THERAPY:

- prevention of long-term complications of chronic HBV
 - o cirrhosis
 - o liver failure
 - o hepatocellular carcinoma
- prevention of reactivation in setting of immunosuppression/biologicals/chemotherapy
- ensure HBV viral suppression in ALF

Ideal endpoint of treatment: Immunological cure with sustained HBV DNA suppression and sustained HBsAg loss, with/without seroconversion to anti-HBs. Virological cure not yet possible.

INDICATIONS FOR TREATMENT:

Patients requiring treatment	Monitoring required
<ul style="list-style-type: none"> • acute liver failure• compensated or decompensated cirrhosis (APRI score >2 in adults) o regardless of ALT levels, HBeAg status or HBV DNA levels • patients receiving chemotherapy, rituximab or immunosuppressive therapy • HBeAg-positive chronic HBV (immune clearance) • HBeAg-negative chronic HBV (immune escape) 	<ul style="list-style-type: none"> • HB-eAg-negative chronic HBV infection (immune control) • HB-eAg-positive chronic HBV infection (immune tolerance)

TREATMENT OPTIONS:

- NUCs: TDF, TAF, Entecavir and Lamivudine
- interferon-based therapy: Pegylated Interferon – only under the supervision of a hepatologist

Tenofovir is the preferred NUC. TAF and Entecavir is reserved for patients with renal impairment. Lamivudine should not routinely be used because of high rate of resistance.

TREATMENT OF SPECIAL POPULATIONS:

- pregnancy: (see PMTCT)
 - o HBsAg screening of pregnant women is essential
 - o indications for therapy: same as usual indications
- HBV/HCV co-infection:
 - o treat HBV before treating HCV
- HIV/HBV co-infection:
 - o All should be treated with an ARV regimen that includes Tenofovir and lamivudine or emtricitabine
- healthcare workers:
 - o HBV DNA level should preferably be undetectable or <200 IU/ml before practicing exposure-prone procedures

PREVENTION:

HBV immunisation:

- recommend HBV birth dose as part of EPI to prevent perinatal transmission
- ideally all South Africans should be vaccinated
- high-risk groups must be vaccinated:
 - o healthcare workers
 - o all laboratory workers working with clinical specimens
 - o police, firefighters and members of the armed forces
 - o persons with end stage renal disease requiring dialysis
 - o persons who inject or use drugs
 - o household contacts of HBsAg-positive persons

- o sex partners of HBsAg-positive persons
- o residents and workers of facilities for the developmentally disabled
- o patients receiving frequent transfusions of blood or blood components
- o transplant candidates before transplantation
- o persons seeking evaluation for treatment of a sexually transmitted disease
- o MSM
- o persons with chronic liver disease
- o persons with HIV infection
- o workers and residents of correctional service facilities

Post-exposure prophylaxis: Needle stick/sexual exposure/percutaneous exposure:

- wounds washed with soap and water
- mucous membranes flushed with water
- source individual screened: HBsAg, HIV and anti-HCV
- exposed individual screened: HBsAg, HBsAb and HB IgG core Ab:
 - o infected, immune or non-immune
- source individual HBsAg-positive or status unknown and exposed individual non-immune:
 - o HBIG (0.06ml/kg or 500IU) IMI and active immunisation (0.1 and two months)
 - o consider repeat HBIG at one month:
 - if contact HBeAg-positive or high DNA levels
 - if exposed individual known non-responder

Prevention of MTCT:

- pregnant women: Tenofovir if HBV DNA > 200 000 IU/ml, starting at 28 to 32 weeks gestation
- neonate: HBV birth dose vaccine and HBIG at different sites within 12 to 24 hours of delivery
Complete EPI HBV vaccine schedule at six, 10 and 14 weeks

Diagnostic, prevention and treatment options at primary, secondary and tertiary levels of care:

DIAGNOSIS:

- viral serology (HBsAg, anti-HBs, HBeAg, anti-HBe, IgG and IgM anti-HB core at all levels of care)
- HBV DNA quantification at secondary and tertiary levels of care

Assessment of clinical severity:

- liver profile and INR at all levels of care; enables APRI scoring to assess for cirrhosis
- ultrasound liver : Secondary and tertiary levels of care
- fibroscan and liver biopsy: Tertiary levels of care

TREATMENT:

- acute HBV:
 - o uncomplicated cases managed at primary care level including screening at six months to exclude progression to chronic HBV
 - o complicated cases with synthetic dysfunction: Refer to secondary care level
 - o fulminant hepatitis: Refer to tertiary care level
- Chronic HBV:
 - o HB-eAg-negative chronic HBV infection (immune control): Follow up at primary care level
 - o HB-eAg-positive chronic HBV infection (immune tolerant): Follow up at primary care level
 - o HBeAg-positive chronic hepatitis (immune clearance): Tertiary level care with option of down-referral to secondary or primary level care when stable on therapy
 - o HBeAg-negative chronic hepatitis (immune escape): Tertiary level care with option of down-referral to secondary or primary level care when stable on therapy

- o cirrhotics (compensated and decompensated): Tertiary level care
- o HIV/HBV, HBV/HCV and HBV/HCV/HIV: Tertiary level care with option of down-referral to secondary or primary level care when stable on therapy

Therapeutic options:

- Lamivudine and TDF : at all levels of care for both HBV mono-infected and HBV/HIV co-infected
- Entecavir, TAF and Pegylated Interferon at tertiary care level


Prophylaxis:

- HBV immunisation: all levels of care
- HBIG: all levels of care

ENTER YOUR PATIENT
CHARACTERISTICS FOR INSTANT
GUIDANCE ON MANAGEMENT
[CLINICALOPTIONS.COM/
HEPBCONSULT](https://www.clinicaloptions.com/hepbconsult)


Guidance: Monitor vs Treat in HBeAg-Positive Patients

Noncirrhotic HBeAg-Positive Patients




Guidance: Monitor vs Treat in HBeAg-Negative Patients

Noncirrhotic HBeAg-Negative Patients



Guidance: Cirrhosis

HBsAg-Positive Patients with CHB



2. Summary of Main Characteristics of HCV

The true burden of chronic HCV in South Africa is not clear, however a high prevalence in at risk groups exist. Following primary infection, 15 to 45 per cent of infected persons spontaneously clear HCV within six months with 55 to 85 per cent developing chronic HCV infection. Genotypes 1 to 5 are found in South Africa with genotype 5a being unique to South Africa.

EPIDEMIOLOGY AND TRANSMISSION IN SOUTH AFRICA:

- HCV seroprevalence and transmission is incompletely characterised
- available data suggests 0.01 to 2.6 per cent seroprevalence in urban blood donors (low risk)
- new data suggests high prevalence in PWID
- parenteral transmission
- sexual transmission is infrequent except in high risk behaviour and MSM
- vertical transmission requires high viral titres as found HIV/HCV co-infected individuals

- high-risk groups include:
 - o recipients of blood, blood products and organs pre-1992
 - o PWID
 - o use of intranasal cocaine
 - o occupational exposure e.g. HCWs with needle stick injuries
 - o haemodialysis patients
 - o tattoos, body piercing, acupuncture with unsafe equipment
 - o infants born to HCV-positive mothers
 - o high-risk sexual practices
 - o surgical procedures including dental/orthodontic procedures before efficient sterilisation procedures were in place

CLINICAL PRESENTATIONS:

- acute infection: 80 to 90 per cent are asymptomatic. Seldom diagnosed as usually subclinical
- fulminant hepatitis: Extremely rare
- chronic infection: Usually asymptomatic until presentation with complications of cirrhosis.

20 per cent may have persistently normal ALT that does not correlate with lack of disease progression

- HCV/HIV co-infection: Accelerated risk of cirrhosis
- extrahepatic manifestations:
 - o autoimmune (e.g. Sjögren's syndrome, Cryoglobulinaemia, Sialadenitis, Polyarteritis nodosa)
 - o porphyria cutanea tarda
 - o lymphoproliferative diseases e.g. B-cell non-Hodgkin's lymphoma)
 - o progressive insulin resistance, impaired fasting glucose and/or frank type 2 diabetes mellitus

DIAGNOSIS:

- anti-HCV (EIA): 95 per cent sensitivity. Detecting antibody in 80 per cent within five to six weeks of infection
- qualitative PCR: Confirmatory nucleic acid testing (NAT) detects HCV within one to three weeks of infection
- quantitative PCR: Assesses viral load and treatment response
- genotype testing: To determine appropriate therapy regimen (not necessarily required with pangenotypic therapy)

TREATMENT AND PREVENTION:

No vaccine or passive immunoglobulin available.

Virological cure is attainable and is sustainable in more than 99 per cent of individuals irrespective of the type of treatment.

DIRECT ANTIVIRAL AGENTS:

There are no DAAs currently registered by SAHPRA in South Africa. They are obtainable via a Section 21 certification process. SVR rates for DAA therapies exceed 90 per cent for 12 weeks treatment in non-cirrhotics.

Previous treatment, viral load, IL28B, presence of cirrhosis are no longer negative factors influencing SVR. Treatment duration and need for Ribavirin is influenced by cirrhosis. Need for monitoring is limited and side-effects are minimal. DAA therapy is effective

in the HIV/HCV co-infected, liver transplant patients and those with chronic kidney disease.

All patients with chronic HCV are eligible for treatment. Pre-treatment check for drug-drug interactions with patients existing drug treatments is mandatory: www.hep-druginteractions.org or HEP iChart (Android or Apple)

DAA regimens in treatment naive patients:

- Sofosbuvir/Ledipasvir : Genotypes 1, 4, 5 and 6*
- Sofosbuvir /Daclatasvir: Genotypes 1 to 5*
- Sofosbuvir/Velpatasvir: Genotypes 1 to 6*
- Glecaprevir/Pibrentasvir: Genotypes 1 to 6

* If cirrhosis present, add Ribavirin or extend to 24 weeks of therapy

If patient DAA experienced, consult an expert

With pangenotypic regimen, genotyping can be omitted

DIAGNOSTIC, PREVENTION AND TREATMENT OPTIONS AT PRIMARY, SECONDARY AND TERTIARY LEVELS OF CARE:

Diagnosis:

- anti-HCV (EIA): All levels of care
- HCV PCR (NAT): All levels of care
- quantitative HCV PCR, Genotype and RAS testing: Tertiary care level

Assessment of clinical severity:

- liver profile and INR at all levels of care; enables APRI scoring to assess for cirrhosis
- ultrasound liver: Secondary and tertiary care levels
- liver biopsy and FibroScanR: Tertiary care levels

Treatment:

Currently refer to tertiary care level and apply for Section 21 SAHPRA permission for DAA therapy.



NOTES:



